WEST Search History

Hide Items Restore Clear Cancel

DATE: Wednesday, March 17, 2004

Hide?	<u>Set</u> <u>Name</u>	Query	<u>Hit</u> <u>Count</u>
	DB=PC	GPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ	
	L16	L15 AND L6	23
	L15	435/368.CCLS.	362
	L14	L13 AND 435/366,368.CCLS.	15
	L13	L11 AND 435/325.CCLS.	279
	L12	L11 AND 435/93.1,93.7.CCLS.	0
	L11	L10 NOT Baker-Kevin-P.IN.	1136
	L10	(L6 NOT Rosen-Craig-A.IN.)	1289
	L9	L6 AND L7 AND L8	9
	L8	435/96.1,93.7,325.CCLS.	14340
	L7	514/1,2.CCLS.	6720
	L6	L1 AND L2 AND L3	1423
	L5	L3 AND L4	1423
	L4	L1 AND L2	1946
	L3	neuron OR neuronal OR neural	66725
	L2	Parkinson OR Huntington OR amyotrophic lateral sclerosis OR Alzheimer OR ischemic cerebral stroke	70645
	L1	(FK506 OR cyclosporin A OR rapamycin)	8237

END OF SEARCH HISTORY

ch

h g

e e

fcg

е









Nucleotide Protein OMIM PMC Journals Genome Structure Book Search PubMed Clear Go for immunophilin AND neuron Limits Preview/Index Clipboard Details History About Entrez Show: |500 ₩ Display Summary Send to Text Items 1-113 of 113 One page. **Text Version** 1: Birge RB, Wadsworth S, Akakura R, Abeysinghe H, Kanojia R, Related Articles, Links MacIelag M, Desbarats J, Escalante M, Singh K, Sundarababu S, Entrez PubMed Parris K, Childs G, August A, Siekierka J, Weinstein DE. Overview Help | FAQ A role for schwann cells in the neuroregenerative effects of a non-Tutoria! immunosuppressive fk506 derivative, jnj460. New/Noteworthy Neuroscience. 2004;124(2):351-66. E-Utilities PMID: 14980385 [PubMed - in process] **PubMed Services** 2: Chiu R, Rey O, Zheng JQ, Twiss JL, Song J, Pang S, Yokoyama Related Articles, Links Journals Database MeSH Database Single Citation Matcher Effects of altered expression and localization of cyclophilin A on **Batch Citation Matcher** differentiation of p19 embryonic carcinoma cells. **Clinical Queries** Cell Mol Neurobiol. 2003 Dec;23(6):929-43. LinkOut PMID: 14964780 [PubMed - in process] Cubby 13: Morot-Gaudry-Talarmain Y, Rezaei H, Guermonprez L, Treguer E. Related Articles, Links Related Resources Grosclaude J. Order Documents Selective prion protein binding to synaptic components is modulated by **NLM Gateway** TOXNET oxidative and nitrosative changes induced by copper(II) and peroxynitrite in Consumer Health cholinergic synaptosomes, unveiling a role for calcineurin B and Clinical Alerts thioredoxin. ClinicalTrials.gov PubMed Central J Neurochem. 2003 Dec;87(6):1456-70. PMID: 14713301 [PubMed - indexed for MEDLINE] Privacy Policy 1 4: Si K, Giustetto M, Etkin A, Hsu R, Janisiewicz AM, Miniaci MC, Related Articles, Links Kim JH, Zhu H, Kandel ER A neuronal isoform of CPEB regulates local protein synthesis and stabilizes synapse-specific long-term facilitation in aplysia. Cell. 2003 Dec 26;115(7):893-904. PMID: 14697206 [PubMed - indexed for MEDLINE] 5: Gordon T, Sulaiman O, Boyd JG. Related Articles, Links Experimental strategies to promote functional recovery after peripheral nerve injuries. J Peripher Nerv Syst. 2003 Dec;8(4):236-50. PMID: 14641648 [PubMed - indexed for MEDLINE] 6: Hamdane M, Delobel P, Sambo AV, Smet C, Begard S, Violleau A, Related Articles, Links Landrieu I, Delacourte A, Lippens G, Flament S, Buee L. Neurofibrillary degeneration of the Alzheimer-type: an alternate pathway to neuronal apoptosis? Biochem Pharmacol. 2003 Oct 15;66(8):1619-25. Review. PMID: 14555242 [PubMed - indexed for MEDLINE] 7: Brecht S, Schwarze K, Waetzig V, Christner C, Heiland S, Fischer Related Articles, Links G, Sartor K, Herdegen T.

Changes in peptidyl-prolyl cis/trans isomerase activity and FK506 binding protein expression following neuroprotection by FK506 in the ischemic rat

b




h cb hgeeefcg



h cb hg e e e fcg

b e

stimulates regenerating axon growth from adult mouse dorsal root ganglia



h cb hg e e e fcg

34: Moss SJ. Birkestrand B. Fowler SC.	Related Articles, Links
The neuroimmunophilin GPI-1046 partially protects a acetylpyridine toxicity in the rat. Neurosci Lett. 2002 Mar 15;321(1-2):53-6. PMID: 11872255 [PubMed - indexed for MEDLINE]	ngainst 3-
135: Tanaka K. Yoshioka M. Miyazaki I, Fujita N. Ogawa N.	Related Articles, Links
GPI1046 prevents dopaminergic dysfunction by activ system in the mouse striatum. Neurosci Lett. 2002 Mar 15;321(1-2):45-8. PMID: 11872253 [PubMed - indexed for MEDLINE]	ating glutathione
36: Quevedo C, Salinas M, Aleazar A.	Related Articles, Links
Regulation of cap-dependent translation by insulin-lik neuronal cells. Biochem Biophys Res Commun. 2002 Mar 1;291(3):560-6. PMID: 11855825 [PubMed - indexed for MEDLINE]	te growth factor-1 in
37: Gold BG, Nutt JG.	Related Articles, Links
Neuroimmunophilin ligands in the treatment of Parkin Curr Opin Pharmacol. 2002 Feb;2(1):82-6. Review. PMID: 11786313 [PubMed - indexed for MEDLINE]	nson's disease.
38: Klettner A. Baumgrass R. Zhang Y. Fischer G. Burger E. Herdegen T. Mielke K.	Related Articles, Links
The neuroprotective actions of FK 506 binding protein survival is triggered by de novo RNA synthesis, but is inhibition of JNK and calcineurin. Brain Res Mol Brain Res. 2001 Dec 16;97(1):21-31. PMID: 11744159 [PubMed - indexed for MEDLINE]	
39: Avramut M. Zeevi A. Achim CL.	Related Articles, Links
The immunosuppressant drug FK506 is a potent troph fetal neurons. Brain Res Dev Brain Res. 2001 Dec 31;132(2):151-7. PMID: 11744119 [PubMed - indexed for MEDLINE]	nic agent for human
40: Suehiro E, Singleton RH, Stone JR, Povlishock JT.	Related Articles, Links
The immunophilin ligand FK506 attenuates the axona with rapid rewarming following posttraumatic hypoth Exp Neurol. 2001 Nov;172(1):199-210. PMID: 11681852 [PubMed - indexed for MEDLINE]	
41: Sezen SF. Hoke A. Burnett Al., Snyder SH.	Related Articles, Links
Immunophilin ligand FK506 is neuroprotective for pe Nat Med. 2001 Oct;7(10):1073-4. No abstract available. PMID: 11590407 [PubMed - indexed for MEDLINE]	nile innervation.
42: Goel M. Garcia R. Estacion M. Schilling WP.	Related Articles, Links
Regulation of Drosophila TRPL channels by immuno J Biol Chem. 2001 Oct 19;276(42):38762-73. Epub 2001 Aug 20 PMID: 11514552 [PubMed - indexed for MEDLINE]	
43: Nahreini P, Hovland AR, Kumar B, Andreatta C, Edwards-Prasa J, Prasad KN	ud Related Articles, Links
Effects of altered cyclophilin A expression on growth human and mouse neuronal cells. Cell Mol Neurobiol. 2001 Feb;21(1):65-79.	and differentiation of

PMID: 11440199 [PubMed - indexed for MEDLINE] 44: Singleton RH, Stone JR, Okonkwo DO, Pellicane AJ, Povlishock Related Articles, Links The immunophilin ligand FK506 attenuates axonal injury in an impactacceleration model of traumatic brain injury. J Neurotrauma. 2001 Jun;18(6):607-14. PMID: 11437083 [PubMed - indexed for MEDLINE] 12 45: Chen J, Sochivko D, Beck H, Marechal D, Wiestler OD, Becker Related Articles, Links <u>AJ</u> Activity-induced expression of common reference genes in individual cns Lab Invest. 2001 Jun;81(6):913-6. No abstract available. PMID: 11406652 [PubMed - indexed for MEDLINE] 46: Guo X, Dawson VL, Dawson TM. Related Articles, Links Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Eur J Neurosci. 2001 May; 13(9):1683-93. PMID: 11359520 [PubMed - indexed for MEDLINE] 12. 47: Weickert CS, Webster MJ, Hyde TM, Herman MM, Bachus SE, Related Articles, Links Bali G, Weinberger DR, Kleinman JE. Reduced GAP-43 mRNA in dorsolateral prefrontal cortex of patients with schizophrenia. Cereb Cortex. 2001 Feb;11(2):136-47. PMID: 11208668 [PubMed - indexed for MEDLINE] 13 48: Emborg ME, Shin P, Roitberg B, Sramek JG, Chu Y, Stebbins GT, Related Articles, Links Hamilton JS, Suzdak PD, Steiner JP, Kordower JH. Systemic administration of the immunophilin ligand GPI 1046 in MPTPtreated monkeys. Exp Neurol. 2001 Mar; 168(1):171-82. PMID: 11170732 [PubMed - indexed for MEDLINE] 49: Tanaka K, Fujita N, Yoshioka M, Ogawa N. Related Articles, Links Immunosuppressive and non-immunosuppressive immunophilin ligands improve H(2)O(2)-induced cell damage by increasing glutathione levels in NG108-15 cells. Brain Res. 2001 Jan 19;889(1-2):225-8. PMID: 11166708 [PubMed - indexed for MEDLINE] 50: Lian Q, Ladner CJ, Magnuson D, Lee JM. Related Articles, Links Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex. Exp Neurol. 2001 Jan;167(1):158-65. PMID: 11161603 [PubMed - indexed for MEDLINE] 51: Freeman EE, Grosskreutz CL. Related Articles, Links The effects of FK506 on retinal ganglion cells after optic nerve crush. Invest Ophthalmol Vis Sci. 2000 Apr;41(5):1111-5. PMID: 10752948 [PubMed - indexed for MEDLINE] 52: Yasojima K, Schwab C, McGeer EG, McGeer PL. Related Articles, Links Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 2000 Dec 22;887(1):80-9.

h cb hg e e fcg

b e

PMID: 11134592 [PubMed - indexed for MEDLINE]

□ 53:	Ross DT, Guo H, Howorth P, Chen Y, Hamilton GS, Steiner JP.	Related Articles, Links
12.00 12.00	The small molecule FKBP ligand GPI 1046 induces part innervation after intranigral 6-hydroxydopamine lesion i Neurosci Lett. 2001 Jan 12;297(2):113-6. PMID: 11121883 [PubMed - indexed for MEDLINE]	
□ 54:	Thorpe JR, Morley SJ, Rulten SL.	Related Articles, Links
	Utilizing the peptidyl-prolyl cis-trans isomerase pin1 as phosphorylated target proteins. Examples of binding to a human kidney cell line and to tau in Alzheimer's diseas J Histochem Cytochem. 2001 Jan;49(1):97-108. PMID: 11118482 [PubMed - indexed for MEDLINE]	nuclear proteins in
□ 55:	Brogan IJ, Pravica V, Hutchinson IV.	Related Articles, Links
	Genetic conservation of the immunophilin-binding dome calcineurin A1 and A2. Transpl Immunol. 2000 Jun;8(2):139-41. PMID: 11005320 [PubMed - indexed for MEDLINE]	ains of human
□ 56:	Zhang W. Li JL, Hosaka M. Janz R. Shelton JM, Albright GM, Richardson JA, Sudhof TC, Victor RG.	Related Articles, Links
	Cyclosporine A-induced hypertension involves synapsin nerve endings. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9765-70. PMID: 10920204 [PubMed - indexed for MEDLINE]	in renal sensory
□ 57:	Terashima A, Taniguchi T, Nakai M, Yasuda M, Kawamata T, Tanaka C.	Related Articles, Links
.88	Rapamycin and FK506 induce long-term potentiation by stimulation via an intracellular Ca(2+) signaling mechan hippocampal CA1 neurons. Neuropharmacology. 2000 Jul 24;39(10):1920-8. PMID: 10884573 [PubMed - indexed for MEDLINE]	
□ 58:	Parker EM, Monopoli A, Ongini E, Lozza G, Babij CM.	Related Articles, Links
	Rapamycin, but not FK506 and GPI-1046, increases neu PC12 cells by inhibiting cell cycle progression. Neuropharmacology. 2000 Jul 24;39(10):1913-9. PMID: 10884572 [PubMed - indexed for MEDLINE]	rite outgrowth in
59:	Castilho RF, Hansson O, Brundin P.	Related Articles, Links
	FK506 and cyclosporin A enhance the survival of cultur embryonic dopamine neurons. Exp Neurol. 2000 Jul;164(1):94-101. PMID: 10877919 [PubMed - indexed for MEDLINE]	ed and grafted rat
□ 60:	Costantini LC, Isacson O.	Related Articles, Links
	Immunophilin ligands and GDNF enhance neurite branc from developing dopamine neurons in culture. Exp Neurol. 2000 Jul;164(1):60-70. PMID: 10877916 [PubMed - indexed for MEDLINE]	hing or elongation
ि 61:	Nakayama H, Ueno S, Ikeuchi T, Hatanaka H.	Related Articles, Links
	Regulation of alpha3 nicotinic acetylcholine receptor subsyncrye growth factor and cyclic AMP in PC12 cells. J Neurochem. 2000 Apr;74(4):1346-54. PMID: 10737589 [PubMed - indexed for MEDLINE]	bunit mRNA levels


cb

h g

e fcg

e

□ 62	: El Majdoubi M, Ramaswamy S, Sahu A, Plant TM	Related Articles, Links
	Effects of orchidectomy on levels of the mRNAs encod releasing hormone and other hypothalamic peptides in trhesus monkey (Macaca mulatta). J Neuroendocrinol. 2000 Feb;12(2):167-76. PMID: 10718912 [PubMed - indexed for MEDLINE]	ing gonadotropin- he adult male
□ 63	Campbell G, Holt JK, Shotton HR, Anderson PN, Bavetta S, Lieberman AR	Related Articles, Links
	Spontaneous axonal regeneration after optic nerve injur Neuroreport. 1999 Dec 16;10(18):3955-60. PMID: 10716240 [PubMed - indexed for MEDLINE]	y in adult rat.
□ 64	: Medina-Ortiz WE, Garcia-Arraras JE.	Related Articles, Links
	Differential regulation of NPY mRNA expression in ensympathetic and chromaffin cultures by NGF. Brain Res Dev Brain Res. 2000 Jan 3;119(1):155-8. PMID: 10648881 [PubMed - indexed for MEDLINE]	bryonic
□ 65	Zeilhofer HU, Blank NM, Neuhuber WL, Swandulla D.	Related Ariicles, Links
	Calcium-dependent inactivation of neuronal calcium chindependent of calcineurin. Neuroscience. 2000;95(1):235-41. PMID: 10619480 [PubMed - indexed for MEDLINE]	annel currents is
□ 66	Sauer H, Francis JM, Jiang H, Hamilton GS, Steiner JP.	Related Articles, Links
	Systemic treatment with GPI 1046 improves spatial me cholinergic neuron atrophy in the medial septal nucleus Brain Res. 1999 Sep 18;842(1):109-18. PMID: 10526101 [PubMed - indexed for MEDLINE]	
□ 67	: Khaspekov L, Friberg H, Halestrap A, Viktorov I, Wieloch T.	Related Articles, Links
	Cyclosporin A and its nonimmunosuppressive analogue cyclosporin A mitigate glucose/oxygen deprivation-indecultured hippocampal neurons. Eur J Neurosci. 1999 Sep;11(9):3194-8. PMID: 10510183 [PubMed - indexed for MEDLINE]	
□ 68	: Falk T, Garver WS, Erickson RP, Wilson JM, Yool AJ.	Related Articles, Links
	Expression of Niemann-Pick type C transcript in rodent and in vitro. Brain Res. 1999 Aug 21;839(1):49-57. PMID: 10482798 [PubMed - indexed for MEDLINE]	cerebellum in vivo
□ 69	Alexanian AR, Bamburg JR.	Related Articles, Links
	Neuronal survival activity of s100betabeta is enhanced inhibitors and requires activation of NF-kappaB. FASEB J. 1999 Sep;13(12):1611-20. PMID: 10463953 [PubMed - indexed for MEDLINE]	by calcineurin
□ 70	: Gold BG.	Related Articles, Links
	FK506 and the role of the immunophilin FKBP-52 in no Drug Metab Rev. 1999 Aug;31(3):649-63. Review. PMID: 10461545 [PubMed - indexed for MEDLINE]	erve regeneration.
□71	Hovland AR, La Rosa FG, Hovland PG, Cole WC, Kumar A, Prasad JE, Prasad KN.	Related Articles, Links
	Cyclosporin A regulates the levels of cyclophilin A in n	euroblastoma cells



h ch h g е е e fcg

b е

A novel immunophilin ligand: distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an

animal model of Parkinson's disease. Neurobiol Dis. 1998 Aug;5(2):97-106.

PMID: 9746907 [PubMed - indexed for MEDLINE]

cb

h g

e fcg

□ 80	Zachor DA, Moore JF, Theibert AB, Percy AK.	Related Articles, Links
	Cocaine-inhibited neuronal differentiation in NGF-indu altered c-fos expression are reversed by C-fos antisense Ann N Y Acad Sci. 1998 Jun 21;846:427-30. No abstract available PMID: 9668442 [PubMed - indexed for MEDLINE]	oligonucleotide.
□81	Terashima A, Nakai M, Hashimoto T, Kawamata T, Taniguchi T, Yasuda M, Maeda K, Tanaka C.	Related Articles, Links
	Single-channel activity of the Ca2+-dependent K+ chan FK506 and rapamycin. Brain Res. 1998 Mar 9;786(1-2):255-8. PMID: 9555045 [PubMed - indexed for MEDLINE]	nel is modulated by
□ 82	Gold BG.	Related Articles, Links
	FK506 and the role of immunophilins in nerve regeneral Mol Neurobiol. 1997 Dec;15(3):285-306. Review. PMID: 9457703 [PubMed - indexed for MEDLINE]	tion.
□ 83	Muller YL. Reitstetter R. Yool AJ.	Related Articles, Links
	Regulation of Ca2+-dependent K+ channel expression i during postnatal development. J Neurosci. 1998 Jan 1;18(1):16-25. PMID: 9412482 [PubMed - indexed for MEDLINE]	n rat cerebellum
□ 84	Easton RM, Deckwerth TL, Parsadanian AS, Johnson EM Jr.	Related Articles, Links
	Analysis of the mechanism of loss of trophic factor deposit with neuronal maturation: a phenotype indistinguishable deletion. J Neurosci. 1997 Dec 15;17(24):9656-66. PMID: 9391020 [PubMed - indexed for MEDLINE]	
□ 85	Yuan A, Mills RG, Bamburg JR, Bray JJ.	Related Articles, Links
	Axonal transport and distribution of cyclophilin A in ch Brain Res. 1997 Oct 17;771(2):203-12. PMID: 9401740 [PubMed - indexed for MEDLINE]	icken neurones.
□ 86	Gold BG, Zeleny-Pooley M, Wang MS, Chaturvedi P, Armistead DM	Related Articles, Links
	A nonimmunosuppressant FKBP-12 ligand increases ne Exp Neurol. 1997 Oct;147(2):269-78. PMID: 9344552 [PubMed - indexed for MEDLINE]	rve regeneration.
□ 87	Blumenthal EM, Conroy WG, Romano SJ, Kassner PD, Berg DK.	Related Articles, Links
	Detection of functional nicotinic receptors blocked by a on PC12 cells and dependence of their expression on poevents. J Neurosci. 1997 Aug 15;17(16):6094-104.	
,	PMID: 9236221 [PubMed - indexed for MEDLINE]	
I! 88:	Eastwood SL, Heffeman J, Harrison PJ. Chronic holomoridal transfer and differentially affects the	Related Articles, Links
	Chronic haloperidol treatment differentially affects the esynaptic and neuronal plasticity-associated genes. Mol Psychiatry. 1997 Jul;2(4):322-9. PMID: 9246673 [PubMed - indexed for MEDLINE]	expression of
□ 89:	Gao Y, He JR, Kapcala LP	Related Articles, Links
	Estrogen inhibits hypothalamic pro-opiomelanocortin generated hypothalamic neuronal cultures	ene expression in

cb

h g

e e

e fcg

Brain Res Mol Brain Res. 1997 May;45(2):340-4. PMID: 9149111 [PubMed - indexed for MEDLINE] 130: Glazner GW, Yadav K, Fitzgerald S, Coven E, Brenneman DE, Related Articles, Links Nelson PG Cholinergic stimulation increases thrombin activity and gene expression in cultured mouse muscle. Brain Res Dev Brain Res. 1997 Apr 18;99(2):148-54. PMID: 9125468 [PubMed - indexed for MEDLINE] 91: Steiner JP, Connolly MA, Valentine HL, Hamilton GS, Dawson Related Articles, Links TM, Hester L. Snyder SH. Neurotrophic actions of nonimmunosuppressive analogues of = immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nat Med. 1997 Apr;3(4):421-8. PMID: 9095176 [PubMed - indexed for MEDLINE] 12 92: Steiner JP, Hamilton GS, Ross DT, Valentine HL, Guo H. Related Articles, Links Connolly MA, Liang S, Ramsey C, Li JH, Huang W, Howorth P, Soni R, Fuller M, Sauer H, Nowotnik AC, Suzdak PD Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2019-24. PMID: 9050897 [PubMed - indexed for MEDLINE] 93: Kuchel GA, Rowe W, Meaney MJ, Richard C. Related Articles, Links Neurotrophin receptor and tyrosine hydroxylase gene expression in aged sympathetic neurons. Neurobiol Aging. 1997 Jan-Feb; 18(1):67-79. PMID: 8983034 [PubMed - indexed for MEDLINE] 94: Evans J. Lillycrop KA. Related Articles, Links Serum growth factor regulation of the paired-box transcription factor Pax-3 in neuronal cells. Neurosci Lett. 1996 Dec 13;220(2):125-8. PMID: 8981489 [PubMed - indexed for MEDLINE] 95: Platt KP, Zwartjes RE, Bristow DR. Related Articles, Links The effect of GABA stimulation on GABAA receptor subunit protein and mRNA expression in rat cultured cerebellar granule cells. Br J Pharmacol. 1996 Dec;119(7):1393-400. PMID: 8968548 [PubMed - indexed for MEDLINE] 96: Yu R, Follesa P, Ticku MK. Related Articles, Links Down-regulation of the GABA receptor subunits mRNA levels in mammalian cultured cortical neurons following chronic neurosteroid Brain Res Mol Brain Res. 1996 Sep 5;41(1-2):163-8. PMID: 8883948 [PubMed - indexed for MEDLINE] 97: Goldner FM. Patrick JW. Related Articles, Links Neuronal localization of the cyclophilin A protein in the adult rat brain. J Comp Neurol. 1996 Aug 19;372(2):283-93. PMID: 8863131 [PubMed - indexed for MEDLINE] 98: Korneev S, Blackshaw SE, Kaiser K, Davies JA. Related Articles, Links cDNA libraries from identified neurons. Proc R Soc Lond B Biol Sci. 1996 Jan 22;263(1366):57-62. PMID: 8587897 [PubMed - indexed for MEDLINE]

b

99: Richtand NM, Kelsoe JR, Segal DS, Kuczenski R. Related Articles, Links Regional quantification of dopamine transporter mRNA in rat brain using a ribonuclease protection assay. Neurosci Lett. 1995 Nov 17;200(2):73-6. PMID: 8614566 [PubMed - indexed for MEDLINE] 100: Pak WL. Related Articles, Links Drosophila in vision research. The Friedenwald Lecture. Invest Ophthalmol Vis Sci. 1995 Nov;36(12):2340-57. Review. PMID: 7591624 [PubMed - indexed for MEDLINE] 101: Ferreira PA, Hom JT, Pak WL. Related Articles, Links Retina-specifically expressed novel subtypes of bovine cyclophilin. J Biol Chem. 1995 Sep 29;270(39):23179-88. PMID: 7559465 [PubMed - indexed for MEDLINE] 102: Perrot-Applanat M, Cibert C, Geraud G, Renoir JM, Baulieu EE. Related Articles, Links The 59 kDa FK 506-binding protein, a 90 kDa heat shock protein binding immunophilin (FKBP59-HBI), is associated with the nucleus, the cytoskeleton and mitotic apparatus. J Cell Sci. 1995 May; 108 (Pt 5):2037-51. PMID: 7544801 [PubMed - indexed for MEDLINE] 103: Lyons WE, Steiner JP, Snyder SH, Dawson TM. Related Articles, Links Neuronal regeneration enhances the expression of the immunophilin FKBP-12. J Neurosci. 1995 Apr;15(4):2985-94. PMID: 7536825 [PubMed - indexed for MEDLINE] 104: Coghlan VM, Perrino BA, Howard M, Langeberg LK, Hicks JB. Related Articles, Links Gallatin WM, Scott JD. Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. Science. 1995 Jan 6;267(5194):108-11. PMID: 7528941 [PubMed - indexed for MEDLINE] 105: Lyons WE, George EB, Dawson TM, Steiner JP, Snyder SH. Related Articles, Links Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3191-5. PMID: 7512727 [PubMed - indexed for MEDLINE] 106: Hu M. Whiting Theobald NL, Gardner PD. Related Articles, Links Nerve growth factor increases the transcriptional activity of the rat neuronal nicotinic acetylcholine receptor beta 4 subunit promoter in transfected PC12 cells. J Neurochem. 1994 Jan;62(1):392-5. PMID: 7505316 [PubMed - indexed for MEDLINE] 107: Sheng HZ, Fields RD, Nelson PG. Related Articles, Links Specific regulation of immediate early genes by patterned neuronal H activity. J Neurosci Res. 1993 Aug 1;35(5):459-67. PMID: 8377220 [PubMed - indexed for MEDLINE] 108; Kuchel GA, Hellendall R, Blum M. Related Articles, Links

Transynaptic regulation of low-affinity p75 nerve growth factor receptor


	sprouting. Exp Neurol. 1992 Oct;118(1):73-84. PMID: 1397179 [PubMed - indexed for MEDLINE]	terai neuronai
□ 109:	Rasmussen DD, Jakubowski M, Allen DL, Roberts JL.	Related Articles, Links
	Positive correlation between proopiomelanocortin and a hydroxylase mRNA levels in the mediobasohypothalan ovariectomized rats: response to estradiol replacement a Neuroendocrinology. 1992 Sep;56(3):285-94. PMID: 1359437 [PubMed - indexed for MEDLINE]	nus of
□ 110:	Nguyen TV, Kosofsky BE, Birnbaum R, Cohen BM, Hyman SE.	Related Articles, Links
	Differential expression of c-fos and zif268 in rat striatu haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci U S A. 1992 May 15;89(10):4270-4. PMID: 1374894 [PubMed - indexed for MEDLINE]	m after
□111:	Colley NJ, Baker EK, Stamnes MA, Zuker CS.	Related Articles, Links
	The cyclophilin homolog ninaA is required in the secre Cell. 1991 Oct 18;67(2):255-63. PMID: 1913822 [PubMed - indexed for MEDLINE]	tory pathway.
□ 112:	Pak WL.	Related Articles, Links
2000 2000 2000 2000 2000 2000	Molecular genetic studies of photoreceptor function usi mutants. Prog Clin Biol Res. 1991;362:1-32. Review. No abstract available PMID: 1825884 [PubMed - indexed for MEDLINE]	
□ 113:	Shieh BH, Stamnes MA, Seavello S, Harris GL, Zuker CS.	Related Articles, Links
	The ninaA gene required for visual transduction in Drophomologue of cyclosporin A-binding protein. Nature. 1989 Mar 2;338(6210):67-70. PMID: 2493138 [PubMed - indexed for MEDLINE]	sophila encodes a
Display		end to Text
	Items 1-113 of 113	One page.

Write to the Help Desk
NCB! | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Mar 15 2004 17:59:45







Nucleotide Entrez Published Protein Genome Structure OMIM PMC Journals Boo: Search PubMed for neuron AND transplantation AND FK506 Gol Clear Limits Preview/Index History Clipboard Details About Entrez Summary Show: 500 * Display Send to Text Items 1-12 of 12 One page. **Text Version** 1: Gillon RS, Cui Q, Dunlop SA, Harvey AR. Related Articles, Links Entrez PubMed Effects of immunosuppression on regrowth of adult rat retinal ganglion cell Overview axons into peripheral nerve allografts. Help | FAQ Tutorial J Neurosci Res. 2003 Nov 15;74(4):524-32. New/Noteworthy PMID: 14598296 [PubMed - indexed for MEDLINE] E-Utilities 2: Udina E, Voda J, Gold BG, Navarro X. Related Articles, Links PubMed Services Comparative dose-dependence study of FK506 on transected mouse sciatic Journals Database nerve repaired by allograft or xenograft. MeSH Database Single Citation Matcher J Peripher Nerv Syst. 2003 Sep;8(3):145-54. Batch Citation Matcher PMID: 12904235 [PubMed - indexed for MEDLINE] Clinical Queries LinkOut 3: Okajima S. Hojo T. Tamai K, Takai S, Hirasawa Y. Related Articles, Links Cubby Histological and electrophysiological analysis of the peripheral nerve allografts using an immunosuppressive agent. Related Resources Order Documents Microsc Res Tech. 2002 Jul 1;58(1):52-8. **NLM Gateway** PMID: 12112423 [PubMed - indexed for MEDLINE] TOXNET Consumer Health 4: Grand AG, Myckatyn TM, Mackinnon SE, Hunter DA. Related Articles, Links Clinical Alerts ClinicalTrials.gov Axonal regeneration after cold preservation of nerve allografts and PubMed Central immunosuppression with tacrolimus in mice. J Neurosurg. 2002 May;96(5):924-32. Privacy Policy PMID: 12005401 [PubMed - indexed for MEDLINE] 5: Prast I, Carlsson PO, Jansson L, Mattsson G. Related Articles, Links Nerve cells in transplanted pancreatic islets: no effects of cyclosporin or tacrolimus on immediate neuronal survival. Ups J Med Sci. 2001;106(2):145-50. PMID: 11888070 [PubMed - indexed for MEDLINE] 6: Avramut M. Zeevi A. Achim CL. Related Articles, Links The immunosuppressant drug FK506 is a potent trophic agent for human fetal neurons. Brain Res Dev Brain Res. 2001 Dec 31;132(2):151-7. PMID: 11744119 [PubMed - indexed for MEDLINE] 7: Navarro X, Udina E, Ceballos D, Gold BG. Related Articles, Links Effects of FK506 on nerve regeneration and reinnervation after graft or tube repair of long nerve gaps. Muscle Nerve. 2001 Jul;24(7):905-15. PMID: 11410918 [PubMed - indexed for MEDLINE] 8: Castilho RF, Hausson O, Brundin P Related Articles, Links

h

cb

hg e e e fcg

embryonic dopamine neurons. Exp Neurol. 2000 Jul;164(1):94-101.

e ch

b e

FK506 and cyclosporin A enhance the survival of cultured and grafted rat

	PMID: 10877919 [PubMed - indexed for MEDLINE]	
□9:	Wang MS, Gold BG.	Related Articles, Links
	FK506 increases the regeneration of spinal cord axons in peripheral nerve autograft. J Spinal Cord Med. 1999 Winter;22(4):287-96. PMID: 10751133 [PubMed - indexed for MEDLINE]	a predegenerated
10	: Fansa H, Keilhoff G, Horn T, Altmann S, Wolf G, Schneider W.	Related Articles, Links
	[Stimulation of Schwann cell growth and axon regeneral nerves by the immunosuppressive drug FK 506] Handchir Mikrochir Plast Chir. 1999 Sep;31(5):323-9; discussion 3 PMID: 10566134 [PubMed - indexed for MEDLINE]	
11	: Sugitani A, Reynolds JC, Nomoto M, Starzl TE, Todo S.	Related Articles, Links
	Intestinal neurons in acute and chronic rejection after so transplantation in dogs. Transplant Proc. 1996 Oct;28(5):2543. No abstract available. PMID: 8907941 [PubMed - indexed for MEDLINE]	nall bowel
□ 12	: Yamamoto S, Nagaki Y, Fukuo Y, Hirata H.	Related Articles, Links
	Cross-species transplantation of photoreceptors with tac (FK506) treatment. Jpn J Ophthalmol. 1995;39(4):334-9. PMID: 8926639 [PubMed - indexed for MEDLINE]	rolimus hydrate
Displ	ay Summary Show: 500 Sort S	end to Text •
	Items 1-12 of 12	One page.

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Mar 15 2004 17:59:45

Related Articles, Links

b e








Enger Published Nucleofide Protein Genome OMIM FMC Journals Structure Boo! Search PubMed for neuron AND transplantation AND cyclosporin A Go Clear Limits Preview/Index Clipboard Details History About Entrez Display Summary Show: 500 ▼ Send to Text Items 1-62 of 62 One page. Text Version 1: Tobias CA, Shumsky JS, Shibata M, Tuszvnski MH, Fischer I. Related Articles, Links Tessler A, Murray M. Entrez PubMed Overview Delayed grafting of BDNF and NT-3 producing fibroblasts into the injured Help | FAQ spinal cord stimulates sprouting, partially rescues axotomized red nucleus Tutorial neurons from loss and atrophy, and provides limited regeneration. New/Noteworthy E-Utilities Exp Neurol. 2003 Nov;184(1):97-113. PMID: 14637084 [PubMed - indexed for MEDLINE] PubMed Services 2: Miyoshi K, Sakagami K, Orita K. Related Articles, Links Journals Database MeSH Database Ex vivo perfusion of canine pancreaticoduodenal allografts using class-II-Single Citation Matcher Batch Citation Matcher specific monoclonal antibody delays the onset of acute rejection. Clinical Queries Transpl Int. 1992;5 Suppl 1:S516-20. LinkOut PMID: 14621864 [PubMed - indexed for MEDLINE] Cubby 3: Gillon RS, Cui Q, Dunlop SA, Harvey AR. Related Articles, Links Related Resources Effects of immunosuppression on regrowth of adult rat retinal ganglion cell Order Documents axons into peripheral nerve allografts. **NLM Gateway** TOXNET J Neurosci Res. 2003 Nov 15;74(4):524-32. Consumer Health PMID: 14598296 [PubMed - indexed for MEDLINE] Clinical Alerts ClinicalTrials.gov 4: Choi D, Raisman G. Related Articles, Links PubMed Central Immune rejection of a facial nerve xenograft does not prevent regeneration Privacy Policy and the return of function; an experimental study. Neuroscience. 2003;121(2):501-7. PMID: 14522009 [PubMed - indexed for MEDLINE] 5: Armstrong RJ, Tyers P, Jain M, Richards A, Dunnett SB, Rosser Related Articles, Links AE, Barker RA. Transplantation of expanded neural precursor cells from the developing pig ventral mesencephalon in a rat model of Parkinson's disease. Exp Brain Res. 2003 Jul;151(2):204-17. Epub 2003 Jun 03. PMID: 12783147 [PubMed - indexed for MEDLINE] 6: Modo M, Rezaie P, Heuschling P, Patel S, Male DK, Hodges H. Related Articles, Links Transplantation of neural stem cells in a rat model of stroke: assessment of short-term graft survival and acute host immunological response. Brain Res. 2002 Dec 20;958(1):70-82. PMID: 12468031 [PubMed - indexed for MEDLINE] 7: Armstrong RJ, Hurelbrink CB, Tyers P, Ratcliffe EL, Richards A, Related Articles, Links Dunnett SB, Rosser AE, Barker RA. The potential for circuit reconstruction by expanded neural precursor cells explored through porcine xenografts in a rat model of Parkinson's disease. Exp Neurol. 2002 May;175(1):98-111. PMID: 12009763 [PubMed - indexed for MEDLINE]

h cb hg e e e fcg e ch

8: Prast I, Carlsson PO, Jansson L, Mattsson G.




h cb hg e e e fcg e ch b e

h g

e e

fcg



e ch

cb

h g

e e

Related Articles, Links

b e

e ch

dystrophic RCS rats. Exp Neurol. 1997 Jul;146(1):1-9. PMID: 9225732 [PubMed - indexed for MEDLINE] 27: Midha R, Munro CA, Mackinnon SE, Ang LC. Related Articles, Links Motor and sensory specificity of host nerve axons influence nerve allograft rejection. J Neuropathol Exp Neurol. 1997 Apr;56(4):421-34. PMID: 9100673 [PubMed - indexed for MEDLINE] 28: Rundqvist B, Casale R, Bergmann-Sverrisdottir Y, Friberg P, Related Articles, Links Mortara A, Elam M. Rapid fall in sympathetic nerve hyperactivity in patients with heart failure after cardiac transplantation. J Card Fail. 1997 Mar;3(1):21-6. PMID: 9110252 [PubMed - indexed for MEDLINE] 29: Strasberg SR, Hertl MC, Mackinnon SE, Lee CK, Watanabe O, Related Articles, Links Tarasidis G, Hunter DA, Wong PY. Peripheral nerve allograft preservation improves regeneration and decreases systemic cyclosporin A requirements. Exp Neurol. 1996 Jun;139(2):306-16. PMID: 8654533 [PubMed - indexed for MEDLINE] 30: Chen XL, Roisen FJ, Gupta M. Related Articles, Links The effect of prior in vitro exposure of donor cells to trophic factors in neurotransplantation. Exp Neurol. 1996 Mar;138(1):64-72. PMID: 8593897 [PubMed - indexed for MEDLINE] 131: Little CW, Castillo B, DiLoreto DA, Cox C, Wyatt J, del Cerro C, Related Articles, Links del Cerro M. Transplantation of human fetal retinal pigment epithelium rescues photoreceptor cells from degeneration in the Royal College of Surgeons rat Invest Ophthalmol Vis Sci. 1996 Jan;37(1):204-11. PMID: 8550325 [PubMed - indexed for MEDLINE] 32: Garcia AR, Deacon TW, Dinsmore J, Isacson O. Related Articles, Links Extensive axonal and glial fiber growth from fetal porcine cortical xenografts in the adult rat cortex. Cell Transplant. 1995 Sep-Oct;4(5):515-27. PMID: 8520835 [PubMed - indexed for MEDLINE] 33: Zalewski AA, Azzam NA, Azzam RN. Related Articles, Links The loss of regenerated host axons in nerve allografts after stopping immunosuppression with cyclosporin A is related to immune effects on allogeneic Schwann cells. Exp Neurol. 1995 Jun; 133(2):189-97. PMID: 7649224 [PubMed - indexed for MEDLINE] 34: Pakzaban P, Deacon TW, Burns LH, Dinsmore J, Isacson O. Related Articles, Links A novel mode of immunoprotection of neural xenotransplants: masking of donor major histocompatibility complex class I enhances transplant survival in the central nervous system. Neuroscience. 1995 Apr;65(4):983-96. Erratum in: Neuroscience 1995 Jun;66(3):761. PMID: 7617173 [PubMed - indexed for MEDLINE]

35: Midha R, Mackinnon SE, Becker LE.

fcg

ch

h g

e fcg

e ch

b e

The fate of Schwann cells in peripheral nerve allografts. J Neuropathol Exp Neurol. 1994 May; 53(3):316-22. PMID: 8176414 [PubMed - indexed for MEDLINE] 36: Archer DR, Leven S, Duncan ID. Related Articles, Links Myelination by cryopreserved xenografts and allografts in the myelindeficient rat. Exp Neurol. 1994 Feb;125(2):268-77. PMID: 8313941 [PubMed - indexed for MEDLINE] 37: Rosenbluth J, Liu Z, Guo D, Schiff R. Related Articles, Links Myelin formation by mouse glia in myelin-deficient rats treated with cyclosporine. J Neurocytol. 1993 Nov;22(11):967-77. PMID: 8301327 [PubMed - indexed for MEDLINE] 38: Ishida O, Daves J, Tsai TM, Breidenbach WC, Firrell J. Related Articles, Links Regeneration following rejection of peripheral nerve allografts of rats on withdrawal of cyclosporine. Plast Reconstr Surg. 1993 Oct;92(5):916-26. PMID: 8415974 [PubMed - indexed for MEDLINE] 139: Trojanowski JQ, Mantione JR, Lee JH, Seid DP, You T, Inge LJ. Related Articles, Links Lee VM. Neurons derived from a human teratocarcinoma cell line establish molecular and structural polarity following transplantation into the rodent brain. Exp Neurol. 1993 Aug;122(2):283-94. PMID: 8405265 [PubMed - indexed for MEDLINE] 1 40: Zalewski AA, Fahy GM, Azzam NA, Azzam RN. Related Articles, Links The fate of cryopreserved nerve isografts and allografts in normal and immunosuppressed rats. J Comp Neurol. 1993 May 1;331(1):134-47. PMID: 8320346 [PubMed - indexed for MEDLINE] 41: Midha R, Evans PJ, Mackinnon SE, Wade JA. Related Articles, Links Temporary immunosuppression for peripheral nerve allografts. Transplant Proc. 1993 Feb;25(1 Pt 1):532-6. No abstract available. PMID: 8438403 [PubMed - indexed for MEDLINE] 1 42: Bain JR, Mackinnon SE, Hudson AR, Wade J, Evans P, Makino A, Related Articles, Links Hunter D. The peripheral nerve allograft in the primate immunosuppressed with Cyclosporin A: I. Histologic and electrophysiologic assessment. Plast Reconstr Surg. 1992 Dec;90(6):1036-46. PMID: 1448498 [PubMed - indexed for MEDLINE] 13: Ansselin AD, Pollard JD, Davey DF. Related Articles, Links Immunosuppression in nerve allografting: is it desirable? J Neurol Sci. 1992 Oct; 112(1-2):160-9. PMID: 1469428 [PubMed - indexed for MEDLINE] 1. 44: Wictorin K, Brundin P, Sauer H, Lindvall O, Bjorklund A. Related Articles, Links Long distance directed axonal growth from human dopaminergic mesencephalic neuroblasts implanted along the nigrostriatal pathway in 6hydroxydopamine lesioned adult rats. J Comp Neurol. 1992 Sep 22;323(4):475-94.

PMID: 1358925 [PubMed - indexed for MEDLINE] 45: Ortega JD, Sagen J, Pappas GD. Related Articles, Links Survival and integration of bovine chromaffin cells transplanted into rat central nervous system without exogenous trophic factors. J Comp Neurol. 1992 Sep 1;323(1):13-24. PMID: 1430313 [PubMed - indexed for MEDLINE] 46: Kopyov OV, Polzik ES, Jacques DB, Kimble HJ, Rand RW, Craft Related Articles, Links Effect of coherent blue light on fetal pig xenotransplants. Transplant Proc. 1992 Apr;24(2):549-50. No abstract available. PMID: 1566425 [PubMed - indexed for MEDLINE] 47: Mackinnon SE, Midha R, Bain J, Hunter D, Wade J. Related Articles, Links An assessment of regeneration across peripheral nerve allografts in rats receiving short courses of cyclosporin A immunosuppression. Neuroscience. 1992;46(3):585-93. PMID: 1545911 [PubMed - indexed for MEDLINE] 48: Gouras P, Lopez R, Brittis M, Kjeldbye H. Related Articles, Links The ultrastructure of transplanted rabbit retinal epithelium. Graefes Arch Clin Exp Ophthalmol. 1992;230(5):468-75. PMID: 1521816 [PubMed - indexed for MEDLINE] 1 49. Ehinger B, Bergstrom A, Seiler M, Aramant RB, Zucker CL. Related Articles, Links Gustavii B, Adolph AR Ultrastructure of human retinal cell transplants with long survival times in Exp Eye Res. 1991 Oct;53(4):447-60. PMID: 1936181 [PubMed - indexed for MEDLINE] 50: Maeda N, Ishiguro N, Inoue G, Miura T, Sugimura K. Related Articles, Links Nerve regeneration in rat composite-tissue allografts. J Reconstr Microsurg. 1991 Oct;7(4):297-301; discussion 303. PMID: 1753370 [PubMed - indexed for MEDLINE] 51: Stromberg I, van Horne C, Bygdeman M, Weiner N, Gerhardt GA. Related Articles, Links Function of intraventricular human mesencephalic xenografts in immunosuppressed rats: an electrophysiological and neurochemical analysis. Exp Neurol. 1991 May;112(2):140-52. PMID: 1674693 [PubMed - indexed for MEDLINE] 52: Crang AJ, Blakemore WF. Related Articles, Links Remyelination of demyelinated rat axons by transplanted mouse = oligodendrocytes. Glia. 1991;4(3):305-13. PMID: 1832658 [PubMed - indexed for MEDLINE] 53: Easterling KJ, Trumble TE. Related Articles, Links The treatment of peripheral nerve injuries using irradiated allografts and temporary host immunosuppression (in a rat model). J Reconstr Microsurg. 1990 Oct;6(4):301-7; discussion 309-10. PMID: 2269950 [PubMed - indexed for MEDLINE] 54: Becker M, Schaller E, Walter GF, Berger A. Related Articles, Links

h cb hg e e e fcg

e ch

Adverse effects of cyclosporin A with special reference to the peripheral

	nervous system] Handchir Mikrochir Plast Chir. 1990 Jul;22(4):196-202. German. PMID: 2391038 [PubMed - indexed for MEDLINE]	
□ 55:	Isacson O, Riche D, Hantraye P, Sofroniew MV, Maziere M.	Related Articles, Links
	A primate model of Huntington's disease: cross-species striatal precursor cells to the excitotoxically lesioned bal putamen. Exp Brain Res. 1989;75(1):213-20. PMID: 2523313 [PubMed - indexed for MEDLINE]	
□ 56:	Howard MA 3rd, Dacey RG Jr. Winn HR.	Related Articles, Links
	Brain xenografts: the effect of cyclosporin A on graft su J Neurosurg. 1988 Jul;69(1):121-6. PMID: 3379465 [PubMed - indexed for MEDLINE]	
□ 57:	Brundin P. Strecker RE. Widner H. Clarke DJ. Nilsson OG, Astedt B. Lindvall O. Bjorklund A.	Related Articles, Links
	Human fetal dopamine neurons grafted in a rat model of disease: immunological aspects, spontaneous and drug-i and dopamine release. Exp Brain Res. 1988;70(1):192-208. PMID: 3402564 [PubMed - indexed for MEDLINE]	
□ 58:	Finsen B. Poulsen PH. Zimmer J.	Related Articles, Links
	Xenografting of fetal mouse hippocampal tissue to the b effects of cyclosporin A treatment. Exp Brain Res. 1988;70(1):117-33. PMID: 3402559 [PubMed - indexed for MEDLINE]	rain of adult rats:
□ 59:	Schaller E. Mailander P. Becker M. Walter GF, Berger A.	Related Articles, Links
	[Nerve regeneration in autologous and allogeneic transp nerve of the rat with and without immunosuppression by Handchir Mikrochir Plast Chir. 1988 Jan;20(1):7-10. German. PMID: 3258265 [PubMed - indexed for MEDLINE]	
□ 60:	Inoue H, Kohsaka S, Yoshida K, Otani M, Toya S, Tsukada Y.	Related Articles, Links
	Immunohistochemical studies on mouse cerebral cortex third ventricle of rats treated with cyclosporin A. Neurosci Lett. 1985 Jun 24;57(3):289-94. PMID: 4034098 [PubMed - indexed for MEDLINE]	grafted into the
□ 61:	Zalewski AA, Gulati AK.	Related Articles, Links
	Rejection of nerve allografts after cessation of immunos cyclosporin A. Transplantation. 1981 Jan;31(1):88-9. No abstract available. PMID: 7233527 [PubMed - indexed for MEDLINE]	uppression with
□ 62:	Zalewski A.A., Gulati AK.	Related Articles, Links
	Survival of nerve and Schwann cells in allografts after cetreatment. Exp Neurol. 1980 Nov;70(2):219-25. No abstract available. PMID: 6968689 [PubMed - indexed for MEDLINE]	yclosporin A
Displa	Summary Show: 500 Sort Sort	end to Text 🗻
	Items 1-62 of 62	One page

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Freedom of Information Act | Disclaimer

Mar 15 2004 17:59:45







Entrez

PubMed

Nucleotide

Protein

Genome

Structure

History

OMIM

FMC

366

Search PubMed

for neuron AND transplantation AND rapamycin Limits Preview/Index

Go

Clear

Clipboard

Details

Journals

About Entrez

No items found.

Text Version

Entrez PubMed Overview Help | FAQ Tutoria! New/Noteworthy E-Utilities

PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries LinkOut Cubby

Related Resources Order Documents **NLM Gateway** TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

Privacy Policy

Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Freedom of Information Act | Disclaimer

Mar 15 2004 17:59:45

cb

h g

e e







PubMed Nucleotide Protein Genome Structure OMIM FMC Journals Boo! Search PubMed Gol Clear for cell transplantation AND rapamycin Limits Preview/Index History Clipboard Details About Entrez Show: 500 Display Send to Summary Text Items 1-88 of 88 One page. **Text Version** 1: Barshes NR. Goodpastor SE, Goss JA. Related Articles, Links Entrez PubMed Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant Overview Help | FAQ recipient. Tutorial Transplantation. 2003 Dec 15;76(11):1649-50. No abstract available. Erratum in: New/Noteworthy Transplantation. 2004 Jan 27;77(2):328. E-Utilities PMID: 14702546 [PubMed - indexed for MEDLINE] 12: Desai NM, Goss JA, Deng S, Wolf BA, Markmann E, Palanjian M, Related Articles, Links PubMed Services Shock AP, Feliciano S, Brunicardi FC, Barker CF, Naji A, Journals Database Markmann JF MeSH Database Single Citation Matcher Elevated portal vein drug levels of sirolimus and tacrolimus in islet Batch Citation Matcher transplant recipients: local immunosuppression or islet toxicity? Clinical Queries LinkOut Transplantation. 2003 Dec 15,76(11):1623-5. Cubby PMID: 14702535 [PubMed - indexed for MEDLINE] 1. 3: Lee I, Wang L, Wells AD, Ye Q. Han R, Dorf ME, Kuziel WA, Related Articles, Links Related Resources Rollins BJ, Chen L, Hancock WW. Order Documents **NLM Gateway** Blocking the monocyte chemoattractant protein-1/CCR2 chemokine TOXNET pathway induces permanent survival of islet allografts through a Consumer Health programmed death-1 ligand-1-dependent mechanism. Clinical Alerts ClinicalTrials.gov J Immunol. 2003 Dec 15;171(12):6929-35. PubMed Central PMID: 14662900 [PubMed - indexed for MEDLINE] 4: Bucher P. Mathe Z, Bosco D, Andres A, Buhler LH, Morel P, Privacy Policy Related Articles, Links Berney T. Islet of Langerhans transplantation for the treatment of type 1 diabetes. Swiss Surg. 2003;9(5):242-6. PMID: 14601328 [PubMed - indexed for MEDLINE] 5: Toso C. Morel P. Bucher P. Mathe Z. Demuylder-Mischler S. Bosco Related Articles, Links D, Berney T, Oberholzer J, Shapiro J, Oberholzer J, Philippe J. Insulin independence after conversion to tacrolimus and sirolimus-based immunosuppression in islet-kidney recipients. Transplantation. 2003 Oct 15;76(7):1133-4. No abstract available. PMID: 14557767 [PubMed - indexed for MEDLINE] 6: Sillaber C, Mayerhofer M, Agis H, Sagaster V, Mannhalter C, Sperr Related Articles, Links WR, Geissler K, Valent P. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. Wien Klin Wochenschr. 2003 Aug 14;115(13-14):485-504. Review. PMID: 13677268 [PubMed - indexed for MEDLINE] 7: Hirshberg B. Preston EH, Xu H, Tal MG, Neeman Z, Bunnell D, Related Articles, Links Soleimanpour S, Hale DA, Kirk AD, Harlan DM. Rabbit antithymocyte globulin induction and sirolimus monotherapy supports prolonged islet allograft function in a nonhuman primate islet transplantation model.

Transplantation. 2003 Jul 15;76(1):55-60.

e ch

b e

fcg

	PMID: 12865786 [PubMed - indexed for MEDLINE]	
□ 8:	Molano RD, Pileggi A, Berney T, Poggioli R, Zahr E, Oliver R, Malek TR, Ricordi C, Inverardi L.	Related Articles, Links
	Long-term islet allograft survival in nonobese diabetic m tacrolimus, rapamycin, and anti-interleukin-2 antibody. Transplantation. 2003 Jun 15;75(11):1812-9. PMID: 12811239 [PubMed - indexed for MEDLINE]	ice treated with
□ 9:	Majewski M, Korecka M, Joergensen J, Fields L, Kossev P, Schuler W, Shaw L, Wasik MA	Related Articles, Links
	Immunosuppressive TOR kinase inhibitor everolimus (R growth of cells derived from posttransplant lymphoprolif allograft-protecting doses. Transplantation. 2003 May 27;75(10):1710-7. PMID: 12777861 [PubMed - indexed for MEDLINE]	
□ 10	: Bachar-Lustig E, Reich-Zeliger S, Reisner Y.	Related Articles, Links
	Anti-third-party veto CTLs overcome rejection of hema synergism with rapamycin and BM cell dose. Blood. 2003 Sep 15;102(6):1943-50. Epub 2003 May 29. PMID: 12775573 [PubMed - indexed for MEDLINE]	topoietic allografts:
□11	: Hering BJ, Wijkstrom M.	Related Articles, Links
	Sirolimus and islet transplants. Transplant Proc. 2003 May;35(3 Suppl):187S-190S. Review. No a PMID: 12742495 [PubMed - indexed for MEDLINE]	bstract available.
□ 12	: Sindhi R.	Related Articles, Links
	Sirolimus in pediatric transplant recipients. Transplant Proc. 2003 May;35(3 Suppl):113S-114S. PMID: 12742479 [PubMed - indexed for MEDLINE]	
□ 13	Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, Hochberg EP, Wu CJ, Alyea EP, Soiffer RJ.	Related Articles, Links
	Sirolimus, tacrolimus, and low-dose methotrexate for gradisease prophylaxis in mismatched related donor or unruransplantation. Blood. 2003 Sep 1;102(5):1601-5. Epub 2003 May 01. PMID: 12730113 [PubMed - indexed for MEDLINE]	raft-versus-host elated donor
□14	Guo Z, Wu T, Sozen H, Pan Y, Heuss N, Kalscheuer H, Sutherland DE, Blazar BR, Hering BJ	Related Articles, Links
	A substantial level of donor hematopoietic chimerism is donor-specific islet grafts in diabetic NOD mice. Transplantation. 2003 Apr 15;75(7):909-15. PMID: 12698073 [PubMed - indexed for MEDLINE]	required to protect
15	Carpenter PA, Sanders JE.	Related Articles, Links
	Steroid-refractory graft-vshost disease: past, present at Pediatr Transplant. 2003;7 Suppl 3:19-31. Review. PMID: 12603689 [PubMed - indexed for MEDLINE]	nd future.
□ 16	Winter WE, Schatz D.	Related Articles, Links
	Prevention strategies for type 1 diabetes mellitus: currer directions. BioDrugs. 2003;17(1):39-64. Review. PMID: 12534319 [PubMed - indexed for MEDLINE]	nt status and future

 $h \hspace{1cm} cb \hspace{1cm} h \hspace{1cm} g \hspace{1cm} e \hspace{1cm} e \hspace{1cm} e \hspace{1cm} ch \hspace{1cm} b \hspace{1cm} e$

h g


e fcg

e ch

b e

cb

		8	
□17:	Hirshberg B, Mog S, Patterson N, Leconte J, Harlan DM.	Related Articles, Links	
	Histopathological study of intrahepatic islets transplanted primate model using edmonton protocol immunosuppred J Clin Endocrinol Metab. 2002 Dec;87(12):5424-9. PMID: 12466330 [PubMed - indexed for MEDLINE]		
□ 18	Blaha P, Bigenzahn S, Kopore Z, Schmid M, Langer F, Selzer E, Bergmeister H, Wrba F, Kurtz J, Kiss C, Roth E, Muchlbacher F, Sykes M, Wekerle T.	Related Articles, Links	
	The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood. 2003 Apr 1;101(7):2886-93. Epub 2002 Nov 14. Erratum in: Blood. 2003 Sep 15;102(6):1950. PMID: 12433677 [PubMed - indexed for MEDLINE]		
□ 19	Taylor PA, Lees CJ, Wilson JM, Ehrhardt MJ, Campbell MT, Noelle RJ, Blazar BR.	Related Articles, Links	
	Combined effects of calcineurin inhibitors or sirolimus mAb on alloengraftment under nonmyeloablative condit Blood. 2002 Nov 1;100(9):3400-7. PMID: 12384443 [PubMed - indexed for MEDLINE]		
□ 20	Hale DA, Gottschalk R, Umemura A, Maki T, Monaco AP.	Related Articles, Links	
	Immunologic mechanisms in tolerance produced in mice nonradiation-based lymphoablation and donor-specific transplantation. 2002 Aug 27;74(4):477-84. PMID: 12352905 [PubMed - indexed for MEDLINE]		
□ 21	Wu T, Levay-Young B, Heuss N, Sozen H, Kirchhof N, Sutherland DE, Hering B, Guo Z.	Related Articles, Links	
	Inducing tolerance to MHC-matched allogeneic islet gra NOD mice by simultaneous islet and bone marrow trans nonirradiative and nonmyeloablative conditioning thera Transplantation. 2002 Jul 15;74(1):22-7. PMID: 12134094 [PubMed - indexed for MEDLINE]	plantation under	
□ 22	Gorczynski RM, Hu J, Chen Z, Kai Y, Lei J.	Related Articles, Links	
	A CD200FC immunoadhesin prolongs rat islet xenograf Transplantation. 2002 Jun 27;73(12):1948-53. PMID: 12131694 [PubMed - indexed for MEDLINE]	t survival in mice.	
□ 23	Wu T, Sozen H, Luo B, Heuss N, Kalscheuer H, Lan P, Sutherland DE, Hering BJ, Guo Z.	Related Articles, Links	
	Rapamycin and T cell costimulatory blockade as post-tr promote fully MHC-mismatched allogeneic bone marro under irradiation-free conditioning therapy. Bone Marrow Transplant. 2002 Jun;29(12):949-56. PMID: 12098061 [PubMed - indexed for MEDLINE]		
□ 24	Hirshberg B, Montgomery S, Wysoki MG, Xu H, Tadaki D, Lee J, Hines K, Gaglia J, Patterson N. Leconte J, Hale D, Chang R, Kirk AD, Harlan DM.	Related Articles, Links	
	Pancreatic islet transplantation using the nonhuman print predicts that the portal vein is superior to the celiac arterinfusion site. Diabetes. 2002 Jul;51(7):2135-40. PMID: 12086943 [PubMed - indexed for MEDLINE]		
□ 25	Shapiro AM, Suarez-Pinzon WL, Power R, Rabinovitch A.	Related Articles, Links	




b e

h cb hg e e e fcg e ch


ch

h g



fcg

e ch



 $h \hspace{1cm} cb \hspace{1cm} h \hspace{1cm} g \hspace{1cm} e \hspace{1cm} e \hspace{1cm} fcg \hspace{1cm} e \hspace{1cm} ch \hspace{1cm} b \hspace{1cm} e$

complement component C6. Transplantation. 1998 Jun 27;65(12):1549-54. PMID: 9665069 [PubMed - indexed for MEDLINE] 54: Boyle MJ, Baghdassarian V, Stepkowski SM, Dumble LJ, Kahan Related Articles, Links Intrasplenic liver parenchymal cells in conjunction with low-dose rapamycin and cyclosporine induce a unique and specific prolongation of rat cardiac and small bowel allograft survival. Cell Transplant. 1998 May-Jun;7(3):247-56. PMID: 9647434 [PubMed - indexed for MEDLINE] 55: Luo H. Chen H. Qi S. Loh D. Daloze P. Veillette A. Xu D. Wu J. Related Articles, Links De novo-developed T cells have compromised response to existing alloantigens: using Ld-specific transgenic 2C T cells as tracers in a mouse heart transplantation model. J Immunol. 1998 Jul 1;161(1):73-82. PMID: 9647209 [PubMed - indexed for MEDLINE] 56: Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Vallera DA. Related Articles, Links Rapamycin inhibits the generation of graft-versus-host disease- and graftversus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. J Immunol. 1998 Jun 1;160(11):5355-65. PMID: 9605135 [PubMed - indexed for MEDLINE] 57: Hale DA, Gottschalk R, Maki T, Monaco AP. Related Articles, Links Determination of an improved sirolimus (rapamycin)-based regimen for induction of allograft tolerance in mice treated with antilymphocyte serum and donor-specific bone marrow. Transplantation. 1998 Feb 27;65(4):473-9. PMID: 9500619 [PubMed - indexed for MEDLINE] 58: Hale DA, Gottschalk R, Maki T, Monaco AP. Related Articles, Links Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival. Transplantation. 1997 Sep 27;64(6):897-900. PMID: 9326417 [PubMed - indexed for MEDLINE] 59: Wennberg L. Karlsson-Parra A. Sundberg B. Rafael E. Liu J. Zhu Related Articles, Links S, Groth CG, Korsgren O Efficacy of immunosuppressive drugs in islet xenotransplantation: leflunomide in combination with cyclosporine and mycophenolate mofetil prevents islet xenograft rejection in the pig-to-rat model. Transplantation. 1997 May 15;63(9):1234-42. PMID: 9158015 [PubMed - indexed for MEDLINE] 60: Homma M, Damoiseaux JG, van Breda Vriesman PJ. Related Articles, Links Differential effects of cyclosporin-A and rapamycin on in vivo thymocyte maturation. Transplant Proc. 1997 May;29(3):1743-4. No abstract available. PMID: 9142256 [PubMed - indexed for MEDLINE]

Superiority of sirolimus (rapamycin) over cyclosporine in augmenting allograft and xenograft survival in mice treated with antilymphocyte serum and donor-specific bone marrow.

[61: Hale DA, Gottschalk R, Fukuzaki T, Wood ML, Maki T, Monaco Related Articles, Links

AP.

cb

h g

e e

е


fcg

Transplantation. 1997 Feb 15;63(3):359-64. PMID: 9039923 [PubMed - indexed for MEDLINE] 62: Troppmann C. Papalois BE, Gruessner AC, Nakhleh RE, Related Articles, Links Gruessner RW FK 506 versus cyclosporine A for steroid-free synergistic combination therapy with rapamycin in a discordant large animal donor xenoislet transplant model. Transplant Proc. 1997 Feb-Mar;29(1-2):914-5. No abstract available. PMID: 9123585 [PubMed - indexed for MEDLINE] 63: Roy-Chaudhury P, Manfro RC, Steiger J, Nickerson PW, Tian Y, Related Articles, Links Zheng XX, Li YS, Strom TB. IL-2 and IL-4 double knock-out mice reject islet allografts: a role for novel T-cell growth factors? Transplant Proc. 1997 Feb-Mar;29(1-2):1083-4. No abstract available. PMID: 9123210 [PubMed - indexed for MEDLINE] 64: Troppmann C, Gruessner AC, Papalois BE, Nakhleh RE, Related Articles, Links Gruessner RW. Discordant xenoislets from a large animal donor undergo accelerated graft failure rather than hyperacute rejection: impact of immunosuppression, islet mass, and transplant site on early outcome. Surgery. 1997 Feb;121(2):194-205. PMID: 9037232 [PubMed - indexed for MEDLINE] 65: Hale DA, Gottschalk R, Fukuzaki T, Wood ML, Maki T, Monaco Related Articles, Links Extended skin allo- and xenograft survival in mice treated with rapamycin. antilymphocyte serum, and donor-specific bone marrow transfusion. Transplant Proc. 1996 Dec; 28(6): 3269. No abstract available. PMID: 8962269 [PubMed - indexed for MEDLINE] 66: Quesniaux V, Gibbons H, Maurer C, Stirnimann R, Wehrli S. Related Articles, Links Effects of rapamycin after syngeneic bone marrow transplantation in irradiated mice. Transplant Proc. 1996 Dec;28(6):3065-71. No abstract available. PMID: 8962188 [PubMed - indexed for MEDLINE] 67: Rivera VM, Clackson T, Natesan S, Pollock R, Amara JF, Keenan Related Articles, Links T. Magari SR, Phillips T, Courage NL, Cerasoli F Jr, Holt DA, Gilman M. A humanized system for pharmacologic control of gene expression. Nat Med. 1996 Sep;2(9):1028-32. PMID: 8782462 [PubMed - indexed for MEDLINE] 68: Sutherland DE. Related Articles, Links Pancreas and islet cell transplantation: now and then. Transplant Proc. 1996 Aug;28(4):2131-3. Review. PMID: 8769178 [PubMed - indexed for MEDLINE] 69: De Fazio SR, Plowey JM, Hartner WC, Gozzo JJ. Related Articles, Links Late adjunctive therapy with single doses of rapamycin in skin-allografted mice treated with antilymphocyte serum and donor bone marrow cells. Transpl Immunol. 1996 Jun;4(2):105-12. PMID: 8843586 [PubMed - indexed for MEDLINE] 70: Kneteman NM, Lakey JR, Wagner T, Finegood D. Related Articles, Links

The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft

b e

e ch



ch

h g

e e

e fcg

e ch

Transplant Proc. 1994 Jun;26(3):1128-9. No abstract available. PMID: 8029857 [PubMed - indexed for MEDLINE] 80: Blazar BR. Taylor PA, Sehgal SN, Vallera DA. Related Articles, Links Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow. Blood. 1994 Jan 15;83(2):600-9. Erratum in: Blood 1994 Jun 1;83(11):3424-5. PMID: 8286755 [PubMed - indexed for MEDLINE] 81: Yakimets WJ, Lakey JR, Yatscoff RW, Katyal D, Ao Z, Finegood Related Articles, Links DT, Rajotte RV, Kneteman NM Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses. Rapamycin efficacy is blood level related. Transplantation. 1993 Dec;56(6):1293-8. PMID: 8278991 [PubMed - indexed for MEDLINE] 82: Blazar BR, Taylor PA, Snover DC, Sehgal SN, Vallera DA. Related Articles, Links Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome. J Immunol. 1993 Nov 15;151(10):5726-41. PMID: 8228258 [PubMed - indexed for MEDLINE] 83: Fabian MC, Lakey JR, Rajotte RV, Kneteman NM. Related Articles, Links The efficacy and toxicity of rapamycin in murine islet transplantation. In = vitro and in vivo studies. Transplantation. 1993 Nov;56(5):1137-42. PMID: 8249114 [PubMed - indexed for MEDLINE] **84:** Bobbio SA, Porter JG, Monaco AP. Related Articles, Links Effect of rapamycin on islet and skin xenograft survival. Transplant Proc. 1993 Aug;25(4):2745-6. No abstract available. PMID: 8356733 [PubMed - indexed for MEDLINE] **85:** Vogelsang GB, Hess AD. Related Articles, Links Rapamycin effects on immunologic reconstitution. Transplant Proc. 1993 Feb;25(1 Pt 1):727-8. No abstract available. PMID: 8438459 [PubMed - indexed for MEDLINE] 86: Bobbio SA, Wood ML, Monaco AP. Related Articles, Links Effect of rapamycin on induction of unresponsiveness in ALS-treated, marrow-injected mice. Transplant Proc. 1993 Feb;25(1 Pt 1):717-8. No abstract available. PMID: 8438453 [PubMed - indexed for MEDLINE] 87: Fabian MC, Lakey JR, Rajotte RV, Kneteman NM. Related Articles, Links Rapamycin prolongs murine islet allograft survival. Transplant Proc. 1992 Dec;24(6):2842. No abstract available. PMID: 1465966 [PubMed - indexed for MEDLINE] 88: Markus PM, Cai X, Selvaggi G, Cooper M, Harnaha J, Fung JJ, Related Articles, Links Starzl TE. The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation.

cb hg e e e fcg e ch b e

Display Summary

h

PMID: 1721418 [PubMed - indexed for MEDLINE]

Transplant Proc. 1991 Dec;23(6):3232-3. No abstract available.

Show: 500 Sort

Send to

Items 1-88 of 88

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Freedom of Information Act | Disclaimer

Mar 15 2004 17:59:45

FILE 'HOME' ENTERED AT 15:37:54 ON 17 MAR 2004

=> file BIOSCIENCE FILE 'ADISCTI' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 15:38:13 ON 17 MAR 2004

FILE 'ANABSTR' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'BIOSIS' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 15:38:13 ON 17 MAR 2004

FILE 'CAPLUS' ENTERED AT 15:38:13 ON 17 MAR 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 15:38:13 ON 17 MAR 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserve

FILE 'DDFB' ACCESS NOT AUTHORIZED

```
FILE 'DDFU' ACCESS NOT AUTHORIZED
```

FILE 'DGENE' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 15:38:13 ON 17 MAR 2004

FILE 'FOMAD' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 15:38:13 ON 17 MAR 2004

FILE 'HEALSAFE' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemi:

FILE 'LIFESCI' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 15:38:13 ON 17 MAR 2004

FILE 'NIOSHTIC' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 15:38:13 ON 17 MAR 2004 Compiled and distributed by the NTIS, U.S. Department of Commerce. It contains copyrighted material. All rights reserved. (2004)

```
FILE 'NUTRACEUT' ENTERED AT 15:38:13 ON 17 MAR 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.
FILE 'OCEAN' ENTERED AT 15:38:13 ON 17 MAR 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)
FILE 'PASCAL' ENTERED AT 15:38:13 ON 17 MAR 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever is prohibited without the prior written agreement of INIST-CNRS.
COPŸRIGHT (C) 2004 INIST-CNRS. All rights reserved.
FILE 'PCTGEN' ENTERED AT 15:38:13 ON 17 MAR 2004
COPYRIGHT (C) 2004 WIPO
FILE 'PHAR' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)
FILE 'PHARMAML' ENTERED AT 15:38:13 ON 17 MAR 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.
FILE 'PHIC' ENTERED AT 15:38:13 ON 17 MAR 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)
FILE 'PHIN' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)
FILE 'PROMT' ENTERED AT 15:38:13 ON 17 MAR 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.
FILE 'RDISCLOSURE' ENTERED AT 15:38:13 ON 17 MAR 2004 COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.
FILE 'SCISEARCH' ENTERED AT 15:38:13 ON 17 MAR 2004
COPYRIGHT 2004 THOMSON ISI
FILE 'SYNTHLINE' ENTERED AT 15:38:13 ON 17 MAR 2004
COPYRIGHT (C) 2004 Prous Science
FILE 'TOXCENTER' ENTERED AT 15:38:13 ON 17 MAR 2004
COPYRIGHT (C) 2004 ACS
FILE 'USPATFULL' ENTERED AT 15:38:13 ON 17 MAR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'USPAT2' ENTERED AT 15:38:13 ON 17 MAR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'VETB' ENTERED AT 15:38:13 ON 17 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT
FILE 'VETU' ENTERED AT 15:38:13 ON 17 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT
FILE 'WPIDS' ENTERED AT 15:38:13 ON 17 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT
FILE 'WPINDEX' ACCESS NOT AUTHORIZED
=> s FK506 OR cyclosporin A OR rapamycin
  11 FILES SEARCHED...
  22 FILES SEARCHED...
  34 FILES SEARCHED...
  52 FILES SEARCHED...
  60 FILES SEARCHED..
L1
         181263 FK506 OR CYCLOSPORIN A OR RAPAMYCIN
=> S neuron OR neuronal OR neural
30 FILES SEARCHED...
62 FILES SEARCHED...
        4349736 NEURON OR NEURONAL OR NEURAL
=> S L1 AND L2
```

57 FILES SEARCHED... 7844 L1 AND L2 => DUP REM L3
FILE 'ADISCTI' ENTERED AT 15:41:57 ON 17 MAR 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 15:41:57 ON 17 MAR 2004

FILE 'ANABSTR' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOSIS' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'BIOTECHDS' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 15:41:57 ON 17 MAR 2004

FILE 'CAPLUS' ENTERED AT 15:41:57 ON 17 MAR 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 15:41:57 ON 17 MAR 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'DISSABS' ENTERED AT 15:41:57 ON 17 MAR 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserve

FILE 'DGENE' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGU' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

```
FILE 'GENBANK' ENTERED AT 15:41:57 ON 17 MAR 2004
FILE 'IFIPAT' ENTERED AT 15:41:57 ON 17 MAR 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)
FILE 'JICST-EPLUS' ENTERED AT 15:41:57 ON 17 MAR 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)
FILE 'LIFESCI' ENTERED AT 15:41:57 ON 17 MAR 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)
FILE 'MEDLINE' ENTERED AT 15:41:57 ON 17 MAR 2004
FILE 'NTIS' ENTERED AT 15:41:57 ON 17 MAR 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)
FILE 'PASCAL' ENTERED AT 15:41:57 ON 17 MAR 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever is prohibited without the prior written agreement of INIST-CNRS. COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.
FILE 'PHAR' ENTERED AT 15:41:57 ON 17 MAR 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)
FILE 'PHARMAML' ENTERED AT 15:41:57 ON 17 MAR 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.
FILE 'PHIN' ENTERED AT 15:41:57 ON 17 MAR 2004 COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)
FILE 'PROMT' ENTERED AT 15:41:57 ON 17 MAR 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.
FILE 'SCISEARCH' ENTERED AT 15:41:57 ON 17 MAR 2004
COPYRIGHT 2004 THOMSON ISI
FILE 'TOXCENTER' ENTERED AT 15:41:57 ON 17 MAR 2004
COPYRIGHT (C) 2004 ACS
FILE 'USPATFULL' ENTERED AT 15:41:57 ON 17 MAR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'USPAT2' ENTERED AT 15:41:57 ON 17 MAR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'WPIDS' ENTERED AT 15:41:57 ON 17 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT
PROCESSING IS APPROXIMATELY
                                17% COMPLETE FOR L3
PROCESSING IS APPROXIMATELY
                                31% COMPLETE FOR L3
PROCESSING IS APPROXIMATELY
                               47% COMPLETE FOR L3
PROCESSING IS APPROXIMATELY
                                68% COMPLETE FOR L3
PROCESSING IS APPROXIMATELY
                                82% COMPLETE FOR L3
PROCESSING IS APPROXIMATELY
                                97% COMPLETE FOR L3
PROCESSING COMPLETED FOR L3
            4517 DUP REM L3 (3327 DUPLICATES REMOVED)
=> S L4 AND PY<=2001
'2001' NOT A VALID FIELD CODE
   6 FILES SEARCHED...
   8 FILES SEARCHED...
  11 FILES SEARCHED...
  16 FILES SEARCHED...
'2001' NOT A VALID FIELD CODE
23 FILES SEARCHED...
'2001' NOT A VALID FIELD CODE
28 FILES SEARCHED...
  30 FILES SEARCHED...
  32 FILES SEARCHED.
'2001' NOT A VALID FIELD CODE
  37 FILES SEARCHED...
  39 FILES SEARCHED...
```

=> S Parkinson OR Huntington OR amyotrophic lateral sclerosis OR Alzheimer OR is 19 FILES SEARCHED... 34 FILES SEARCHED... 1056852 PARKINSON OR HUNTINGTON OR AMYOTROPHIC LATERAL SCLEROSIS OR L6 ALZHEIMER OR ISCHEMIC CEREBRAL STROKE => S L5 AND L6 448 L5 AND L6 L7 => DUP REM L7 DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, IMSRESEARCH, FEDRIP, GENBANK, PHAR, PHARMAML' ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE PROCESSING COMPLETED FOR L7 448 DUP REM L7 (0 DUPLICATES REMOVED) L8 => S L8 AND transplantation 32 FILES SEARCHED... 175 L8 AND TRANSPLANTATION L9 => D L9 1-175 ANSWER 1 OF 175 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2002:140375 BIOSIS L9AN DN PREV200200140375 Liposomal tacrolimus administered systemically and within the donor cell TI suspension improves xenograft survival in hemiparkinsonian rats. Alemdar, A. Y.; Baker, K. A.; Sadi, D.; McAlister, V. C.; Mendez, I. AU [Reprint author] Neural Transplantation Laboratory, Department of Anatomy and Neurobiology, Dalhousie University, Room 12H-1, Sir Charles Tupper Medical Building, Halifax, Nova Scotia, B3H 4H7, Canada CS mendez@is.dal.ca Experimental Neurology, (December, 2001) Vol. 172, No. 2, pp. 416-424. SO print. CODEN: EXNEAC. ISSN: 0014-4886. DT Article English LА Entered STN: 6 Feb 2002 EDLast Updated on STN: 26 Feb 2002 ANSWER 2 OF 175 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2002:24694 BIOSIS L9 ANPREV200200024694 DN ***neural*** xenografts in rats and mice: Donor tissue TI Porcine development and characteristics of rejection. Larsson, Lena C. [Reprint author]; Frielingsdorf, Helena; Mirza, Bilal; AU Hansson, Sophia J:dtr; Anderson, Per; Czech, Kimberly A.; Strandberg, Maria; Widner, Hakan Sedtion for Neuronal Survival, Department of Physiological Sciences, Wallenberg Neuroscience Center, Lund University, BMCA10, SE-221 84, Lund, CS Sweden Lena.Larsson@mphy.lu.se Experimental Neurology, (November, 2001) Vol. 172, No. 1, pp. 100-114. SO print. CODEN: EXNEAC. ISSN: 0014-4886. DT Article LΑ English Entered STN: 26 Dec 2001 EDLast Updated on STN: 25 Feb 2002 ANSWER 3 OF 175 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN L9 AN 2001:519992 BIOSIS PREV200100519992 DN***transplantation*** in a rat model of ΤI Embryonic stem cell ***Parkinson*** 's disease: II. Attenuation of levodopa-induced dyskinesias and amphetamine-induced rotational behavior. McNaught, K. S. P. [Reprint author]; Bjorklund, L. [Reprint author]; Sanchez-Pernaute, S. [Reprint author]; Kim, K. S. [Reprint author]; Isacson, O. [Reprint author] AU

Neuroregeneration Laboratories and Udall Parkinson's Disease Center of Excellence, McLean Hospital/Harvard Medical School, Belmont, MA, USA Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 970. print.

Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San

CS SO

ISSN: 0190-5295. DT Conference; (Meeting) Conference; Abstract; (Meeting Abstract) LA English Entered STN: 7 Nov 2001 EDLast Updated on STN: 23 Feb 2002 ANSWER 4 OF 175 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN L9 BIOSIS 2001:519987 ANDN PREV200100519987 TI Grafting a human ventral mesencephalic immortalized cell line into a ***Parkinson*** rat model. Paul, G. [Reprint author]; Ahn, Y. H. [Reprint author]; Raymon, H.; Brundin, P. [Reprint author]; Schierle, G. Kaminski [Reprint author] Section for Neuronal Survival, Wallenberg Neuroscience Center, Lund, ΑU CS Sweden Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 969. print. Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San SO California, USA. November ĭ0-15, 2001. ISSN: 0190-5295. Conference; (Meeting)
Conference; Abstract; (Meeting Abstract) DT English LΑ Entered STN: 7 Nov 2001 EDLast Updated on STN: 23 Feb 2002 ANSWER 5 OF 175 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN L9 2001:205545 BIOSIS AN PREV200100205545 DN Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Keep, Marcus [Reprint author]; Elmer, Eskil; Fong, Keith S. K.; Csiszar, ΤI ΑU Laboratory of Matrix Pathobiology, Pacific Biomedical Research Center, University of Hawaii, 1960 East-West Road, Honolulu, HI, 96822, USA CS mkeep@aloha.net (16 March, 2001) Vol. 894, No. 2, pp. 327-331. print. SO Brain Research, CODEN: BRREAP. ISSN: 0006-8993. Article DT LΑ English ED Entered STN: 25 Apr 2001 Last Updated on STN: 18 Feb 2002 ANSWER 6 OF 175 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2001:98512 BIOSIS L9 ANPREV200100098512 DN Survival of intrastriatal xenografts of ventral mesencephalic dopamine TI***neurons*** from MHC-deficient mice to adult rats. Duan, Wei-Ming; Westerman, Marcus; Flores, Tina; Low, Walter C. [Reprint ΑU CS Department of Neurosurgery, University of Minnesota Medical School, Minneapolis, MN, 55455, USA lowwalt@tc.umn.edu Experimental Neurology, (January, 2001) Vol. 167, No. 1, pp. 108-117. SO print. CODEN: EXNEAC. ISSN: 0014-4886. DTArticle LΑ English Entered STN: 21 Feb 2001 EDLast Updated on STN: 15 Feb 2002 ANSWER 7 OF 175 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2000:56073 BIOSIS L9

Dopa-producing astrocytes generated by adenoviral transduction of human

Hida, Hideki; Hashimoto, Mitsuhiro; Fujimoto, Ichiro; Nakajima, Keiya;

Department of Physiology, Nagoya City University Medical School, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan Neuroscience Research, (Nov., 1999) Vol. 35, No. 2, pp. 101-112. print.

Shimano, Yasunobu; Nagatsu, Toshiharu; Mikoshiba, Katsuhiko; Nishino,

transplantation

tyrosine hydroxylase gene: In vitro study and

ANDN

TI

ΑU

CS

SO

DT

LА

Article English

PREV20000056073

hemiparkinsonian model rats.

CODEN: NERADN. ISSN: 0168-0102.

Hitoo [Reprint author]

Last Updated on STN: 3 Jan 2002

L9 ANSWER 8 OF 175 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

1997:504051 BIOSIS AN

- DN PREV199799803254
- Implantation of xenogeneic transgenic ***neural***
 Parkinsonian rat brain. TI plate tissues into
- Hara, Koichi [Reprint author]; Uchida, Koichi; Fukunaga, Atsushi; Toya, AU Shigeo; Kawase, Takeshi
- Dep. Neurosurg., Keio Univ. Sch. Med., 35 Shinanomachi, Shinjuku-ku, CS Tokyo, Japan
- Cell Transplantation, (1997) Vol. 6, No. 5, pp. 515-519. SO ISSN: 0963-6897.
- DT Article
- English TιA
- Entered STN: 21 Nov 1997 Last Updated on STN: 21 Nov 1997 ED
- ANSWER 9 OF 175 BI 1997:395812 BIOSIS L9 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
- AN
- DN PREV199799695015
- Effects of graft pooling of foetal rat and mouse tissue and TIimmunosuppression in the 6-hydroxydopamine rat model of ***Parkinson*** 's disease.
- Schwarz, Sigrid C. [Reprint author]; Sauer, Hansjorg; Oertel, Wolfgang H.; Earl, Christopher D.; Kupsch, Andreas R. Univ. Ulm, Dep. Neurol., Oberer Eselsberg 45, D-89081 Ulm, Germany Experimental Brain Research, (1997) Vol. 115, No. 1, pp. 71-82. ΑU
- CS
- SO CODEN: EXBRAP. ISSN: 0014-4819.
- DT Article
- English LА
- ED Entered STN: 10 Sep 1997
 - Last Updated on STN: 10 Sep 1997
- ANSWER 10 OF 175 B 1992:526247 BIOSIS BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN L9
- AN
- PREV199294134322; BA94:134322 DN
- LONG DISTANCE DIRECTED AXONAL GROWTH FROM HUMAN DOPAMINERGIC MESENCEPHALIC TI NEUROBLASTS IMPLANTED ALONG THE NIGROSTRIATAL PATHWAY IN 6 HYDROXYDOPAMINE LESIONED ADULT RATS.
- AU WICTORIN K [Reprint author]; BRUNDIN P; SAUER H; LINDVALL O; BJORKLUND A
- CS DEP MED CELL RES, BISKOPSGATAN 5, S-223 62 LUND, SWED
- Journal of Comparative Neurology, (1992) Vol. 323, No. 4, pp. 475-494. CODEN: JCNEAM. ISSN: 0021-9967. SO
- DT Article
- FS BA
- **ENGLISH** LΑ
- ED Entered STN: 19 Nov 1992
 - Last Updated on STN: 20 Nov 1992
- ANSWER 11 OF 175 B 1989:270921 BIOSIS L9 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
- AN
- PREV198988007003; BA88:7003 DN
- TI A PRIMATE MODEL OF ***HUNTINGTON*** 'S DISEASE CROSS-SPECIES IMPLANTATION OF STRIATAL PRECURSOR CELLS TO THE EXCITOTOXICALLY LESIONED BABOON CAUDATE-PUTAMEN.
- AU
- CS
- ISACSON O [Reprint author]; RICHE D; HANTRAYE P; SOFRONIEW M V; MAZIERE M MCLEAN HOSP, BELMONT, MASS 02178, USA Experimental Brain Research, (1989) Vol. 75, No. 1, pp. 213-220. SO CODEN: EXBRAP. ISSN: 0014-4819.
- DT Article
- FS BA
- LΆ **ENGLISH**
- Entered STN: 6 Jun 1989 ED
 - Last Updated on STN: 6 Jun 1989
- L9 ANSWER 12 OF 175 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
- 1988:289677 BIOSIS AN
- DN PREV198886017944; BA86:17944
- ***NEURONS*** TI HUMAN FETAL DOPAMINE GRAFTED IN A RAT MODEL OF ***PARKINSON*** 'S DISEASE IMMUNOLOGICAL ASPECTS SPONTANEOUS AND DRUG-INDUCED BEHAVIOR AND DOPAMINE RELEASE.
- ΑU BRUNDIN P [Reprint author]; STRECKER R E; WIDNER H; CLARKE D J; NILSSON O G; ASTEDT B; LINDVALL O; BJORKLUND A
- CS DEP MED CELL RES, UNIV LUND, BISKOPSGATAN 5, S-223 62 LUND, SWEDEN

```
CODEN: EXBRAP. ISSN: 0014-4819.
DT
      Article
FS
      BA
LΑ
      ENGLISH
      Entered STN: 16 Jun 1988
ED
      Last Updated on STN: 16 Jun 1988
L9
       ANSWER 13 OF 175
                           BIOTECHNO
                                        COPYRIGHT 2004 Elsevier Science B.V. on STN
AN
       2000:30058341
                        BIOTECHNO
TI
       Neuroprotective strategies for basal ganglia degeneration:
       ***Parkinson*** 's and ***Huntington*** 's diseases
Alexi T.; Borlongan C.V.; Faull R.L.M.; Williams C.E.; Clark R.G.;
ΑU
       Gluckman P.D.; Hughes P.E.
       T. Alexi, Research Centre, School of Medicine, University of Auckland, Auckland, New Zealand.
CS
       E-mail: t.alexi@auckland.ac.nz
SO
       Progress in Neurobiology, ( ***2000*** ), 60/5 (409-470), 727
       reference(s)
       CODEN: PGNBA5
                        ISSN: 0301-0082
PUI
       S0301008299000325
DT
       Journal; General Review
       United Kingdom
CY
LА
       English
SL
       English
                                         COPYRIGHT 2004 Elsevier Science B.V. on STN
L9
       ANSWER 14 OF 175 BIOTECHNO
AN
       1996:26292127
                         BIOTECHNO
TI
       CNS immunological modulation of
                                               ***neural***
                                                                graft rejection and
       survival
ΑU
       Borlongan C.V.; Stahl C.E.; Cameron D.F.; Saporta S.; Freeman T.B.;
       Cahill D.W.; Sanberg P.R.
Division of Neurological Surgery, Department of Surgery, Univ. of South
Florida Coll. of Med., 12901 Bruce B. Downs Blvd, Tampa, FL 33612, United
CS
       States.
SO
       Neurological Research, ( ***1996*** ), 18/4 (297-304)
       CODEN: NRESDZ ISSN: 0161-6412
DT
       Journal; General Review
CY
       United States
       English
English
LA
\operatorname{SL}
       ANSWER 15 OF 175 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
L9
       1993:24012242
                         BIOTECHNO
AN
         ***Neural***
TI
                             ***transplantation*** : A report on the IVth
       international symposium
ΑU
       Freed W.J.; Rosenstein J.M.
      NIMH Neuroscience Center, St Elizabeths, 2700 Martin Luther King Ave, Washington DC 20032, United States.

Journal of Neural Transplantation and Plasticity, ( ***1993*** ), 4/2
CS
SO
       (61-96)
       CODEN: JNPLEW
                       ISSN: 0792-8483
DT
       Journal; Conference Article
CY
       Israel
LΑ
       English
L9
     ANSWER 16 OF 175 CAPLUS COPYRIGHT 2004 ACS on STN
      2001:499762 CAPLUS
AN
      135:91542
DN
                 ***neural***
TI
     Porcine
                                   cells and their use in treatment of neurological
     deficits due to neurodegenerative diseases
IN
      Isacson, Ole; Dinsmore, Jonathan
PA
     Diacrin, Inc., USA
SO
     U.S., 68 pp., Cont.-in-part of U.S. Ser. No. 424,851.
     CODEN: USXXAM
DT
     Patent
     English
LΑ
FAN. CNT 8
     PATENT NO.
                         KIND
                                DATE
                                                  APPLICATION NO.
                                                                      DATE
                         _ _ _ _
                          B1
PΙ
     US 6258353
                                20010710
                                                  US 1995-554779
                                                                      19951107 <--
     US 6294383
                          B1
                                20010925
                                                  US 1995-424851
                                                                      19950419 <--
     US 2002009461
                                                  US 2001-847881
                          A1
                                20020124
                                                                      20010502
PRAI US 1994-336856
                          B2
                                19941108
     US 1995-424851
                          A2
                                19950419
                          Α3
     US 1995-554779
                                19951107
```

ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
L9
      ANSWER 17 OF 175 CAPLUS COPYRIGHT 2004 ACS on STN
      2000:769012
AN
                       CAPLUS
      133:293209
DN
ΤI
      Isolated and modified porcine cerebral cortical cells.
      Dinsmore, Jonathan
Diacrin, Inc., USA
U.S., 64 pp., Cont.-in-part of U.S. Ser. No. 424,856.
IN
PA
SO
      CODEN: USXXAM
DT
      Patent
LA English
FAN.CNT 8
      PATENT NO.
                            KIND DATE
                                                       APPLICATION NO.
                                                                            DATE
                           ____
                                    _____
                             Α
                                                       US 1995-551820
PI
      US 6140116
                                    20001031
                                                                             19951107 <--
                                                       US 1995-424856
      US 6204053
                             B1
                                                                            19950419 <--
                                   20010320
                         B2
A2
PRAI US 1994-336856
                                   19940419
      US 1995-424856
                                   19950419
                  THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 23
                  ALL CITATIONS AVAILABLE IN THE RE FORMAT
Ь9
      ANSWER 18 OF 175 CAPLUS COPYRIGHT 2004 ACS on STN
      1995:490887 CAPLUS
\mathbf{N}\mathbf{A}
DN
      122:237302
      A novel mode of immunoprotection of
                                                     ***neural***
TI
                                                                          xenotransplants:
      masking of donor major histocompatibility complex class I enhances
      transplant survival in the central nervous system
      Pakzaban, P.; Deacon, T. W.; Burns, L. H.; Dinsmore, J.; Isacson, O. Neurogeneration Lab., McLean Hospital, Belmont, MA, 02178, USA Neuroscience (Oxford) ( ***1995*** ), 65(4), 983-96
ΑU
CS
SO
      CODEN: NRSCDN; ISSN: 0306-4522
PB
      Elsevier
DT
      Journal
      English
LA
L9
      ANSWER 19 OF 175 CAPLUS COPYRIGHT 2004 ACS on STN
AN
      1994:645527 CAPLUS
DN
      121:245527
      No adverse effects of ***cyclosporin*** ***A*** on cellular functional development of fetal rat dopaminergic mesencephalic ***neurons*** grafted into the 6-hydroxydopamine rat model of ***Parkinson*** 's disease
TI
                                                                              on cellular and
AU
      Earl, Christopher D.; Frodl, Eva M.; Pupeter, Sigrid C.; Oertel, Wolfgang
      H.; Kupsch, Andreas
      Department of Neurology, Klinikum Grosshadern, Munich, 81377, Germany
CS
      Restorative Neurology and Neuroscience ( ***1994*** ), 7(1), 1-4
SO
      CODEN: RNNEEL; ISSN: 0922-6028
DT
      Journal
LΑ
      English
L9
      ANSWER 20 OF 175 CAPLUS COPYRIGHT 2004 ACS on STN
ΑN
      1992:529568 CAPLUS
DN
TI
                ***neural*** graft function in rats treated with
      Human
      anti-interleukin II receptor antibody
      Honey, Christopher R.; Clarke, Debbie J.; Dallman, Maggie J.; Charlton, Harry M.
Dep. Hum. Anat., Oxford Univ., Oxford, OX1 3QX, UK
NeuroReport ( ***1990*** ), 1(3-4), 247-9
AU
CS
SO
      CODEN: NERPEZ; ISSN: 0959-4965
DT
      Journal
LΑ
      English
L9
      ANSWER 21 OF 175 CAPLUS COPYRIGHT 2004 ACS on STN
AN
      1988:466555 CAPLUS
DN
      109:66555
TI
      Brain xenografts: the effect of ***cyclosporin***
                                                                                            on
      graft survival
      Howard, Matthew A., III; Dacey, Ralph G., Jr.; Winn, H. Richard Sch. Med., Univ. Washington, Seattle, WA, 98104, USA Journal of Neurosurgery ( ***1988*** ), 69(1), 121-6
AU
CS
SO
      CODEN: JONSAC; ISSN: 0022-3085
DT
      Journal
```

LΑ

English

```
ANSWER 22 OF 175 DISSABS COPYRIGHT (C) 2004 ProQuest Information and
L9
     Learning Company; All Rights Reserved on STN 88:1749 DISSABS Order Number: AARC049573
AN
                           Order Number: AARC049573 (not available for sale by
     UMI)
                   ***TRANSPLANTATION***
TT
      TOWARDS A
                                              THERAPY FOR
                                                              ***PARKINSON***
     DISEASE: AN EXPERIMENTAL STUDY ON INTRACEREBRAL GRAFTS OF FETAL DOPAMINE
        ***NEURONS***
AU
     BRUNDIN, PATRIK [MED.DR]
CS
     LUNDS UNIVERSITET (SWEDEN) (0899)
     Dissertation Abstracts International, ( ***1988*** ) Vol. 49, No. 4C, p. 601. Order No.: AARC049573 (not available for sale by UMI). 224 pages. DEPARTMENT OF MEDICAL CELL RESEARCH, BISKOPSGATAN 5, S-223 62 LUND,
SO
     SWEDEN.
      ISBN: 91-7900-492-X.
DT
     Dissertation
FS
     DAI
LΑ
     English
ED
     Entered STN: 19921118
     Last Updated on STN: 19921118
L9
     ANSWER 23 OF 175
                        EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
     RESERVED. on STN
AN
      2001241381
                  EMBASE
     Effects of immunosuppressive treatment on host responses against
TI
      intracerebral porcine ***neural***
                                                 tissue xenografts in rats.
     Wennberg L.; Czech K.A.; Larsson L.C.; Mirza B.; Bennet W.; Song Z.;
ΑU
CS
     Dr. L. Wennberg, Dept. of Transplantation Surgery, Karolinska Institute,
     Huddinge University Hospital, 141 86 Stockholm, Sweden.
     lars.wennberg@transpl.hs.sll.se
SO
     Transplantation, (27 \text{ Jun } 2001) 71/12 (1797-1806).
     Refs: 52
ISSN: 0041-1337 CODEN: TRPLAU
     United States
CY
DT
     Journal; Article
FS
              Neurology and Neurosurgery
     037
              Drug Literature Index
T.A
     English
     English
SL
                         EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
L9
     ANSWER 24 OF 175
     RESERVED. on STN
     2000407300 EMBASE
AN
TI
     No evidence for infection of human cells with porcine endogenous
     retrovirus (PERV) after exposure to porcine fetal
                                                                ***neuronal***
     cells.
AU
     Dinsmore J.H.; Manhart C.; Raineri R.; Jacoby D.B.; Moore A.
     Dr. J.H. Dinsmore, Diacrin, Inc., Building 96, 13th Street, Charlestown,
CS
     MA 02129, United States
SO
     Transplantation, (15 Nov 2000) 70/9 (1382-1389).
     Refs: 38
     ISSN: 0041-1337
                       CODEN: TRPLAU
CY
     United States
DT
     Journal; Article
FS
     004
              Microbiology
     800
              Neurology and Neurosurgery
              Immunology, Serology and Transplantation
     026
     037
              Drug Literature Index
LA
     English
     English
SL
L9
     ANSWER 25 OF 175
                         EMBASE
                                  COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
     RESERVED. on STN
     2000360002
AN
                  EMBASE
TI
        ***Transplantation***
                                  therapy for ***Parkinson***
                                                                     's disease.
ΑU
     Borlongan C.V.
     C.V. Borlongan, Cellular Neurobiology Branch, Intramural Research Program,
CS
     National Institute on Drug Abuse, 5500 Nathan Shock Drive, Baltimore, MD
     21224, United States. cborlong@intra.nida.nih.gov
Expert Opinion on Investigational Drugs, (2000) 9/10 (2319-2330).
SO
     Refs: 67
     ISSN: 1354-3784
                       CODEN: EOIDER
CY
     United Kingdom
DT
     Journal; General Review
FS
     800
              Neurology and Neurosurgery
```

```
Pharmacology
      030
      037
                Drug Literature Index
LΑ
      English
SL
      English
L9
      ANSWER 26 OF 175
                            EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
      RESERVED. on STN
AN
      2000310606 EMBASE
ΤI
         ***Neural***
                           tissue xenografting.
      Larsson L.C.; Widner H.
ΑU
CS
      Dr. L.C. Larsson, Section for Neuronal Survival, Wallenberg Neuroscience
      Center, Solvegatan 17, S-223 62 Lund, Sweden. Lena.Larsson@mphy.lu.se
SO
      Scandinavian Journal of Immunology, (2000) 52/3 (249-256).
      Refs: 64
      ISSN: 0300-9475 CODEN: SJIMAX
CY
      United Kingdom
DT
      Journal; General Review
FS
                Neurology and Neurosurgery
      800
      009
                Surgery
                Immunology, Serology and Transplantation
      026
      037
                Drug Literature Index
LA
      English
SL
      English
T.9
      ANSWER 27 OF 175
                            EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
      RESERVED. on STN
AN
      2000268854
                     EMBASE
ΤI
      Additive effects of caspase inhibitor and lazaroid on the survival of
      transplanted rat and human embryonic dopamine ***neurons***
Hansson O.; Castilho R.F.; Kaminski Schierle G.S.; Karlsson J.; Nicotera
ΑU
      P.; Leist M.; Brundin P.
      O. Hansson, Section for Neuronal Survival, Wallenberg Neuroscience Center, Solvegatan 17, SE-22362 Lund, Sweden Experimental Neurology, (2000) 164/1 (102-111).
CS
SO
      Refs: 55
      ISSN: 0014-4886
                          CODEN: EXNEAC
      United States
CY
DT
      Journal; Article
FS
      008
                Neurology and Neurosurgery
      037
                Drug Literature Index
LA
      English
SL
      English
L9
      ANSWER 28 OF 175
                            EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
      RESERVED. on STN
                    EMBASE
AN
      2000165796
TI
      Intrastriatal ventral mesencephalic xenografts of porcine tissue in rats:
      Immune responses and functional effects.
      Larsson L.C.; Czech K.A.; Brundin P.; Widner H.
L.C. Larsson, Section for Neuronal Survival, Department of Physiological
ΑU
CS
      Sciences, Wallenberg Neuroscience Center, Solvegatan 17, SE-223 62 Lund,
      Sweden. Lena.Larsson@mphy.lu.se
SO
      Cell Transplantation, (2000) 9/2 (261-272).
      Refs: 55
      ISSN: 0963-6897 CODEN: CTRAE8
      United States
CY
DT
      Journal; Article
                Neurology and Neurosurgery
Immunology, Serology and Transplantation
FS
      800
      026
      037
                Drug Literature Index
LΑ
      English
SL
      English
L9
      ANSWER 29 OF 175
                            EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
      RESERVED. on STN
AN
      2000037948
                    EMBASE
TI
      Cyclosporine-A enhances choline acetyltransferase immunoreactivity in the
      septal region of adult rats.
Borlongan C.V.; Stahl C.E.; Keep M.F.; Elmer E.; Watanabe S.
C.V. Borlongan, National Institutes of Health, National Institute Drug
Abuse, Intramural Research Program, 5500 Nathan Shock Drive, Baltimore, MD
21224, United States. cborlong@intra.nida.nih.gov
ΑÜ
CS
SO
      Neuroscience Letters, (2000) 279/2 (73-76).
      Refs: 20
```

ISSN: 0304-3940 CODEN: NELED5

```
CY
       Ireland
DT
       Journal; Article
FS
       029
                 Clinical Biochemistry
                 Pharmacology
       030
       037
                 Drug Literature Index
       800
                 Neurology and Neurosurgery
LA
      English
      English
SL
L9
      ANSWER 30 OF 175
                             EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
      RESERVED. on STN
      1999304347
AN
                     EMBASE
      Cyclosporine A-induced hyperactivity in rats: Is it mediated by immunosuppression, neurotrophism, or both?.

Borlongan C.V.; Stahl C.E.; Fujisaki T.; Sanberg P.R.; Watanabe S. C.V. Borlongan, National Institutes of Health, National Institute on Drug Abuse, Intram. Res. Prog. Cell. Nuerobiol., 5500 Nathan Shock Drive,
TI
AU
CS
      Baltimore, MD 21224, United States. cborlong@intra.nida.nih.gov
SO
      Cell Transplantation, (1999) 8/1 (153-159).
      Refs: 30
      ISSN: 0963-6897 CODEN: CTRAE8
      United States
CY
DT
      Journal; Article
                 Neurology and Neurosurgery
FS
      026
                 Immunology, Serology and Transplantation
LΑ
      English
      English
SL
L9
      ANSWER 31 OF 175
                             EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
      RESERVED. on STN
AN
      96318613
                   EMBASE
DN
      1996318613
ΤI
      Cyclosporine-A increases locomotor activity in rats with 6-
      hydroxydopamine-induced hemiparkinsonism: Relevance to
                                                                               ***neural***
         ***transplantation***
AU
      Borlongan C.V.; Freeman T.B.; Hauser R.A.; Cahill D.W.; Sanberg P.R.;
      Tasker R.R.
      Division of Neurological Surgery, Department of Surgery, Univ. of South
CS
      Florida Coll. of Med., 12901 Bruce B Downs Blvd., Tampa, FL 33612, United
      States
      Surgical Neurology, (1996) 46/4 (384-388). ISSN: 0090-3019 CODEN: SGNRAI
SO
CY
      United States
      Journal; Article
DT
FS
      800
                Neurology and Neurosurgery
      026
                 Immunology, Serology and Transplantation
      037
                Drug Literature Index
LА
      English
SL
      English
L9
      ANSWER 32 OF 175
                             EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
      RESERVED. on STN
AN
      96111630
                  EMBASE
DN
      1996111630
         ***Neural***
TI
                            transplants for
                                                 ***Parkinson***
                                                                         's disease.
      Freed C.R.; Breeze R.E.; Leehey M.; O'Brien C.F.; Schneck S.A. Div. Clinical Pharmacol./Toxicology, University of Colorado, Health Sciences Center, Denver, CO, United States
IM - Internal Medicine, (1996) 17/3 (40-42).
ISSN: 1056-9286 CODEN: IMEIEI
AU
CS
SO
      United States
CY
DT
      Journal; (Short Survey)
FS
      800
                Neurology and Neurosurgery
      020
                Gerontology and Geriatrics
      037
                Drug Literature Index
      English
TιA
      English
SL
      ANSWER 33 OF 175 RESERVED. on STN
L9
                             EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
AN
      95051558
                  EMBASE
      1995051558
DN
TI
      Cyclosporine-A increases spontaneous and dopamine agonist-induced
      locomotor behavior in normal rats.
ΑU
      Borlongan C.V.; Freeman T.B.; Scorcia T.A.; Sherman K.A.; Olanow W.C.;
```

```
CS
      Division of Neurological Surgery, Department of Surgery, South Florida
      Univ. College of Med., 12901 Bruce B. Downs Blvd., Tampa, FL 33612, United
      States
SO
      Cell Transplantation, (1995) 4/1 (65-73).
      ISSN: 0963-6897 CODEN: CTRAE8
CY
      United States
DT
      Journal; Conference Article
FS
      800
               Neurology and Neurosurgery
      009
               Surgery
      037
               Drug Literature Index
LΑ
      English
SL
      English
L9
     ANSWER 34 OF 175
                          EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
     RESERVED. on STN
AN
      94105806
                 EMBASE
DN
      1994105806
TI
     A long term follow-up of fetal dopaminergic
                                                           ***neurons***
                                   into the brain of three parkinsonian patients.
        ***transplantation***
     Zabek M.; Mazurowski W.; Dymecki J.; Stelmachow J.; Zawada E.
AU
     Department of Neuropathology, Inst. of Psychiatry and Neurology,
CS
     Sobieskiego 1/9,02-957 Warsaw, Poland
SO
     Restorative Neurology and Neuroscience, (1994) 6/2 (97-106).
     ISSN: 0922-6028 CODEN: RNNEEL
CY
     Ireland
DT
     Journal; Article
FS
     800
               Neurology and Neurosurgery
               Drug Literature Index
     037
     English
LA
SL
     English
L9
     ANSWER 35 OF 175
                          EMBASE
                                   COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
     RESERVED. on STN
AN
     92350615
                EMBASE
     1992350615
DN
TI
                     ***transplantation***
     Unilateral
                                                of human fetal mesencephalic tissue
     into the caudate nucleus of patients with ***Parkinson*** 's Spencer D.D.; Robbins R.J.; Naftolin F.; Marek K.L.; Vollmer T.;
                                                                           's disease.
AII
                                                                               Leranth
     C.; Roth R.H.; Price L.H.; Gjedde A.; Bunney B.S.; Sass K.J.; Elsworth J.D.; Kier E.L.; Makuch R.; Hoffer P.B.; Redmond Jr. D.E.
     Section of Neurosurgery, Yale University School of Medicine, P.O. Box 3333, New Haven, CT 06510, United States
CS
SO
     New England Journal of Medicine, (1992) 327/22 (1541-1548).
     ISSN: 0028-4793
                        CODEN: NEJMAG
CY
     United States
DT
     Journal; Article
FS
     800
               Neurology and Neurosurgery
     037
               Drug Literature Index
     English
LA
SL
     English
L9
     ANSWER 36 OF 175
                          EMBASE
                                   COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
     RESERVED. on STN
AN
     91245772
                EMBASE
DN
     1991245772
TI
     Development of human
                                ***neural***
                                                   ***transplantation***
ΑU
     Madrazo I.; Franco-Bourland R.; Aguilera M.; Ostrosky-Solis F.; Cuevas C.;
     Castrejon H.; Magallon E.; Madrazo M.; Apuzzo M.L.J.; Penn R.D. Department of Clinical Research in Neurology and Neurosurgery, Centro
CS
     Medico Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City,
     Mexico
     Neurosurgery, (1991) 29/2 (165
ISSN: 0148-396X CODEN: NRSRDY
SO
                    (1991) 29/2 (165-177).
CY
     United States
DT
     Journal; General Review
FS
     800
              Neurology and Neurosurgery
     037
              Drug Literature Index
     English
LΑ
SL
     English
     ANSWER 37 OF 175 RESERVED. on STN
Ь9
                          EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
AN
     87071513
                 EMBASE
     1987071513
DN
TI
     Behavioural effects of human fetal dopamine ***neurons***
                                                                             grafted in a
```

```
Brundin P.; Nilsson O.G.; Strecker R.E.; et al.
Department of Histology, University of Lund, S 223 62 Lund, Sweden
Experimental Brain Research, (1987) 65/1 (235-240).
AU
CS
SO
     CODEN: EXBRAP
CY
     Germany
DT
     Journal
FS
     037
              Drug Literature Index
              Physiology
     002
     800
              Neurology and Neurosurgery
              Gerontology and Geriatrics
     020
LА
     English
     ANSWER 38 OF 175 PROMT COPYRIGHT 2004 Gale Group on STN
L9
ACCESSION NUMBER:
                     2000:669286
                                  PROMT
                     SCIENCE SCAN.
TITLE:
AUTHOR (S):
                     Leff, David N.
                                          ***2 Aug 1999*** ) Vol. 10, No. 147.
SOURCE:
                     BIOWORLD Today,
PUBLISHER:
                     American Health Consultants, Inc.
DOCUMENT TYPE:
                     Newsletter
LANGUAGE:
                     English
                     723
WORD COUNT:
                     *FULL TEXT IS AVAILABLE IN THE ALL FORMAT*
L9
     ANSWER 39 OF 175 PROMT COPYRIGHT 2004 Gale Group on STN
ACCESSION NUMBER:
                     2000:204926 PROMT
TITLE:
                     Cyclosporin Neuroprotection: Maas BiolAB's Canadian Patent.
SOURCE:
                     Business Wire, ( ***22 Mar 2000*** ) pp. 120.
PUBLISHER:
                     Business Wire
DOCUMENT TYPE:
                     Newsletter
LANGUAGE:
                     English
WORD COUNT:
                     392
                     *FULL TEXT IS AVAILABLE IN THE ALL FORMAT*
L9
     ANSWER 40 OF 175 PROMT
                               COPYRIGHT 2004 Gale Group on STN
ACCESSION NUMBER:
                     1999:208043
                                   PROMT
TITLE:
                     Best PIPELINES.
AUTHOR(S):
                     Engel, Styli
                     Meď Ad News, (
SOURCE:
                                      ***March 1999*** ) Vol. 18, No. 3, pp.
                     1(1).
                     ISSN: 0745-0907.
PUBLISHER:
                     Engel Communications, Inc.
DOCUMENT TYPE:
                     Newsletter
LANGUAGE:
                     English
WORD COUNT:
                     41331
                     *FULL TEXT IS AVAILABLE IN THE ALL FORMAT*
L9
     ANSWER 41 OF 175 PROMT
                                COPYRIGHT 2004 Gale Group on STN
ACCESSION NUMBER:
                     96:631604
                                 PROMT
TITLE:
                     Approaches to Overcoming The Immune Response
                     Genesis Report-Rx, ( ***1 Oct 1996*** ) pp. N/A.
SOURCE:
                     ISSN: 1061-2270.
LANGUAGE:
                     English
                        737
WORD COUNT:
                     *FULL TEXT IS AVAILABLE IN THE ALL FORMAT*
     ANSWER 42 OF 175
                        PROMT
                                COPYRIGHT 2004 Gale Group on STN
ACCESSION NUMBER:
                     92:160979
                                 PROMT
TITLE:
                                                              ***Transplantation***
                     Market Studies: Future Prospects of
                     - What Will Happen in the Next 20 Years?
                     Biomedical Market Newsletter, ( ***Jan 1992*** ) pp. N/A.
SOURCE:
LANGUAGE:
                     English
                     2496
WORD COUNT:
                     *FULL TEXT IS AVAILABLE IN THE ALL FORMAT*
L9
     ANSWER 43 OF 175
                        SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
AN
     2000:831671 SCISEARCH
GA
     The Genuine Article (R) Number: 369JA
TI
     Neuroimmunophilin ligand enhances neurite outgrowth and effect of fetal
     dopamine transplants
ΑU
     Costantini L C; Isacson O (Reprint)
```

```
BELMONT, MA 02178 (Reprint); MCLEAN HOSP, MASSACHUSETTS GEN HOSP, DEPT NEUROL & PSYCHIAT, BELMONT, MA 02178; HARVARD UNIV, MCLEAN HOSP, SCH MED, NEUROREGENERAT LAB, BELMONT, MA 02178
CYA
SO
       NEUROSCIENCE,
                             ***SEP 2000***
                                                 ) Vol. 100, No. 3, pp. 515-520.
       Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE,
       KIDLINGTON, OXFORD OX5 1GB, ENGLAND.
       ISSN: 0306-4522.
DT
       Article; Journal
FS
       LIFE
LΑ
       English
REC
       Reference Count: 50
       *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
       ANSWER 44 OF 175
L9
                             SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
                    SCISEARCH
AN
       92:199848
GΑ
       The Genuine Article (R) Number: HK089
       PHOTORECEPTOR DIFFERENTIATION IN RETINAL XENOGRAFTS OF FETAL MONKEY RETINA
TI
ΑU
       DELCERRO M (Reprint); KORDOWER J H; LAZAR E; GROVER D A; DELCERRO C
      UNIV ROCHESTER, SCH MED, DEPT NEUROBIOL, PO 603, ROCHESTER, NY, 14642 (Reprint); UNIV ROCHESTER, SCH MED, DEPT ANAT, ROCHESTER, NY, 14642; UNIV ROCHESTER, SCH MED, DEPT OPHTHALMOL, ROCHESTER, NY, 14642; RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT NEUROL SCI, CHICAGO, IL, 60612
CS
CYA
       USA
       BRAIN RESEARCH, (
                              ***06 MAR 1992*** ) Vol. 574, No. 1-2, pp. 1-8.
SO
       ISSN: 0006-8993.
DT
       Article; Journal
FS
       LIFE
LА
       ENGLISH
REC
       Reference Count: 27
       *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
L9
      ANSWER 45 OF 175
                             SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
ΑN
       92:24960 SCISEARCH
GA
       The Genuine Article (R) Number: GV928
       THE EFFECT OF A NEW IMMUNOSUPPRESSIVE AGENT, FK-506, ON XENOGENEIC
TI
         ***NEURAL***
                               ***TRANSPLANTATION***
                                                               IN RODENTS
      SAKAI K (Reprint); DATE I; YOSHIMOTO Y; ARISAWA T; NAKASHIMA H; FURUTA T; ASARI S; OHMOTO T OKAYAMA UNIV, SCH MED, DEPT NEUROL SURG, 2-5-1 SHIKATA CHO, OKAYAMA 700,
AU
CS
       JAPAN (Reprint)
CYA
      JAPAN
      BRAIN RESEARCH, ( ***22 NOV 1991*** ) Vol. 565, No. 1, pp. 167-170.
SO
       ISSN: 0006-8993.
DT
      Note; Journal
FS
      LIFE
LΑ
      ENGLISH
REC
      Reference Count: 32
       *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
L9
      ANSWER 46 OF 175
                             USPATFULL on STN
AN
         2003:6968 USPATFULL
ΤI
         GDNF receptor
         Klein, Robert D., South San Francisco, CA, United States
Moore, Mark W., San Francisco, CA, United States
Rosenthal, Arnon, Burlingham, CA, United States
Ryan, Anne M., Millbrae, CA, United States
TN
         Genentech, Inc., South San Francisco, CA, United States (U.S.
PA
         corporation)
         US 6504007
PI
                                        20030107
                                 B1
         WO 9733912
                        19970918
                                                                                        <--
ΑŢ
         US 1997-860370
                                        19970606 (8)
         WO 1997-US4363
                                        19970313
                                        19970606
                                                     PCT 371 date
RLI
         Continuation-in-part of Ser. No. US 1996-618236, filed on 14 Mar 1996,
         now abandoned Continuation-in-part of Ser. No. US 1996-615902, filed on
         14 Mar 1996, now abandoned
DT
         Utility
FS
         GRANTED
LN.CNT
         4881
INCL
         INCLM: 530/350.000
         INCLS: 930/010.000
NCL
         NCLM:
                  530/350.000
         NCLS:
                  930/010.000
IC
         [7]
```

```
EXF
            536/23.1; 536/23.4; 536/23.5; 435/69.1; 435/325; 435/320.1; 530/350;
            930/10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
        ANSWER 47 OF 175 USPATFULL on STN
Ь9
            2002:160547
ΑN
                                 USPATFULL
TI
            Tyrosine kinase receptors and ligands
IN
            Valenzuela, David M., Yorktown Heights, NY, United States
            Glass, David J., Cortlandt Manor, NY, United States
Bowen, David C., Washington, DC, United States
            Yancopoulos, George D., Yorktown Heights, NY, United States
PA
            Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States (U.S.
            corporation)
PΙ
            US 6413740
                                                    20020702
            WO 9721811
                                19970619
                                                                                                                  <--
            US 1998-77955
                                                    19980910 (9)
ΑI
            WO 1996-US20695
                                                    19961213
                                                    19980910
                                                                    PCT 371 date
            Continuation-in-part of Ser. No. US 1996-644271, filed on 10 May 1996,
RLI
            now patented, Pat. No. US 5814478
            US 1995-8657P
                                             19951215 (60)
PRAI
            Utility
DT
FS
            GRANTED
LN.CNT
           3819
INCL
            INCLM: 435/069.100
            INCLS: 435/070.100; 435/071.100; 435/071.200; 536/023.500; 530/350.000
NCL
            NCLM:
                       435/069.100
                       435/070.100; 435/071.100; 435/071.200; 530/350.000; 536/023.500
            NCLS:
IC
            [7]
            ICM: C12P021-06
ICS: C12P021-04; C07H021-04; C07K001-00; C12N015-74

EXF 514/2; 530/350; 530/300; 536/23.1; 536/23.5; 435/69.1; 435/70.1;

435/71.1; 435/71.2; 435/252.3; 435/320.1; 435/325; 435/471

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
        ANSWER 48 OF 175 USPATFULL 2001:231277 USPATFULL
L9
                                     USPATFULL on STN
AN
            Carboxylic acids and carboxylic acid isosteres of N-heterocyclic
TI
            compounds
           Hamilton, Gregory S., Catonsville, MD, United States
Norman, Mark H., Thousand Oaks, CA, United States
Wu, Yong-Qian, Columbia, MD, United States
GPI Nil Holdings, Inc., Wilmigton, DE, United States (U.S. corporation)
IN
PA
PI
            US 6331537
                                                    20011218
                                           B1
AΙ
            US 1999-453571
                                                    19991202 (9)
            Continuation-in-part of Ser. No. US 1998-204237, filed on 3 Dec 1998,
RLI
            now abandoned
DT
            Utility
FS
            GRANTED
LN.CNT
           3547
            INCLM: 514/215.000
INCL
            INCLS: 548/200.000; 548/201.000; 548/123.000; 548/124.000; 548/127.000;
                       548/128.000; 548/131.000; 548/132.000; 548/134.000; 548/135.000;
                       548/128.000; 548/131.000; 548/132.000; 548/134.000; 548/135.000; 548/136.000; 548/136.000; 548/136.000; 548/215.000; 548/240.000; 548/255.000; 548/262.200; 548/300.100; 548/311.100; 548/356.100; 548/364.100; 548/366.400; 548/540.000; 548/212.000; 548/326.000; 548/360.000; 548/361.000; 548/362.000; 548/363.000; 548/364.000; 548/365.000; 548/369.000; 548/371.000; 548/572.000; 548/374.000; 548/376.000; 548/378.000; 548/380.000; 548/383.000; 548/396.000; 548/401.000; 548/402.000; 548/406.000; 540/596.000; 540/597.000; 540/603.000; 546/207.000; 546/208.000;
                       546/209.000; 546/210.000
                       514/215.000
NCL
            NCLM:
                       540/596.000; 540/597.000; 540/602.000; 540/603.000; 546/207.000;
            NCLS:
                       540/596.000; 540/597.000; 540/602.000; 540/603.000; 546/207.000; 546/208.000; 546/209.000; 546/210.000; 548/123.000; 548/124.000; 548/127.000; 548/128.000; 548/131.000; 548/132.000; 548/134.000; 548/135.000; 548/136.000; 548/143.000; 548/182.000; 548/200.000; 548/201.000; 548/206.000; 548/212.000; 548/215.000; 548/240.000; 548/255.000; 548/262.200; 548/300.100; 548/311.100; 548/356.100; 548/364.100; 548/364.000; 548/401.000; 548/402.000; 548/406.000;
                       548/540.000; 548/572.000
IC
            [7]
            ICM: A01N043-46
            ICS: A61K031-55; C07D403-12
EXF
            548/200; 548/201; 548/540; 548/123; 548/124; 548/127; 548/128; 548/131;
```

```
548/250; 548/255; 548/262.2; 548/300.1; 548/311.1; 548/356.1; 548/364.1;
        548/366.4; 514/360; 514/361; 514/362; 514/363; 514/364; 514/365;
514/369; 514/371; 514/372; 514/374; 514/376; 514/378; 514/380; 514/383; 514/396; 514/401; 514/402; 514/406; 514/326; 514/212; 514/215
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
     ANSWER 49 OF 175
                           USPATFULL on STN
        2001:231143 USPATFULL
AN
TI
        Arrays for identifying agents which mimic or inhibit the activity of
        interferons
IN
        Silverman, Robert H., Beachwood, OH, United States
        Williams, Bryan R. G., Cleveland, OH, United States
Der, Sandy, Cleveland, OH, United States
PA
        The Cleveland Clinic Foundation, Cleveland, OH, United States (U.S.
        corporation)
                                     20011218
PΙ
        US 6331396
                              В1
        US 1999-405438
                                     19990923 (9)
AΙ
        US 1998-101497P
                                19980923 (60)
PRAI
DT
        Utility
FS
        GRANTEĎ
LN.CNT
        9639
        INCLM: 435/006.000
INCL
        INCLS: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310
                435/006.000
NCL
        NCLM:
        NCLS:
                435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310
        [7]
IC
        ICM: C12Q001-68
        ICS: C12M001-36; C07H021-04
        435/6; 435/287.2; 536/23.1; 536/24.31; 536/23.52
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
     ANSWER 50 OF 175
                          USPATFULL on STN
                       USPATFULL
AN
        2001:224608
        METHOD FOR PROVIDING PATHOGEN-FREE PORCINE TISSUE SUITABLE FOR HUMAN
ΤI
          ***TRANSPLANTATION***
IN
        HUNTER, RICHARD, PRINCETON, NJ, United States
        EGAN, E. MICHAEL, BROOKLINE, MA,
                                               United States
        DIACRIN, INC. (U.S. corporation)
PA
        US 2001049827
                              A1
PI
                                    20011206
        US 1997-906009
                              Α1
                                    19970804 (8)
AI
        Continuation of Ser. No. US 1996-630282, filed on 10 Apr 1996, ABANDONED
RLI
DT
        Utility
        APPLICATION
FS
LN.CNT
        1007
INCL
        INCLM: 800/008.000
        INCLS: 435/178.000; 424/093.100; 424/093.700; 424/093.210
NCL
                800/008.000
        NCLM:
        NCLS:
                435/178.000; 424/093.100; 424/093.700; 424/093.210
IC
        [7]
        ICM: A01K067-00
        ICS: A01K067-033; A61K048-00
                          USPATFULL on STN
L9
     ANSWER 51 OF 175
AN
        2001:212419 USPATFULL
        Inhibition of apoptosis using interleukin-1B-converting enzyme
TI
        (ICE)/CED-3 family inhibitors
        Fritz, Lawrence C., Rancho Santa Fe, CA, United States Tomaselli, Kevin J., San Diego, CA, United States Karanewski, Donald S., Escondido, CA, United States Linton, Steven D., San Diego, CA, United States Bai, Xu, Carlsbad, CA, United States
IN
        US 2001044415
                              A1
                                    20011122
PΙ
        US 2001-737169
AΙ
                              A1
                                    20010312
        Continuation of Ser. No. US 1997-979909, filed on 12 Sep 1997, GRANTED,
RLI
        Pat. No. US 6200969
PRAI
        US 1996-26011P
                                19960912 (60)
DT
        Utility
        APPLICĀTION
FS
LN.CNT
        4242
INCL
        INCLM: 514/044.000
NCL
        NCLM:
                514/044.000
IC
        [7]
        ICM: A61K048-00
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
2001:202682 USPATFULL
AN
TI
          Therapeutic methods employing disulfide derivatives of dithiocarbonates
          and compositions useful therefor
         Lai, Ching-San, Encinitas, CA, United States
Vassilev, Vassil, San Diego, CA, United States
Medinox, Inc., San Diego, CA, United States (U.S. corporation)
US 6316502 B1 20011113 <
IN
PA
          US 6316502
PΙ
         US 2000-565666
                                           20000505 (9)
ΑI
         Division of Ser. No. US 1998-103639, filed on 23 Jun 1998, now patented,
RLI
          Pat. No. US 6093743
DT
          Utility
          GRANTED
FS
LN.CNT 2591
         INCLM: 514/599.000
INCLS: 514/707.000; 514/825.000; 514/838.000; 514/851.000; 514/861.000; 514/866.000; 514/885.000; 514/903.000; 514/912.000; 514/925.000
INCL
                   514/599.000
514/707.000; 514/825.000; 514/838.000; 514/851.000; 514/861.000;
         NCLM:
NCL
         NCLS:
                   514/866.000; 514/885.000; 514/903.000; 514/912.000; 514/925.000
          [7]
IC
          ICM: A01N037-18
EXF 514/599; 514/707; 514/825; 514/838; 514/851; 514/861; 514/863; 514/885; 514/866; 514/903; 514/912; 514/925 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
       ANSWER 53 OF 175 USPATFULL on STN
          2001:202588 USPATFULL
AN
TI
            ***Cyclosporin***
                                          ***a***
                                                        conjugates and uses therefor
         Rich, Daniel H., Madison, WI, United States
IN
          Solomon, Michael E., Arlington, MA, United States
PA
         Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S.
         corporation)
         US 6316405
US 1999-242724
                                           20011113
                                                                                              <--
PΙ
                                    B1
                                           19990222
AI
                                                       (9)
         WO 1998-US17544
                                           19980825
                                           19990222
                                                        PCT 371 date
                                                        PCT 102(e) date
                                           19990222
         US 1997-57751P
PRAI
                                     19970826 (60)
DT
         Utility
         GRANTEĎ
FS
LN.CNT
         2215
          INCLM: 514/009.000
INCLS: 514/002.000; 514/014.000; 514/012.000; 435/007.100; 530/317.000; 530/326.000; 530/327.000
INCL
NCL
         NCLM:
                   514/009.000
         NCLS:
                   435/007.100; 514/002.000; 514/012.000; 514/014.000; 530/317.000;
                   530/326.000; 530/327.000
IC
          [7]
          ICM: A61K038-00
ICS: A61K038-12; C07K016-00; C07K017-00

EXF 514/2; 514/9; 514/14; 514/12; 435/7.1; 530/317; 530/326; 530/327

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
       ANSWER 54 OF 175
                              USPATFULL on STN
AN
         2001:200558 USPATFULL
TI
          Cloned ungulate embryos and animals, use of cells, tissues and organs
                            ***transplantation***
          thereof for
                                                            therapies including
            ***parkinson***
                                    's disease
         Stice, Steven L., Belchertown, MA, United States
Cibelli, Jose, Amherst, MA, United States
Robl, James M., Belchertown, MA, United States
University of Massachusetts, Amherst, MA, United States (U.S.
IN
PA
         corporation)
         US 2001039667
PI
                                    A 1
                                           20011108
AΙ
         US 2001-845352
                                   A1
                                          20010501 (9)
          Continuation of Ser. No. US 1998-66652, filed on 27 Apr 1998, PENDING
RLI
         Continuation-in-part of Ser. No. US 1998-4606, filed on 8 Jan 1998, GRANTED, Pat. No. US 6215041 Continuation-in-part of Ser. No. US
         1997-888057, filed on 3 Jul 1997, GRANTED, Pat. No. US 6235969
Continuation-in-part of Ser. No. US 1997-781752, filed on 10 Jan 1997, GRANTED, Pat. No. US 5945577
DT
         Utility
FS
         APPLICATION
LN.CNT
         3256
INCL
         INCLM: 800/015.000
```

```
800/015.000
NCL
        NCLM:
                424/093.210; 435/325.000
        NCLS:
IC
        [7]
        ICM: A01K067-027
        ICS: A61K048-00; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 55 OF 175
L9
                         USPATFULL on STN
        2001:194124 USPATFULL
AN
TI
        Combinatorial enzymatic complexes
        Nolan, Garry P., Menlo Park, CA, United States
IN
        Payan, Donald, Hillsborough, CA, United States Rigel Pharmaceuticals, Inc. (U.S. corporation)
PA
        US 2001036638
                                    20011101
                              A1
PI
        US 2001-789652
                              A1
                                    20010220 (9)
AI
        Division of Ser. No. US 1997-873601, filed on 12 Jun 1997, PENDING
RLI
DT
        Utility
        APPLICATION
FS
LN.CNT
        2249
        INCLM: 435/007.100
INCL
        INCLS: 435/325.000
NCL
        NCLM:
                435/007.100
        NCLS:
                435/325.000
IC
        [7]
        ICM: G01N033-53
        ICS: C12N005-06; C12N005-08; C12N005-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 56 OF 175
                          USPATFULL on STN
L9
AN
        2001:188210
                      USPATFULL
        Methods for inducing T cell tolerance to a tissue or organ graft Noelle, Randolph J., Cornish, NH, United States Durie, Fiona H., Seattle, WA, United States
TI
IN
PA
        Trustees of Dartmouth College, Hanover, NH, United States (U.S.
        corporation)
PΙ
        US 2001033840
                                    20011025
                              Α1
        US 2001-888639
AΙ
                              A1
                                    20010626 (9)
        Continuation of Ser. No. US 1999-227081, filed on 5 Jan 1999, PENDING
RLI
        Division of Ser. No. US 1997-906332, filed on 5 Aug 1997, GRANTED, Pat. No. US 5902585 Division of Ser. No. US 1994-234987, filed on 25 Apr
        1994, GRANTED, Pat. No. US 5683693
Utility
APPLICATION
DT
FS
LN.CNT
        1061
INCL
        INCLM: 424/144.100
NCL
        NCLM:
                424/144.100
        [7]
IC
        ICM: A61K039-395
L9
     ANSWER 57 OF 175
                          USPATFULL on STN
AN
        2001:185549
                       USPATFULL
        Infection of human
                                ***neural***
TI
                                                  xenografts
        Epstein, Leon G., 80 Council Rock Ave., Rochester, NY, United States
IN
        14610
        Del Cerro, Manuel, 13 Tall Acres Dr., Pittsford, NY, United States
        Blumberg, Benjamin M., 32 Calumet St., Rochester, NY, United States
        14610
        US 6307122
US 1992-965901
PΙ
                                    20011023
                              B1
ΑI
                                    19921023
        Continuation-in-part of Ser. No. US 1991-786449, filed on 1 Nov 1991
RLI
DT
        Utility
FS
        GRANTEĎ
LN.CNT
        829
INCL
        INCLM: 800/011.000
        INCLS: 800/003.000; 800/018.000; 424/009.000; 424/093.100
NCL
        NCLM:
                800/011.000
        NCLS:
                424/093.100; 800/003.000; 800/018.000
IC
        [7]
        ICM: A01N063-00
424/9; 424/93; 424/570; 424/571; 424/520; 424/582; 424/578; 800/2;
EXF
        800/DÍG.2; 800/DÍG.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

ANSWER 58 OF 175 USPATFULL on STN

```
TI
                               ***neural***
              Porcine
                                                            cells and their use in treatment of
              neurological deficits due to neurodegenerative diseases
             Isacson, Ole, Cambridge, MA, United States
Dinsmore, Jonathan, Brookline, MA, United States
The McLean Hospital Corporation, Belmont, MA, United States (U.S.
IN
PA
              corporation)
             Diacrin, Inc., Charlestown, MA, United States (U.S. corporation) US 6294383 B1 20010925 <--
PI
ΑI
              US 1995-424851
                                                            19950419 (8)
              Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994,
RLI
              now abandoned
DT
              Utility
FS
              GRANTED
LN.CNT
             4123
              INCLM: 435/379.000
INCL
              INCLS: 435/325.000
                          435/379.000
NCL
             NCLM:
             NCLS:
                          435/325.000
              [7]
IC
              ICM: C12N005-00
              ICS: C12N005-02
              435/240.1; 435/240.2; 435/325; 435/379
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
         ANSWER 59 OF 175
L9
                                           USPATFULL on STN
              2001:163016 USPATFULL
AN
              Use of multipotent
                                                     ***neural***
TI
                                                                                 stem cells and their progeny for the
              screening of drugs and other biological agents
             Weiss, Samuel, Calgary, Canada
Reynolds, Brent, Calgary, Canada
Hammang, Joseph P., Barrington, RI, United States
Baetge, E. Edward, Barrington, RI, United States
Neurospheres Holdings, Ltd., Alberta, Canada (non-U.S. corporation)
IN
PA
                                                           20010925
ΡI
             US 6294346
                                                 B1
ΑI
             US 1995-484406
                                                           19950607 (8)
             Continuation-in-part of Ser. No. US 1995-385404, filed on 7 Feb 1995,
RLI
             Continuation-in-part of Ser. No. US 1995-385404, filed on 7 Feb 1995, now abandoned, said Ser. No. US 484406 And Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned, said Ser. No. US 484406 And Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned, said Ser. No. US 484406 And Ser. No. US 1994-338730, filed on 14 Nov 1994, now abandoned, said Ser. No. US 484406 And Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned, said Ser. No. US 484406 And Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned, said Ser. No. US 484406 And Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned Continuation of Ser. No. US 1992-961813, filed on 16 Oct
             now abandoned Continuation of Ser. No. US 1992-961813, filed on 16 Oct
             now abandoned Continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned Continuation-in-part of Ser. No. US 726812

Continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, now abandoned Continuation-in-part of Ser. No. US 726812 Continuation of Ser. No. US 1994-221655, filed on 1 Apr 1994, now abandoned Continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned Continuation-in-part of Ser. No. US 726812, said Ser. No. US 338730

Continuation-in-part of Ser. No. US 726812, said Ser. No. US 311099

Continuation-in-part of Ser. No. US 726812, said Ser. No. US 270412
             Continuation-in-part of Ser. No. US 726812 , said Ser. No. US 270412
             Continuation-in-part of Ser. No. US 726812
DT
             Utility
             GRANTED
FS
LN.CNT
             4153
              INCLM: 435/007.210
INCL
             INCLS: 435/368.000; 435/377.000; 435/375.000
                           435/007.210
NCL
             NCLM:
             NCLS:
                          435/368.000; 435/375.000; 435/377.000
IC
              [7]
             ICM: G01N033-554
             ICS: C12N005-00
EXF 435/7.21; 435/368; 435/378; 435/377; 435/375 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
         ANSWER 60 OF 175 USPATFULL 2001:152476 USPATFULL
L9
                                          USPATFULL on STN
AN
TI
             Devices containing cells or tissue and an agent that inhibits damage by
             a host cell molecule
IN
             Lanza, Robert P., Clinton, MA, United States
             Ecker, Dawn M., Shrewsbury, MA, United States
```

Ringeling, John, Boston, MA, United States

```
Chick, William, Wellesley, MA, United States
PA
          BioHybrio Technologies LLC, Shrewsbury, MA, United States (U.S.
          corporation)
PI
                                           20010911
          US 6287558
                                    B1
AI
          US 1997-904808
                                           19970801 (8)
DT
          Utility
FS
          GRANTED
LN.CNT
         3319
INCL
          INCLM: 424/093.700
          INCLS: 424/130.100; 424/423.000; 435/177.000; 435/178.000; 435/182.000; 435/382.000; 435/395.000; 435/397.000; 436/528.000; 436/529.000; 436/535.000; 530/812.000; 530/813.000; 530/817.000
                   424/093.700
NCL
          NCLM:
                   424/130.100; 424/423.000; 435/177.000; 435/178.000; 435/182.000; 435/382.000; 435/395.000; 435/397.000; 436/528.000; 436/529.000; 436/535.000; 530/812.000; 530/813.000; 530/817.000
          NCLS:
          [7]
IC
          ICM: A61K035-12
          ICS: C12N011-00; C12N011-04; C12N005-00
          435/174; 435/177; 435/178; 435/182; 435/395; 435/397; 435/382; 424/93.7; 424/423; 424/130.1; 436/528; 436/529; 436/535; 530/812; 530/813; 530/817
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
       ANSWER 61 OF 175
                               USPATFULL on STN
AN
          2001:136181 USPATFULL
                       ***neural***
TI
                                            cells and their use in treatment of
          Porcine
         neurological deficits due to neurodegenerative diseases
IN
          Fraser, Thomas, Newton, MA, United States
         Dinsmore, Jonathan, Brookline, MA, United States
         Diacrin,
PA
                      Inc., Charlestown, MA, United States (U.S. corporation)
         US 6277372
US 1995-424855
PI
                                   В1
                                           20010821
         US 1995-424855 19950419 (8)
Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994,
AI
RLI
         now abandoned
DT
         Utility
FS
          GRANTED
LN.CNT
         4112
INCL
          INCLM: 424/093.700
          INCLS: 424/093.100; 435/325.000
NCLM: 424/093.700
NCL
         NCLM:
                   424/093.100; 435/325.000
         NCLS:
          [7]
IC
          ICM: A01N063-00
          ICS: C12N005-02; C12N005-06
EXF
          435/325; 424/93.1; 424/93.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
       ANSWER 62 OF 175
                               USPATFULL on STN
         2001:131342 USPATFULL
AN
         Conjugates of dithiocarbamate disulfides with pharmacologically active
TI
         agents and uses therefor
         Lai, Ching-San, Encinitas, CA, United States
IN
         Vassilev, Vassil P., San Diego, CA, United States
Wang, Tingmin, San Marcos, CA, United States
Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PA
         US 6274627
US 1999-41
PI
                                   B1
                                           20010814
AΙ
             1999-416619
                                           19991012 (9)
         Utility
DT
FS
         GRANTED
LN.CNT
         2173
INCL
         INCLM: 514/599.000
         INCLS: 514/706.000; 514/707.000
                   514/599.000
NCL
         NCLM:
                   514/706.000; 514/707.000
         NCLS:
IC
          [7]
         ICM: A61K031-16
ICS: A61K031-095; A61K031-105
EXF 514/599; 514/706; 514/707
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
Ь9
       ANSWER 63 OF 175
                               USPATFULL on STN
         2001:126193 USPATFULL
AN
         Cells and methods for the generation of transgenic pigs
Piedrahita, Jorge A., College Station, TX, United States
Bazer, Fuller W., College Station, TX, United States
TI
IN
```

```
(U.S. corporation)
PI
           US 6271436
                                       B1
                                               20010807
                                                                                                        <--
           US 1997-949155
AΙ
                                                19971010 (8)
           US 1996-27338P
                                         19961011 (60)
PRAI
           US 1997-46094P
                                         19970509 (60)
DT
           Utility
           GRANTED
FS
LN.CNT 8905
INCL
           INCLM: 800/021.000
           INCLS: 800/022.000; 800/024.000; 800/025.000; 800/014.000; 800/017.000; 800/018.000; 800/015.000; 800/016.000; 435/325.000; 435/383.000;
                     435/384.000; 435/455.000; 435/463.000; 435/461.000; 435/459.000;
                     435/462.000
                     800/021.000
NCL
           NCLM:
                     435/325.000; 435/383.000; 435/384.000; 435/455.000; 435/459.000; 435/461.000; 435/462.000; 435/463.000; 800/014.000; 800/015.000; 800/016.000; 800/017.000; 800/018.000; 800/022.000; 800/024.000;
           NCLS:
                     800/025.000
IC
           [7]
           ICM: C12N015-09
           ICS: C12N015-00; C12N015-63; C12N005-00
           435/325; 435/383; 435/384; 435/455; 435/463; 435/461; 435/459; 435/462; 800/13; 800/14; 800/15; 800/16; 800/17; 800/21; 800/22; 800/24; 800/25;
EXF
           800/18
       ANSWER 64 OF 175
L9
                                  USPATFULL on STN
AN
           2001:126109
                             USPATFULL
TI
           Tetracycline-inducible transcriptional inhibitor fusion proteins
           Bujard, Hermann, Heidelberg, Germany, Federal Republic of
Gossen, Manfred, El Cerrito, CA, United States
IN
           BASF Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of
PA
           (non-U.S. corporation)
           Knoll Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of
           (non-U.S. corporation)
           ÚS 6271348
PΙ
                                               20010807
ΑI
           US 2000-489777
                                               20000124 (9)
          Division of Ser. No. US 1998-162184, filed on 28 Sep 1998, now patented, Pat. No. US 6136954 Continuation of Ser. No. US 1995-485978, filed on 7
RLI
          Jun 1995, now patented, Pat. No. US 5814618 Continuation-in-part of Ser. No. US 1995-383754, filed on 3 Feb 1995, now patented, Pat. No. US 5789156 Continuation-in-part of Ser. No. US 1994-275876, filed on 15 Jul 1994, now patented, Pat. No. US 5654168 Continuation-in-part of Ser. No. US 1994-270637, filed on 1 Jul 1994, now abandoned Continuation-in-part of Ser. No. US 1994-260452, filed on 14 Jun 1994, now patented, Pat. No. US 5650298 Continuation-in-part of Ser. No. US 1993-76327, filed on 19
           Jun 1993, now abandoned Continuation-in-part of Ser. No. US 1993-76726,
           filed on 14 Jun 1993, now patented, Pat. No. US 5464758
DT
           Utility
           GRANTED
FS
LN.CNT
          4009
INCL
           INCLM: 530/350.000
           INCLS: 435/006.000; 435/069.100; 536/023.400
NCL
                     530/350.000
          NCLS:
                     435/006.000; 435/069.100; 536/023.400
IC
           [7]
           ICM: C07K019-00
     ICS: C07K014-195
530/350; 435/6; 435/69.1; 536/23.4
INDEXING IS AVAILABLE FOR THIS PATENT.
EXF
CAS
       ANSWER 65 OF 175
L9
                                  USPATFULL on STN
AN
           2001:126102 USPATFULL
           Transcriptional activators with graded transactivation potential
ΤI
          Baron, Udo, St. Ilgen, Germany, Federal Republic of
Gossen, Manfred, El Cerrito, CA, United States
Bujard, Hermann, Heidelberg, Germany, Federal Republic of
IN
          BASF Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of
PA
           (non-U.S. corporation)
          Udo Baron, St. Ilgen, Germany, Federal Republic of (non-U.S.
           corporation)
PΙ
          US 6271341
                                               20010807
                                       B1
ΑI
          US 2000-577027
                                               20000523
                                                             (9)
          Division of Ser. No. US 1997-888080, filed on 3 Jul 1997, now patented,
RLI
           Pat. No. US 6087166
DT
```

Utility

```
LN.CNT 1847
          INCLM: 530/300.000
INCLS: 530/324.000; 530/350.000
NCLM: 530/300.000
NCLS: 530/324.000; 530/350.000
INCL
NCL
IC
           [7]
          ICM: C07K019-00
EXF 530/300; 530/324; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
       ANSWER 66 OF 175
                                USPATFULL on STN
ΑN
          2001:116980 USPATFULL
          Peptide T and related peptides in the treatment of inflammation,
TI
          including multiple sclerosis
Andersen, Anders Jorgen, Kokkedal, Denmark
Aston, Roger, Wiltshire, United Kingdom
Carlen, Peter Louis, Ontario, Canada
Doob, Penelope Reed, Ontario, Canada
IN
          MacFadden, Douglas Kevin, Ontario, Canada
          Phipps, David James, Ontario, Canada
          Rathjen, Deborah, New South Wales, Australia Widmer, Fred, New South Wales, Australia
          Advanced Immuni T, Inc., Stonybrook, NY, United States (U.S.
PA
          corporation)
ΡI
          US 6265374
                                             20010724
          US 1999-421845
ΑI
                                             19991020 (9)
          Continuation of Ser. No. US 1998-82837, filed on 21 May 1998, now
RLI
          patented, Pat. No. US 6011014 Continuation of Ser. No. US 1995-302829,
          filed on 24 Feb 1995, now patented, Pat. No. US 5756449 Continuation of Ser. No. WO 1993-GB649, filed on 29 Mar 1993 Continuation of Ser. No. US 1992-987674, filed on 9 Dec 1992, now abandoned Continuation-in-part of Ser. No. US 1992-915118, filed on 17 Jul 1992, now abandoned Continuation-in-part of Ser. No. US 1992-858832, filed on 27 Mar 1992,
          now abandoned
          Utility
DT
FS
          GRANTED
LN.CNT
          2172
INCL
          INCLM: 514/008.000
          INCLS: 514/015.000; 514/016.000; 514/017.000; 530/300.000; 530/322.000; 530/328.000; 530/329.000; 424/185.100
                    514/008.000
NCL
          NCLM:
                    424/185.100; 514/015.000; 514/016.000; 514/017.000; 530/300.000;
          NCLS:
                    530/322.000; 530/328.000; 530/329.000
IC
          ICM: A61K038-00
          ICS: A61K038-16; A61K038-04; C07K005-00; C07K007-00
EXF 514/8; 514/15; 514/16; 514/17; 514/18; 514/19; 530/300; 530/322; 530/328; 530/329; 530/330; 530/331; 424/185.1 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 67 OF 175
L9
                                 USPATFULL on STN
AN
          2001:98155
                          USPATFULL
TI
          Transgenic organisms having tetracycline-regulated transcriptional
          regulatory systems
          Bujard, Hermann, Heidelberg, Germany, Federal Republic of
Gossen, Manfred, El Cerrito, CA, United States
IN
          Salfeld, Jochen G., North Grafton, MA, United States
          Voss, Jeffrey W., West Boylston, MA, United States
BASF Aktiengesellschaft, Germany, Federal Republic of (non-U.S.
PA
          corporation)
          Knoll Aktiengesellschaft, Germany, Federal Republic of (non-U.S.
          corporation)
          US 6252136
PI
                                             20010626
                                                                                                    <--
AI
          US 1998-163269
                                             19980929 (9)
RLI
          Continuation of Ser. No. US 1995-481970, filed on 7 Jun 1995, now
          patented, Pat. No. US 5859310 Continuation-in-part of Ser. No. US
          1994-260452, filed on 14 Jun 1994, now patented, Pat. No. US 5650298 Continuation-in-part of Ser. No. US 1993-76327, filed on 14 Jun 1993,
          now abandoned Utility
DT
FS
          GRANTED
          3033
LN.CNT
INCL
          INCLM: 800/278.000
          INCLS: 435/069.100; 435/069.700; 435/320.100; 435/468.000; 800/288.000;
                    800/298.000
```

```
NCLS:
                 435/069.100; 435/069.700; 435/320.100; 435/468.000; 800/288.000;
                 800/298.000
IC
         [7]
         ICM: C12N015-09
         ICS: C12N015-82; C12N015-87; C12N015-90; A01H005-00
         435/69.1; 435/410; 435/419; 435/468; 435/69.7; 435/320.1; 800/278; 800/288; 800/295; 800/298
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 68 OF 175
                           USPATFULL on STN
AN
         2001:89522
                       USPATFULL
           ***Neural***
                                ***transplantation*** using pluripotent
TI
         neuroepithelial cells
         Sinden, John, London, Great Britain
IN
         Gray, Jeffrey A., London, Great Britain
         Hodges, Helen, London, Great Britain
        Kershaw, Timothy, London, Great Britain
Rashid-Doubell, Fiza, Oxford, Great Britain
PΙ
        US 2001001662
                                      20010524
                                A1
        US 2001-760274
ΑI
                               A1
                                      20010112
RLI
         Continuation of Ser. No. US 2000-672606, filed on 28 Sep 2000, UNKNOWN
PRAI
        GB 1995-18606
                                 19950912
DT
         Utility
        APPLICATION
FS
LN.CNT
        1036
INCL
         INCLM: 424/093.210
         INCLS: 424/093.700
NCL
                 424/093.210
        NCLM:
        NCLS:
                 424/093.700
IC
         [7]
         ICM: A61K048-00
         ICS: A01N063-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 69 OF 175
                            USPATFULL on STN
AN
        2001:82992
                      USPATFULL
TI
        Transgenic organisms having tetracycline-regulated transcriptional
        regulatory systems
IN
        Bujard, Hermann, Heidelberg, Germany, Federal Republic of
        Gossen, Manfred, El Cerrito, CA, United States
PA
        BASF Aktiengesellschaft, Germany, Federal Republic of (non-U.S.
        corporation)
        Knoll Aktiengesekkscgaft, Germany, Federal Republic of (non-U.S.
        corporation)
PΙ
        US 6242667
                                      20010605
                                B1
AΙ
        US 1998-161902
                                      19980928 (9)
        Continuation of Ser. No. US 1995-487472, filed on 7 Jun 1995, now
RLI
        patented, Pat. No. US 5694426 Continuation-in-part of Ser. No. US
        1995-383754, filed on 3 Feb 1995, now patented, Pat. No. US 5789156
        Continuation-in-part of Ser. No. US 1994-275876, filed on 15 Jul 1994,
        now patented, Pat. No. US 5654168 Continuation-in-part of Ser. No. US 1994-270637, filed on 1 Jul 1994, now abandoned Continuation-in-part of Ser. No. US 1994-260452, filed on 14 Jun 1994, now patented, Pat. No. US 5650298 Continuation-in-part of Ser. No. US 1993-76327, filed on 14 Jun 1994, now patented, Pat. No. US 1993-76327, filed on 14 Jun 1993-76327, filed on 14 Jun 1993-76328
        1993, now abandoned Continuation-in-part of Ser. No. US 1993-76726,
        filed on 14 Jun 1993, now patented, Pat. No. US 5464758
DT
        Utility
FS
        Granted
LN.CNT
        4161
        INCLM: 800/278.000
INCL
        INCLS:
                 435/069.100; 435/069.700; 435/320.100; 435/468.000; 800/287.000;
                 800/288.000; 800/298.000
        NCLM:
                 800/278.000
NCL
                 435/069.100; 435/069.700; 435/320.100; 435/468.000; 800/287.000;
        NCLS:
                 800/288.000; 800/298.000
IC
         [7]
        ICM: C12N015-09
        ICS: C12N015-82; C12N015-87; C12N015-90; A01H005-00
EXF 435/455; 435/69.1; 435/320.1; 435/468; 435/69.7; 800/8; 800/21; 800/278; 800/288; 800/295; 800/298; 800/287
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

AN

ΤI

ANSWER 70 OF 175

2001:55995

USPATFULL on STN

Aminoiminoquinone and aminoquinone alkaloid compounds and methods of use

USPATFULL

```
McCarthy, Peter J., Vero Beach, FL, United States
Longley, Ross E., Vero Beach, FL, United States
Pomponi, Shirley A., Ft. Pierce, FL, United States
Wright, Amy E., Ft. Pierce, FL, United States
        Harbor Branch Oceanographic Institution, Inc., Fort Pierce, FL, United
PA
        States (U.S. corporation)
PI
        US 6218419
                                     20010417
        US 1999-349070
AΙ
                                     19990708 (9)
        US 1998-92020P
                                19980708 (60)
PRAI
DT
        Utility
FS
        Granted
LN.CNT
        2227
INCL
        INCLM: 514/415.000
        INCLS: 514/427.000; 548/469.000; 548/494.000; 548/511.000; 548/516.000
NCL
        NCLM:
                 514/415.000
        NCLS:
                 514/427.000; 548/469.000; 548/494.000; 548/511.000; 548/516.000
         [7]
IC
        ICM: A61K031-404
        ICS: A61P035-00; A61P037-02; C07D209-04; C07D209-12
EXF
        514/415; 514/427; 548/469; 548/494; 548/511; 548/516
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 71 OF 175
                          USPATFULL on STN
                     USPATFULL
AN
        2001:55464
TI
        Materials and methods for making improved micelle compositions
        Onyuksel, Hayat, Western Springs, IL, United States
Rubinstein, Israel, Highland Park, IL, United States
IN
        The Board of Trustees of the University of Illinois, Urbana, IL, United
PA
        States (U.S. corporation)
PI
        US 6217886
                                     20010417
        US 1999-239069
                                     19990127 (9)
AΙ
RLI
        Continuation-in-part of Ser. No. WO 1998-US14316, filed on 9 Jul 1998
PRAI
        US 1997-52078P
                            19970714 (60)
DT
        Utility
        Granted
FS
LN.CNT
        2282
INCL
        INCLM: 424/401.000
        INCLS: 424/450.000; 424/001.210; 424/009.321; 424/009.510; 514/002.000;
                 514/021.000; 514/937.000; 264/004.100; 264/004.300; 264/004.600
NCL
        NCLM:
                 424/401.000
        NCLS:
                 264/004.100; 264/004.300; 264/004.600; 424/001.210; 424/009.321;
                 424/009.510; 424/450.000; 514/002.000; 514/021.000; 514/937.000
IC
        ICM: A61K009-10
        ICS: A61K009-127
EXF
        424/450; 424/1.21; 424/9.321; 424/9.51; 424/417; 424/96.3; 424/401;
        514/2; 514/21; 514/937-943; 264/4.1; 264/4.3; 264/4.6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 72 OF 175
2001:40462 USI
                          USPATFULL on STN
L9
\mathbf{N}\mathbf{A}
                     USPATFULL
TI
        Pharmaceutical preparations of glutathione and methods of administration
        thereof
        Demopoulos, Harry B., Scarsdale, NY, United States Seligman, Myron L., Fairfield, CT, United States
IN
        Antioxidant Pharmaceuticals Corp., Elmsford, NY, United States (U.S.
PA
        corporation)
PΙ
        US 6204248
                                     20010320
                               B1
        US 1999-457642
AΙ
                                     19991209 (9)
        Continuation of Ser. No. US 331947 Continuation of Ser. No. US 1997-2100, filed on 31 Dec 1997, now abandoned
RLI
PRAI
        US 1996-34101P
                                19961231 (60)
        Utility
DT
FS
        Granted
LN.CNT
        5144
INCL
        INCLM: 514/021.000
        INCLS: 514/018.000
NCL
                514/021.000
        NCLM:
        NCLS:
                514/018.000
IC
        [7]
        ICM: A61K031-00
514/21; 514/18
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

ANSWER 73 OF 175 USPATFULL on STN

```
TI
         Porcine cortical cells and their use in treatment of neurological
         deficits due to neurodegenerative diseases
         Dinsmore, Jonathan, Brookline, MA, United States
Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)
IN
PA
         US 6204053
PI
                                       20010320
                                B1
ΑI
         US 1995-424856
                                       19950419 (8)
         Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994,
RLI
         now abandoned
DT
         Utility
         Granted
FS
LN.CNT
         3891
INCL
         INCLM: 435/325.000
         INCLS: 424/093.700; 435/374.000
NCLM: 435/325.000
NCL
                 424/093.700; 435/374.000
         NCLS:
IC
         [7]
         ICM: C12N005-00
EXF
         435/240.2; 435/325; 435/374; 424/93.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 74 OF 175 USPATFULL on STN
                       USPATFULL
AN
         2001:36816
TI
         Inhibition of apoptosis using interleukin-1.beta.-converting enzyme
         (ICE)/CED-3 family inhibitors
         Fritz, Lawrence C., Rancho Santa Fe, CA, United States
Tomaselli, Kevin J., San Diego, CA, United States
Karanewski, Donald S., Escondido, CA, United States
Linton, Steven D., San Diego, CA, United States
Bai, Xu, Carlsbad, CA, United States
Bdun Pharmaceuticals, Inc., La Jolla, CA, United States
Corporation
IN
PA
         corporation)
PI
         US 6200969
                                       20010313
                                B1
                                                                                     <--
AΙ
         US 1997-979909
                                       19970912
                                                  (8)
PRAI
         US 1996-26011P
                                 19960912 (60)
DT
         Utility
FS
         Granted
LN.CNT 4190
         INCLM: 514/214.000
INCLS: 514/419.000
NCLM: 514/212.050
INCL
NCL
         NCLM:
                 514/419.000
         NCLS:
IC
         [7]
         ICM: A61K031-55
         514/214; 514/419
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 75 OF 175 USPATE 2001:33078 USPATFULL
L9
                            USPATFULL on STN
AN
TI
         Human adenylate cyclase and use therefor
         Antoni, Ferenc, Edinburgh, United Kingdom
IN
         Paterson, Janice M, Edinburgh, United Kingdom
PA
         Medical Research Council, London, United Kingdom (non-U.S. corporation)
PI
         US 6197581
                                B1
                                      20010306
ΑI
         US 1999-398193
                                      19990917 (9)
RLI
         Continuation-in-part of Ser. No. US 894173, now patented, Pat. No. US
         6090612
PRAI
         GB 1995-2806
                                 19950214
         GB 1995-16528
                                 19950811
        Utility
DT
         Granted
LN.CNT
        2249
INCL
         INCLM: 435/325.000
         INCLS: 435/252.300; 435/252.330; 435/320.100; 435/369.000; 536/023.200
NCL
        NCLM:
                 435/325.000
        NCLS:
                 435/252.300; 435/252.330; 435/320.100; 435/369.000; 536/023.200
IC
         ICM: C12N005-10
        ICS: C12N005-00; C12N001-20; C12N015-00; C07H021-04
EXF 435/320.1; 435/232; 435/369; 435/252.3; 435/252.33; 435/325; 536/23.2 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 76 OF 175 USPATFULL on STN
AN
         2001:25652 USPATFULL
TI
        Expression of an exogenous gene in a mammalian cell by use of a
        non-mammalian DNA virus having an altered coat protein
```

```
Barsoum, James G., Lexington, MA, United States
PA
         The General Hospital Corporation, Boston, MA, United States (U.S.
         corporation)
        Biogen, Inc., Cambridge, MA, United States (U.S. corporation) US 6190887 B1 20010220
PΙ
         US 2000-514953
ΑI
                                      20000228 (9)
         Division of Ser. No. US 1997-927317, filed on 11 Sep 1997
RLI
DT
         Utility
FS
        Granted
LN.CNT
        2998
         INCLM: 435/069.700
INCL
         INCLS: 435/007.230; 435/069.100; 435/320.100; 514/012.000; 424/246.100
NCL
        NCLM:
                 435/069.700
        NCLS:
                 424/246.100; 435/007.230; 435/069.100; 435/320.100; 514/012.000
IC
         [7]
        ICM: C12P021-04
        ICS: C12P021-06; G01N033-574; C12N015-70; A61K039-07 435/69.7; 435/7.23; 435/920.1; 435/69.1; 435/230.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 77 OF 175 USPATFULL on STN
                      USPATFULL
AN
        2001:25458
        Methods for treating inflammatory conditions Mak, Vivien H. W., Menlo Park, CA, United States
TI
IN
        Adolor Corporation, Malvern, PA, United States (U.S. corporation)
PA
                               B1
PI
        US 6190691
                                     20010220
ΑI
        US 1998-97440
                                     19980615 (9)
\mathtt{RLI}
        Continuation of Ser. No. US 1995-463819, filed on 5 Jun 1995, now
        abandoned Continuation-in-part of Ser. No. US 1995-400234, filed on 3
        Mar 1995, now abandoned Continuation-in-part of Ser. No. US 1994-271287,
        filed on 6 Jul 1994, now abandoned Continuation-in-part of Ser. No. US 1994-225991, filed on 12 Apr 1994, now abandoned
DT
        Utility
FS
        Granted
LN.CNT
        5240
INCL
        INCLM: 424/449.000
        INCLS: 514/859.000; 514/861.000; 514/863.000; 514/886.000; 514/887.000;
                 604/020.000
                 424/449.000
514/859.000; 514/861.000; 514/863.000; 514/886.000; 514/887.000;
NCL
        NCLM:
        NCLS:
                 604/020.000
IC
         [7]
        ICM: A61F013-00
        424/449; 514/859; 514/861; 514/863; 514/886; 514/887; 604/20
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 78 OF 175
                           USPATFULL on STN
AN
        2001:18240
                      USPATFULL
TI
        Complement-resistant non-mammalian DNA viruses and uses thereof
        Boyce, Frederick M., Belmont, MA, United States
Barsoum, James G., Lexington, MA, United States
The General Hospital Corporation, Boston, MA, United States (U.S.
IN
PA
        corporation)
        Biogen, Inc., Cambridge, MA, United States (U.S. corporation)
PI
        US 6183993
                                     20010206
                              B1
AΙ
        US 1999-329368
                                     19990610 (9)
        Continuation-in-part of Ser. No. US 1997-927317, filed on 11 Sep 1997
RLI
DT
        Utility
FS
        Granted
LN.CNT
        3502
INCL
        INCLM: 435/069.700
        INCLS: 435/069.100; 435/172.300; 424/246.100; 536/023.400; 536/023.710
NCL
        NCLM:
                 435/069.700
                 424/246.100; 435/069.100; 435/235.100; 435/456.000; 536/023.400;
        NCLS:
                 536/023.710
IC
        [7]
        ICM: C12P021-04
ICS: C12P021-06; C12N013-00; A61K039-07; C07H021-04
EXF 435/69.7; 435/69.1; 435/172.3; 424/246.1; 536/23.4; 536/23.71
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 79 OF 175 USPATFULL on STN
AN
        2001:14493
                      USPATFULL
```

1,2,5-trisubstituted 1,2-dihydroindazol-3-ones having anti-asthmatic, anti-allergic, anti-inflammatory, immunomodulating and neuroprotective

TI

```
Schindler, Rudolf, Dresden, Germany, Federal Republic of Hofgen, Norbert, Medingen, Germany, Federal Republic of Poppe, Hildegard, Dresden, Germany, Federal Republic of Brune, Kay, Marloffstein, Germany, Federal Republic of Arzneimittel
IN
PA
           corporation)
PI
           US 6180637
                                                  20010130
                                                                                                               <---
           US 1999-305602
                                                  19990505 (9)
AT
PRAI
           DE 1998-19821003
                                            19980511
           Utility
DT
FS
           Granted
LN.CNT
           962
           INCLM: 514/259.000
INCLS: 514/259.000;
546/153.000;
INCL
                      514/259.000; 514/254.090; 514/365.000; 514/405.000; 546/275.700; 546/153.000; 544/235.000; 544/144.000; 544/284.000; 544/298.000; 544/333.000; 544/371.000; 548/131.000; 548/159.000; 548/181.000; 548/240.000; 548/305.100; 548/306.700; 548/361.500
NCL
                       514/266.230
           NCLM:
                       514/254.090; 514/365.000; 514/405.000; 544/144.000; 544/235.000;
           NCLS:
                      544/284.000; 544/298.000; 544/333.000; 544/371.000; 546/153.000; 546/275.700; 548/131.000; 548/159.000; 548/181.000; 548/240.000; 548/305.100; 548/306.700; 548/361.500
            [7]
IC
           ICM: A61K031-513
           ICS: A61K031-4152; C07D231-56
           548/361.5; 548/131; 548/159; 548/181; 548/240; 548/305.1; 548/306.7; 514/405; 514/259; 514/245.06; 514/365; 546/275.7; 546/153; 544/235; 544/371; 544/298; 544/284; 544/144; 544/333
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
        ANSWER 80 OF 175
                                    USPATFULL on STN
           2000:174649 USPATFULL
AN
TI
           1,5- and 3-O-substituted 1H-indazoles having anti-asthmatic,
           anti-allergic, anti-inflammatory, immunomodulating and neuroprotective
           action, process for their preparation and their use as medicaments Schindler, Rudolf, Dresden, Germany, Federal Republic of Hofgen, Norbert, Medingen, Germany, Federal Republic of Poppe, Hildegard, Dresden, Germany, Federal Republic of Brune, Kay, Marloffstein, Germany, Federal Republic of Arzneimittelwerk Dresden GmbH, Germany, Federal Republic of (non-U.S. Corporation)
IN
PA
           corporation)
PΙ
           US 6166023
                                                  20001226
                                                                                                              <--
AΙ
           US 1999-305601
                                                  19990505 (9)
PRAI
           DE 1998-19821002
                                         19980511
           Utility
DT
FS
           Granted
LN.CNT
           1239
           INCLM: 514/258.000
INCLS: 514/312.000; 514/364.000; 514/365.000; 514/418.000; 544/270.000; 546/158.000; 548/131.000; 548/204.000; 548/361.500
NCLM: 514/234.500
INCL
NCL
           NCLM:
                      514/266.230; 514/312.000; 514/364.000; 514/365.000; 514/418.000; 544/270.000; 546/158.000; 548/131.000; 548/204.000; 548/361.500
           NCLS:
IC
           [7]
           ICM: A61K031-513
           ICS: A61K031-4709; C07D231-56
EXF
           548/361.5; 548/131; 548/204; 514/418; 514/364; 514/365; 514/312;
514/258; 544/270; 546/158
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
        ANSWER 81 OF 175 USPATFULL on STN
           2000:160777 USPATFULL
AN
           Methods for screening for transdominant intracellular effector peptides
TI
           and RNA molecules
IN
           Nolan, Garry P., Palo Alto, CA, United States
           Rothenberg, S. Michael, Palo Alto, CA, United States
PA
           Rigel Pharmaceuticals, Inc., Sunnyvale, CA, United States (U.S.
           corporation)
           The Board of Trustees for the Leland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)
PΙ
           US 6153380
                                                  20001128
ΑI
           US 1997-789333
                                                  19970123 (8)
           Continuation of Ser. No. US 1996-589108, filed on 23 Jan 1996, now
RLI
           abandoned And a continuation of Ser. No. US 1996-589911, filed on 23
```

Jan 1996, now abandoned

```
FS
           Granted
LN.CNT 4104
INCL
           INCLM: 435/006.000
           INCLS: 435/069.100; 435/070.100; 435/091.100; 435/325.000; 536/023.100;
                       536/024.300; 536/024.310; 536/024.500
                      435/006.000
NCL
           NCLM:
                      435/069.100; 435/070.100; 435/091.100; 435/325.000; 536/023.100; 536/024.300; 536/024.310; 536/024.500
           NCLS:
IC
           ICM: C120001-68
           ICS: C12P019-34; C12N005-00; C07H021-04
           435/6; 435/70.1; 435/325; 435/69.1; 435/91.1; 536/23.1; 536/24.3;
EXF
           536/24.31; 536/24.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
        ANSWER 82 OF 175
                                   USPATFULL on STN
           2000:142520 USPATFULL
AN
           Tetracycline-inducible transcriptional activator fusion proteins
TI
           Bujard, Hermann, Heidelberg, Germany, Federal Republic of
Gossen, Manfred, El Cerrito, CA, United States
IN
           BASF Aktiengesellschaft, Worcester, MA, United States (U.S. corporation)
PA
           Knoll Aktiengesellschaft, Germany, Federal Republic of (non-U.S.
           corporation)
           US 6136954
US 1998-162184
PΙ
                                                  20001024
ΑI
                                                  19980928 (9)
           Continuation of Ser. No. US 1995-485978, filed on 7 Jun 1995, now patented, Pat. No. US 5814618 which is a continuation-in-part of Ser. No. US 1995-383754, filed on 3 Feb 1995, now patented, Pat. No. US 5789156 which is a continuation-in-part of Ser. No. US 1994-275876,
RLI
          filed on 15 Jul 1994, now patented, Pat. No. US 5654168 which is a continuation-in-part of Ser. No. US 1994-270637, filed on 1 Jul 1994, now abandoned And a continuation-in-part of Ser. No. US 1994-260452, filed on 14 Jun 1994, now patented, Pat. No. US 5650298 which is a continuation-in-part of Ser. No. US 1993-76327, filed on 14 Jun 1993, now abandoned And a continuation-in-part of Ser. No. US 1993-76726, filed on 14 Jun 1993, now patented, Pat. No. US 5464758
DT
           Utility
FS
           Granted
LN.CNT
          4871
INCL
           INCLM: 530/350.000
           INCLS: 536/023.400
NCLM: 530/350.000
NCLS: 536/023.400
NCL
IC
           [7]
           ICM: C07K014-00
           ICS: C12N015-11
EXF
           530/350; 536/23.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
        ANSWER 83 OF 175 USPATFU
2000:131410 USPATFULL
L9
                                   USPATFULL on STN
AN
TI
           Microcapsules and composite microreactors for immunoisolation of cells Lanza, Robert P., Clinton, MA, United States
TN
           Kuhtreiber, Willem M., Shrewsbury, MA, United States
Chick, William L., Wellesley, MA, United States
BioHybrid Technologies LLC, Shrewsbury, MA, United States (U.S.
PA
           corporation)
           US 6126936
US 1995-402209
PI
                                                 20001003
                                                                                                             <--
AΙ
                                                 19950310 (8)
DT
           Utility
FS
           Granted
LN.CNT
          4433
INCL
           INCLM: 424/093.700
           INCLS: 424/423.000; 435/177.000; 435/178.000; 435/182.000; 435/382.000;
                      435/395.000; 435/397.000
NCL
           NCLM:
                      424/093.700
           NCLS:
                      424/423.000; 435/177.000; 435/178.000; 435/182.000; 435/382.000;
                      435/395.000; 435/397.000
IC
           [7]
           ICM: A61K035-12
           ICS: C12N011-10; C12N011-04; C12N005-00 435/174; 435/177; 435/178; 435/180; 435/182; 435/240.2; 435/240.23; 435/382; 435/395; 435/397; 424/93.7
EXF
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
AN
          2000:125047 USPATFULL
ΤI
          Epoxide-containing compounds
         Underiner, Gail, Brier, WA, United States
Klein, J. Peter, Vashon, WA, United States
Michnick, John, Seattle, WA, United States
Leigh, Alistair, Brier, WA, United States
Kumar, Anil, Seattle, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States
US 6121270
20000919
2--
IN
PA
PΙ
ΑI
          US 1998-98473
                                            19980617 (9)
          Division of Ser. No. US 1997-778563, filed on 3 Jan 1997 which is a
RLI
          continuation of Ser. No. US 1993-167600, filed on 13 Dec 1993, now
          abandoned And a continuation-in-part of Ser. No. US 1992-991655, filed
          on 16 Dec 1992, now abandoned
          Utility
DT
FS
          Granted
LN.CNT
          3145
          INCLM:
INCL
                    514/263.000
          INCLS:
                    544/263.000
                    514/263.230
NCL
          NCLM:
          NCLS:
                    544/263.000
IC
          [7]
          ICM: A61K031-52
          ICS: C07D473-04
544/267; 514/263
EXF
     INDEXING IS AVAILABLE FOR THIS PATENT.
CAS
L9
       ANSWER 85 OF 175
                                USPATFULL on STN
          2000:109610
                            USPATFULL
AN
         Modulators of anchoring protein function
Lockerbie, Robert Owen, Kirkland, WA, United States
ΤI
IN
         Howard, Monique L., Seattle, WA, United States
Gallatin, W. Michael, Mercer Island, WA, United States
          Lai, Yvonne, Seattle, WA, United States ICOS Corporation, Bothell, WA, United States (U.S. corporation)
PA
          US 6107104
PI
                                            20000822
AΙ
          US 1996-721458
                                            19960927
                                                         (8)
          Continuation-in-part of Ser. No. US 1995-503226, filed on 17 Jul 1995
RLI
         which is a continuation-in-part of Ser. No. US 1995-404731, filed on 15 Mar 1995, now patented, Pat. No. US 5744354 which is a continuation-in-part of Ser. No. US 1994-344227, filed on 23 Nov 1994,
         now patented, Pat. No. US 5807693
Utility
DT
FS
          Granted
LN.CNT
         3568
INCL
          INCLM: 436/578.000
          INCLS: 435/004.000; 435/007.100; 435/007.200; 435/007.930
NCL
                    436/518.000
          NCLM:
          NCLS:
                    435/004.000; 435/007.100; 435/007.200; 435/007.930
IC
          [7]
          ICM: G01N033-543
435/4; 435/7.1; 435/7.2; 435/7.93; 436/501; 530/350; 530/780; 536/23.1;
EXF
          536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
       ANSWER 86 OF 175
                                USPATFULL on STN
AN
          2000:105913 USPATFULL
TI
          Amine substituted compounds
         Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Ridgers, Lance H., Bothell, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States
US 6103730
20000815
---
IN
PA
PΙ
ΑI
          US 1995-486264
                                            19950607 (8)
RLI
          Continuation of Ser. No. US 1994-217051, filed on 24 Mar 1994, now
          abandoned
DT
          Utility
FS
          Granted
LN.CNT
          1702
                   514/263.000
514/265.000; 544/268.000; 544/269.000; 544/270.000; 544/271.000;
544/272.000
INCL
          INCLM:
          INCLS:
NCL
                    514/263.200
          NCLM:
                    514/151.000; 514/210.210; 514/263.210; 514/263.220; 514/263.230;
```

```
544/271.000; 544/272.000
IC
        [7]
        ICM: A61K031-522
        ICS: C07D473-10
    544/268; 544/269; 544/220; 544/271; 544/272; 514/263; 514/265 INDEXING IS AVAILABLE FOR THIS PATENT.
EXF
CAS
      ANSWER 87 OF 175
L9
                          USPATFULL on STN
        2000:105417
AN
                      USPATFULL
ΤI
        Neurite growth regulatory factors
        Schwab, Martin E., Zurich, Switzerland
IN
                Pierenrico W., Zurich, Switzerland
        Paganetti, Paolo A., Zurich, Switzerland
        Erziehungsdirektion of the Canton Zurich, Zurich, Switzerland (non-U.S.
PA
        corporation)
PI
        US 6103232
                                   20000815
        US 1995-464509
ΑI
                                   19950605 (8)
        Continuation of Ser. No. US 1989-401212, filed on 30 Aug 1989, now
RLI
        patented, Pat. No. US 5684133 which is a continuation-in-part of Ser.
        No. US 1988-267941, filed on 4 Nov 1988, now abandoned
DT
        Utility
FS
        Granted
LN.CNT 4223
        INCLM: 424/130.100
INCLS: 530/387.100; 530/350.000
NCLM: 424/130.100
INCL
NCL
        NCLS:
                530/350.000; 530/387.100
IC
        [7]
        ICM: C07K016-00
EXF 424/130.1; 530/350; 530/387.1 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 88 OF 175
2000:98222 US
L9
                          USPATFULL on STN
                    USPATFULL
AN
TI
        Cells with multiple altered epitopes on a surface antigen for use in
          ***transplantation***
IN
        Chappel, Scott C., Milton, MA, United States
PA
        Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)
PI
        US 6096537
                                   20000801
        US 1997-946637
ΑI
                                   19971007 (8)
RLI
        Continuation of Ser. No. US 1994-240150, filed on 10 May 1994, now
        patented, Pat. No. US 5679340 which is a continuation-in-part of Ser.
            US 1994-220741, filed on 31 Mar 1994, now abandoned
        No.
        Utility
DT
FS
        Granted
LN.CNT
        940
INCL
        INCLM: 435/325.000
        INCLS: 424/422.000; 424/133.100; 424/143.100; 424/093.700; 435/007.100;
                435/007.200; 435/007.210; 530/388.220
NCL
        NCLM:
                435/325.000
                424/093.700; 424/133.100; 424/143.100; 424/422.000; 435/007.100; 435/007.200; 435/007.210; 530/388.220
        NCLS:
        [7]
IC
        ICM: C12N005-00
        ICS: A61F013-00; G01N033-53; C07K016-00
        424/93.7; 424/422; 424/133.1; 424/143.1; 435/325; 435/7.1; 435/7.2; 435/7.21; 530/388.22
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
     ANSWER 89 OF 175
                          USPATFULL on STN
                    USPATFULL
ИA
        2000:95042
TI
        Therapeutic methods employing disulfide derivatives of dithiocarbamates
        and compositions useful therefor
IN
             Ching-San, Encinitas, CA, United States
        Vassilev, Vassil, San Diego, CA, United States
Medinox Inc., San Diego, CA, United States (U.S. corporation)
PA
ΡI
        US 6093743
                                   20000725
ΑI
        US 1998-103639
                                   19980623 (9)
        Utility
DT
FS
        Granted
LN.CNT
        2691
INCL
        INCLM:
               514/599.000
        INCLS:
                514/706.000;
                              514/707.000; 514/851.000; 514/861.000; 514/863.000;
                514/866.000; 514/909.000; 514/912.000
NCL
        NCLM:
                514/599.000
```

```
514/866.000; 514/909.000; 514/912.000
IC
         ICM: A61K031-16
         ICS: A61K031-095; A61K031-105
         514/599; 514/706; 514/707; 514/851; 514/861; 514/863; 514/866; 514/909;
EXF
         514/912
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 90 OF 175 USPATFULL on STN 2000:91767 USPATFULL
L9
AN
TI
        Calcineurin regulatable adenylate cyclase Antoni, Ferenc, Edinburgh, United Kingdom
ΙN
         Paterson, Janice MacKenzie, Edinburgh, United Kingdom
        Medical Research Council, London, United Kingdom (non-U.S. corporation)
US 6090612 20000718 <--
PA
PΙ
        WO 9625502
                       19960822
                                                                                    <---
                                      19970813 (8)
AΙ
        US 1997-894173
        WO 1996-GB312
                                      19960214
                                      19970813
                                                   PCT 371 date
                                                   PCT 102(e) date
                                      19970813
        GB 1995-2806
PRAI
                                 19950214
        GB 1995-16528
                                 19950811
DT
        Utility
FS
        Granted
LN.CNT 2856
INCL
        INCLM: 435/252.330
        INCLS: 435/320.100; 435/325.000; 435/369.000; 536/023.200
NCL
        NCLM:
                435/252.330
        NCLS:
                 435/320.100; 435/325.000; 435/369.000; 536/023.200
IC
         [7]
        ICM: C12N001-20
        ICS: C12N015-00; C12N005-00; C07H021-04
435/325; 435/369; 435/320.1; 435/252.33; 536/23.2
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 91 OF 175 USPATFULL on STN
L9
AN
        2000:87996 USPATFULL
ΤI
        Transcriptional activators with graded transactivation potential
        Baron, Udo, Theodor-Heuss-Str. 4, D-69181 St. Ilgen, Germany, Federal Republic of
IN
        Gossen, Manfred, El Cerrito, CA, United States
Bujard, Hermann, Heidelberg, Germany, Federal Republic of
        BASF Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of
PA
         (non-U.S. corporation)
        Baron, Udo, St. Ilgen, Germany, Federal Republic of (non-U.S.
        individual)
        US 6087166
US 1997-888080
Utility
PI
                                      20000711
                                                                                    <--
AΙ
                                      19970703 (8)
DT
FS
        Granted
LN.CNT
        1967
INCL
        INCLM: 435/325.000
        INCLS: 435/243.000; 435/320.100; 435/410.000; 536/023.400
NCL
        NCLM:
                 435/325.000
        NCLS:
                 435/243.000; 435/320.100; 435/410.000; 536/023.400
IC
         [7]
        ICM: C12N005-10
ICS: C12N001-00; C12N015-62; C12N015-63

EXF 536/23.4; 435/325; 435/410; 435/243; 435/320.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 92 OF 175
                           USPATFULL on STN
AN
        2000:77196 USPATFULL
TI
        ShK toxin compositions and methods of use
IN
        Kem, William R., Gainesville, FL, United States
        Pennington, Michael W., Cherry Hill, NJ, United States
        Norton, Raymond S., Ivanhoe, Australia
Chandy, K. George, Laguna Beach, CA, United States
Kalman, Katalin, Irvine, CA, United States
The University of Florida, Gainesville, FL, United States (U.S.
PA
        corporation)
        Bachem Bioscience, Ing., King of Prussia, PA, United States (U.S.
        corporation)
        Biomolecular Research Institute, Parkville, Australia (non-U.S.
        corporation)
```

```
(U.S. corporation) US 6077680
PI
                                                 20000620
                                                                                                          <--
           US 1997-980858
                                                19971126 (8)
AΙ
           US 1996-59126P 19961127 (60)
PRAI
DT
           Utility
FS
           Granted
LN.CNT
          5831
INCL
           INCLM: 435/007.240
           INCLS: 514/012.000; 514/009.000; 514/002.000; 424/185.100; 530/300.000;
                      530/324.000; 530/855.000
                      435/007.240
NCL
           NCLM:
                      424/185.100; 514/002.000; 514/009.000; 514/012.000; 530/300.000;
           NCLS:
                      530/324.000; 530/855.000
           [7]
IC
           ICM: G01N033-566
           ICS: A61K038-17; C07K014-435; A01N037-20
           514/12; 514/2; 514/9; 530/300; 530/324; 530/855; 424/185.1; 435/7.24
EXF
CAS
      INDEXING IS AVAILABLE FOR THIS PATENT.
L9
                                  USPATFULL on STN
        ANSWER 93 OF 175
AN
           2000:70818 USPATFULL
TI
           In vivo genetic modification of growth factor-responsive ***neural***
           precursor cells
IN
           Weiss, Samuel, Alberta, Canada
          Reynolds, Brent, Alberta, Canada
Hammang, Joseph P., Barrington, RI, United States
Baetge, E. Edward, Barrington, RI, United States
PA
           NeuroSpheres Holdings Ltd., Calgary, Canada (non-U.S. corporation)
PΙ
                                                20000606
           US 6071889
          US 1995-479795 19950607 (8)
Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned And a continuation-in-part of Ser. No. US 1995-385404,
ΑI
RLI
          filed on 7 Feb 1995, now abandoned And a continuation-in-part of Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned And a
           continuation-in-part of Ser. No. US 1995-376062, filed on 20 Jan 1995,
           now abandoned And a continuation-in-part of Ser. No. US 1993-149508,
          filed on 9 Nov 1993, now abandoned And a continuation-in-part of Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned And a continuation-in-part of Ser. No. US 1994-38730, filed on 14 Nov 1994,
          now abandoned which is a continuation of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned which is a continuation of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US
           1995-385404, filed on 7 Feb 1995, now abandoned which is a continuation
          of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned which is
          a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991,
          now abandoned , said Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned which is a continuation of Ser. No. US 1994-221655, filed on 1
          Apr 1994, now abandoned which is a continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned which is a continuation of Ser. No. US 1993-10829, filed on 29
           Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US
          1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812,
           filed on 8 Jul 1991, now abandoned
DT
          Utility
FS
          Granted
LN.CNT 4261
INCL
           INCLM: 514/044.000
           INCLS: 424/093.100; 424/093.200; 424/093.210; 435/440.000; 435/455.000
NCL
          NCLM:
                     514/044.000
          NCLS:
                     424/093.100; 424/093.200; 424/093.210; 435/440.000; 435/455.000
IC
           [7]
           ICM: A61K035-00
           ICS: A61K048-00
EXF
           514/44; 514/2; 536/23.1; 424/93.1; 424/93.2; 424/93.21; 435/455; 435/440
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

AN

ANSWER 94 OF 175 USPATFULL on STN

2000:57345 USPATFULL

```
Beschorner, William E., Baldwin, MD, United States Ximerex, Inc., Omaha, NE, United States (U.S. corporation)
IN
PA
         US 6060049
PΙ
                                       20000509
                                                                                      <--
         WO 9427622
                        19931208
                                                                                      <--
         US 1995-295899
                                       19950606 (8)
ΑI
                                       19940524
         WO 1994-US5844
                                       19950606
                                                    PCT 371 date
                                       19950606
                                                    PCT 102(e) date
RLI
         Continuation of Ser. No. US 1993-65370, filed on 24 May 1993
DT
         Utility
FS
         Granted
LN.CNT
         3065
INCL
         INCLM: 424/093.210
         INCLS: 424/093.300; 424/577.000; 800/008.000; 435/001.100
                  424/093.210
NCL
         NCLM:
                 424/093.300; 424/577.000; 435/001.100; 800/008.000
         NCLS:
         [7]
IC
         ICM: A61K048-00
         ICS: C12N015-00; A01N001-02
         424/529; 424/577; 424/93.7; 424/93.21; 424/93.71; 424/2; 424/9; 424/93.3; 435/1; 435/240.2; 435/375; 435/377; 800/DIG.5; 800/2; 800/8
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 95 OF 175
                             USPATFULL on STN
AN
         2000:54116
                       USPATFULL
TI
         Discorhabdin compounds and methods of use
        Gunaskera, Sarath P., Vero Beach, FL, United States McCarthy, Peter J., Vero Beach, FL, United States Pomponi, Shirley A., Fort Pierce, FL, United States Wright, Amy E., Fort Pierce, FL, United States Longley, Ross E., Vero Beach, FL, United States
IN
         Harbor Branch Oceanographic Institution, Inc., Ft. Pierce, FL, United States (U.S. corporation)
PA
         US 6057333
PΙ
                                       20000502
                                                                                      <--
         US 1998-122572
                                       19980724
AΙ
                                                  (9)
         US 1997-53752P
                                  19970725 (60)
PRAI
         Utility
DT
FS
         Granted
LN.CNT
         606
INCL
         INCLM: 514/278.000
         INCLS: 546/018.000; 424/573.000; 435/240.200
NCL
                  514/278.000
         NCLM:
         NCLS:
                 424/573.000; 435/375.000; 546/018.000
IC
         [7]
         ICM: A61K031-44
         ICS: C07D401-14
    514/278; 546/18; 424/573; 435/240.2 INDEXING IS AVAILABLE FOR THIS PATENT.
EXF
CAS
L9
      ANSWER 96 OF 175
                            USPATFULL on STN
AN
         2000:18418 USPATFULL
         Treatment of CNS tumors with metalloprotease inhibitors
TI
IN
         Schwab, Martin E., Zurich, Switzerland
         Caroni, Pierenrico W., Zurich, Switzerland
         Paganetti, Paolo A., Birmensdorferstr., Switzerland
PA
         Erziehungsdirektion of the Canton Zurich, Zurich, Switzerland (non-U.S.
         corporation)
PΙ
         US 6025333
                                       20000215
         US 1995-462312
                                       19950605 (8)
AΙ
        Division of Ser. No. US 1989-401212, filed on 30 Aug 1989 which is a continuation-in-part of Ser. No. US 1988-267941, filed on 4 Nov 1988,
RLI
         now abandoned
DT
         Utility
FS
         Granted
LN.CNT 4299
INCL
         INCLM: 514/018.000
         INCLS: 514/019.000; 514/292.000; 424/DIG.006; 424/094.670
NCL
         NCLM:
                  514/217.090
         NCLS:
                 424/094.670; 424/DIG.006; 514/019.000; 514/292.000
         [7]
IC
         ICM: A61K038-06
         ICS: A61K038-05; A61K038-55
                 514/18; 514/19; 514/292; 514/566; 514/738; 424/DIG.6; 424/94.67
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
AN
        2000:18243 USPATFULL
TI
        Neurturin receptor
        Klein, Robert D., Palo Alto, CA, United States
Rosenthal, Arnon, Burlingame, CA, United States
IN
        Hynes, Mary A., San Mateo, CA, United States
Genentech, Inc., United States (U.S. corporation)
PA
PI
        US 6025157
                                   20000215
                                                                            <--
                                   19971024 (8)
AΙ
        US 1997-957063
PRAI
        US 1997-38839P
                              19970218 (60)
                              19970609 (60)
        US 1997-49818P
        Utility
DT
FS
        Granted
LN.CNT
        5116
        INCLM: 435/069.100
INCL
        INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.100; 536/023.500
                435/069.100
NCL
        NCLM:
        NCLS:
                435/320.100; 435/325.000; 536/023.100; 536/023.500
IC
        [7]
        ICM: C12P021-06
        ICS: C12N015-00; C07H021-02; C07H021-04
        536/23.5; 536/23.1; 435/325; 435/320.1; 435/69.1; 800/8
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
     ANSWER 98 OF 175
                         USPATFULL on STN
ΑN
        2000:15639
                    USPATFULL
        Regulation of gene expression
TI
IN
        Peyman, John A., Cheshire, CT, United States
PA
        Yale University, New Haven, CT, United States (U.S. corporation)
ΡI
                                   20000208
        US 6022863
ΑI
        US 1996-646789
                                   19960521 (8)
DT
        Utility
FS
        Granted
LN.CNT
       4750
INCL
        INCLM: 514/044.000
        INCLS:
               536/024.100; 435/325.000; 435/001.100; 435/091.100; 800/013.000;
                800/025.000
NCL
       NCLM:
               514/044.000
       NCLS:
               435/001.100; 435/091.100; 435/325.000; 536/024.100; 800/013.000;
                800/025.000
IC
        [6]
        ICM: C12N015-11
        536/23.1; 536/24.1; 536/24.33; 435/325; 435/1.1; 435/91.1; 514/44;
EXF
        800/13; 800/25
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
     ANSWER 99 OF 175
                         USPATFULL on STN
AN
        2000:1857
                   USPATFULL
TI
        Peptide T and related peptides in the treatment of inflammation,
        including multiple sclerosis
       Andersen, Anders Jorgen, Kokkedal, Denma
Aston, Roger, Wiltshire, United Kingdom
IN
                                              Denmark
        Carlen, Peter Louis, Ontario, Canada
       Doob, Penelope Reed, Ontario, Canada
       MacFadden, Douglas Kevin, Ontario, Canada
        Phipps, David James, Ontario, Canada
        Rathjen, Deborah, New South Wales, Australia
       Widmer, Fred, New South Wales, Australia
Advanced Immunit, Inc., Stony Brook, NY, United States (U.S.
PA
        corporation)
PΙ
                                   20000104
       US 6011014
                                                                            <--
ΑI
       US 1998-82837
                                  19980521 (9)
RLI
        Continuation of Ser. No. US 302829
DT
        Utility
FS
        Granted
LN.CNT
       2387
INCL
        INCLM: 514/015.000
               514/016.000; 514/017.000; 514/018.000; 530/328.000; 530/329.000;
        INCLS:
                530/330.000
NCL
                514/015.000
       NCLM:
       NCLS:
                514/016.000; 514/017.000; 514/018.000; 530/328.000; 530/329.000;
               530/330.000
IC
        [6]
        ICM: A61K038-00
        ICS: C07K005-00; C07K007-00
EXF
        514/16; 514/15; 514/17; 514/18; 530/328; 530/330
```

```
L9
        ANSWER 100 OF 175
                                    USPATFULL on STN
ΑN
           1999:166981
                              USPATFULL
          Methods for regulating gene expression
Bujard, Hermann, Heidelberg, Germany, Federal Republic of
Gossen, Manfred, El Cerrito, CA, United States
TI
IN
           BASF Aktiengesellschaft, Germany, Federal Republic of (non-U.S.
PA
           corporation)
           BASF Bioresearch Corporation, Worcester, MA, United States (U.S.
           corporation)
           Knoll Aktiengelellschaft, Germany, Federal Republic of (non-U.S.
           corporation)
           US 6004941
US 1995-485740
PΙ
                                                19991221
          US 1995-485740 19950607 (8)
Continuation-in-part of Ser. No. US 1995-383754, filed on 3 Feb 1995, now patented, Pat. No. US 5789156 And a continuation-in-part of Ser. No. US 1994-275876, filed on 15 Jul 1994, now patented, Pat. No. US 5654168
ΑI
RLI
          which is a continuation-in-part of Ser. No. US 1994-270637, filed on 1 Jul 1994, now abandoned And a continuation-in-part of Ser. No. US 1994-260452, filed on 14 Jun 1994, now patented, Pat. No. US 5650298 which is a continuation-in-part of Ser. No. US 1993-76327, filed on 14 Jun 1993, now abandoned And a continuation-in-part of Ser. No. US 1993-76726, filed on 14 Jun 1993, now patented. Pat. No. US 5464758
           1993-76726, filed on 14 Jun 1993, now patented, Pat. No. US 5464758
DT
           Utility
FS
          Granted
LN.CNT 4771
INCL
           INCLM: 514/044.000
           INCLS: 435/069.100; 435/070.100; 435/320.100; 435/325.000; 435/455.000; 536/023.400; 536/024.100; 424/093.210
                      514/044.000
NCL
           NCLM:
                      424/093.210; 435/069.100; 435/070.100; 435/320.100; 435/325.000; 435/455.000; 536/023.400; 536/024.100
           NCLS:
IC
           [6]
           ICM: A61K048-00
EXF
           435/69.1; 435/70.1; 435/172.3; 435/325; 435/320.1; 435/455; 435/6;
           536/23.4; 536/24.1; 514/44; 935/22; 935/23; 935/33; 935/34; 935/59;
           935/66; 424/93.21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 101 OF 175 USPATFULL on STN 1999:155687 USPATFULL
Ь9
\mathbf{AN}
           PKA-binding proteins and uses thereof
TI
          Lockerbie, Robert Owen, Kirkland, WA, United States
Kashishian, Adam, Mountlake Terrace, WA, United States
IN
           ICOS Corporation, Bothell, WA, United States (U.S. corporation)
PA
          US 5994304
                                                19991130
PI
          US 1998-135211
AΙ
                                                19980817
                                                              (9)
          Division of Ser. No. US 1995-503172, filed on 17 Jul 1995, now patented, Pat. No. US 5795735
RLI
DT
           Utility
           Granted
FS
LN.CNT
          1298
INCL
           INCLM: 514/012.000
           INCLS: 514/002.000; 530/350.000
NCL
                     514/012.000
          NCLM:
          NCLS:
                      514/002.000; 530/350.000
IC
           [6]
ICM: C07K014-435
EXF 514/2; 514/12; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
        ANSWER 102 OF 175 USPATFULL on STN
           1999:155184 USPATFULL
AN
TI
          Methods for prolonging the expression of a heterologous gene of interest
           using soluble CTLA4 molecules and an antiCD40 ligand
IN
          Linsley, Peter S., Seattle, WA, United States
           Kay, Mark A., Seattle, WA, United States
          Wilson, Christopher B., Seattle, WA, United States
Ledbetter, Jeffrey, Seattle, WA, United States
Aruffo, Alejandro A., Seattle, WA, United States
Hollenbaugh, Diane L., Seattle, WA, United States
Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S.
PA
           corporation)
                                                19991130
PΙ
          US 5993800
          US 1995-474210
ΑI
                                                19950606 (8)
```

```
now_abandoned
DT
             Utility
FS
             Granted
LN.CNT
            1336
INCL
             INCLM: 424/093.210
             INCLS: 435/069.100; 435/320.100; 435/325.000; 514/044.000; 424/093.100
                         424/093.210
NCL
             NCLS:
                         424/093.100; 435/069.100; 435/320.100; 435/325.000; 514/044.000
IC
             [6]
             ICM: A61K048-00
EXF 424/93.1; 424/93.21; 514/2; 514/2.1; 514/44; 536/22.1; 436/85-87; 435/325; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
         ANSWER 103 OF 175
1999:141292 USF
L9
                                         USPATFULL on STN
                                  USPATFULL
AN
TI
             Growth factor-induced proliferation of ***neural***
                                                                                                                precursor cells
IN
            Weiss, Samuel, Alberta, Canada
            Reynolds, Brent, Alberta, Canada
NeuroSpheres Holdings Ltd., Calgary, Canada (non-U.S. corporation)
US 5980885 19991109 <--
PA
PI
            US 1995-486307
AI
                                                        19950607 (8)
            Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned Ser. No. Ser. No. US 1995-385404, filed on 7 Feb 1995, now
RLI
            abandoned Ser. No. Ser. No. US 1994-359945, filed on 20 Dec 1994, now
            abandoned Ser. No. Ser. No. US 1995-376062, filed on 20 Jan 1995, now
            abandoned Ser. No. Ser. No. US 1995-3/6002, Illed on 20 Jan 1995, now abandoned Ser. No. Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned Ser. No. Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned And Ser. No. US 1994-338730, filed on 14 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US 270412 which is a continuation of Ser. No. US 726812, said Ser. No. US 385404 which is a continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 726812, said
            abandoned which is a continuation-in-part of Ser. No. US 726812
            Ser. No. US 359945 which is a continuation of Ser. No. US 1994-221655,
            filed on 1 Apr 1994, now abandoned which is a continuation of Ser. No.
            US 1992-967622, filed on 28 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 726812, said Ser. No. US 376062 which is a continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 726812,
            said Ser. No. US 149508 which is a continuation-in-part of Ser. No.
                           said Ser. No. US 311099 which is a continuation-in-part of Ser.
            No. US 726812
DT
            Utility
FS
            Granted
LN.CNT
            4215
INCL
            INCLM: 424/093.210
            INCLS: 424/093.100; 424/093.200; 435/325.000; 435/360.000; 435/366.000; 435/368.000; 435/377.000; 435/383.000; 435/384.000; 435/440.000; 435/455.000; 435/456.000; 435/457.000; 514/002.000; 514/044.000
NCL
            NCLM:
                         424/093.210
                        424/093.100; 424/093.200; 435/325.000; 435/360.000; 435/366.000; 435/368.000; 435/377.000; 435/383.000; 435/384.000; 435/440.000; 435/455.000; 435/456.000; 435/457.000; 514/002.000; 514/044.000
            NCLS:
IC
             [6]
             ICM: A01N063-00
            ICS: A01N043-04; C12N005-00; C12N005-08
435/240.2; 435/325; 435/360; 435/366; 435/368; 435/377; 435/383;
435/455; 435/456; 435/457; 514/2; 514/44; 424/93.1; 424/93.2; 424/93.21
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
         ANSWER 104 OF 175 USPATFULL on STN
AN
            1999:124900 USPATFULL
            Enantiomerically pure hydroxylated xanthine compounds Bianco, James A., Seattle, WA, United States Woodson, Paul, Bothell, WA, United States Porubek, David, Edmonds, WA, United States Singer, Jack, Seattle, WA, United States
ΤI
IN
            Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5965564 19991012 <--
PA
ΡI
ΑI
            US 1998-44976
                                                       19980320 (9)
            Continuation of Ser. No. US 1995-457703, filed on 1 Jun 1995, now
RLI
            patented, Pat. No. US 5739138 which is a division of Ser. No. US
```

1994-343810, filed on 22 Nov 1994, now patented, Pat. No. US 5652243

```
now patented, Pat. No. US 5648357 which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US
         1992-846354, filed on 4 Mar 1992, now abandoned
DT
         Utility
FS
         Granted
LN.CNT
        1770
INCL
         INCLM: 514/263.000
         INCLS: 514/267.000; 514/270.000; 514/271.000
NCL
         NCLM:
                 514/263.360
         NCLS:
                 514/265.100; 514/267.000; 514/270.000; 514/271.000
IC
         [6]
         ICM: A61K031-52
514/263; 514/262; 514/265
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 105 OF 175
                             USPATFULL on STN
         1999:121379 USPATFULL
AN
TI
         Screening methods for cytokine inhibitors
        Mak, Vivian, Menlo Park, CA, United States
Adolor Corporation, Malvern, PA, United States (U.S. corporation)
US 5962477 19991005 <--
IN
PA
PΙ
         US 1998-97441
ΑI
                                       19980615
        Continuation-in-part of Ser. No. WO 1995-US4677, filed on 11 Apr 1995 which is a continuation-in-part of Ser. No. US 1995-400234, filed on 3
RLI
         Mar 1995, now abandoned which is a continuation-in-part of Ser. No. US
         1994-271287, filed on 6 Jul 1994, now abandoned which is a
         continuation-in-part of Ser. No. US 1994-225991, filed on 12 Apr 1994,
         now abandoned
DT
         Utility
         Granted
FS
LN.CNT
        5138
INCL
         INCLM: 514/327.000
         INCLS: 424/078.050
NCL
         NCLM:
                 514/327.000
                 424/078.050
         NCLS:
IC
         [6]
    ICM: A61K031-445
514/327; 424/78.05
INDEXING IS AVAILABLE FOR THIS PATENT.
EXF
CAS
L9
      ANSWER 106 OF 175
                              USPATFULL on STN
AN
         1999:92325
                       USPATFULL
         Reversing excitotoxic CNS damage by cellular implantation
ΤI
         Sagen, Jăqueline, 2509 W. Farwell, Chicago, IL, United States 60645
IN
ΡI
                                       19990810
         US 5935606
                                       19950731 (8)
         US 1995-509522
AΙ
DT
         Utility
FS
         Granted
LN.CNT
        1140
INCL
         INCLM: 424/562.000
         INCLS: 424/093.700
NCL
         NCLM:
                 424/562.000
         NCLS:
                 424/093.700
IC
         [6]
         ICM: A61K035-55
EXF
         435/240.2; 424/93.1; 424/93.7; 424/562; 424/523
L9
      ANSWER 107 OF 175
                             USPATFULL on STN
                       USPATFULL
         1999:81832
AN
TI
         Apoptosis regulating composition
         Nakai, Satoru, Tokushima-ken, Japan
IN
         Aihara, Koutoku, Tokushima-ken, Japan
        Mori, Hitomi, Tokushima, Japan
         Tominaga, Michiaki, Tokushima-ken, Japan
        Adachi, Masakazu, Takasaki, Japan
Ichikawa, Hiroyuki, Tokushima, Japan
         Akamatsu, Seiji, Naruto, Japan
Saito, Fumio, Takasaki, Japan
PA
         Otsuka Pharmaceutical Co. Ltd.
                                                 Tokyo, Japan (non-U.S. corporation)
PΙ
                                       19990720
         US 5925640
         US 1997-853745
ΑI
                                       19970509 (8)
RLI
         Division of Ser. No. US 1995-466449, filed on 6 Jun 1995, now patented,
         Pat. No. US 5672603 which is a continuation of Ser. No. US 989028
```

```
JP 1991-162587
                                    19910703
         JP 1992-33469
                                    19920220
         JP 1992-45178
                                    19920303
         Utility
DT
FS
         Granted
LN.CNT
         1240
INCL
         INCLM: 514/255.000
NCL
         NCLM:
                  514/253.070
IC
          [6]
         ICM: A61K031-495
514/255
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
       ANSWER 108 OF 175
                               USPATFULL on STN
         1999:72602 USPATFULL
AN
TI
         Conjugates of dithiocarbamates with pharmacologically active agents and
         uses therefore
         Lai, Ching-San, Encinitas, CA, United States
Medinox, Inc., San Diego, CA, United States (U.S. corporation)
US 5916910 19990629 <
IN
PA
PI
ΑI
         US 1997-869158
                                         19970604 (8)
         Utility
DT
FS
         Granted
LN.CNT
         1842
INCL
         INCLM: 514/423.000
         INCLS: 514/514.000; 548/564.000; 548/573.000; 558/235.000
NCL
         NCLM:
                   514/423.000
         NCLS:
                   514/514.000; 548/564.000; 548/573.000; 558/235.000
IC
          [6]
         ICM: C07D207-04
         ICS: C07D207-30; A61K031-27; A61K031-40 514/514; 514/423; 548/565; 548/573; 558/235
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 109 OF 175 USPATFULL on STN
AN
         1999:72582 USPATFULL
TI
         Apoptosis regulating composition
IN
         Nakai, Satoru, Tokushima, Japan
         Aihara, Koutoku, Tokushima, Japan
Mori, Hitomi, Tokushima, Japan
Tominaga, Michiaki, Tokushima, Japan
Adachi, Masakazu, Gunma, Japan
Ichikawa, Hiroyuki, Tokushima, Japan
         Akamatsu, Seiji, Tokushima, Japan
         Saito, Fumio, Gunma, Japan
         Otsuka Pharmaceutical Co., Ltd., US 5916890 19990629
PA
                                                     Tokyo, Japan (non-U.S. corporation)
PΙ
         US 1997-854073
AΙ
                                         19970509 (8)
         Division of Ser. No. US 1995-466449, filed on 6 Jun 1995, now patented, Pat. No. US 5672603 which is a continuation of Ser. No. US 1993-989028,
RLI
         filed on 30 Apr 1993, now abandoned which is a continuation of Ser. No. WO 1992-JP841, filed on 2 Jul 1992
PRAI
         JP 1991-162587
                                    19910703
         JP 1992-33469
                                    19920220
         JP 1992-45178
                                    19920303
         JP 1992-585
                                    19920325
         Utility
DT
FS
         Granted
LN.CNT
         1244
INCL
         INCLM: 514/255.000
         NCLM:
                  514/253.070
NCL
IC
         [6]
         ICM: A61K031-495
514/255
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 110 OF 175 USPAT
1999:67430 USPATFULL
L9
                               USPATFULL on STN
AN
         Mice transgenic for a tetracycline-inducible transcriptional activator Bujard, Hermann, Heidelberg, Germany, Federal Republic of Gossen, Manfred, El Cerrito, CA, United States
TI
IN
         University of Heidelberg, Heidelberg, Germany, Federal Republic of
PA
         (non-U.S. corporation)
PI
         US 5912411
                                         19990615
                                                                                           < - -
ΑI
         US 1995-487472
                                         19950607 (8)
```

```
a continuation-in-part of Ser. No. US 1994-275876, filed on 15 Jul 1994, now patented, Pat. No. US 5654168 which is a continuation-in-part of Ser. No. US 1994-270637, filed on 1 Jul 1994, now abandoned, said Ser. No. US 487472 which is a continuation-in-part of Ser. No. US 1994-260452, filed on 14 Jun 1994, now patented, Pat. No. US 5650298 which is a continuation-in-part of Ser. No. US 1993-76327, filed on 14 Jun 1993, now abandoned, said Ser. No. US 1995-487472, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1993-76726, filed on
            1995 which is a continuation-in-part of Ser. No. US 1993-76726, filed on
            14 Jun 1993, now patented, Pat. No. US 5464758
            Utility
DT
FS
            Granted
LN.CNT
           4690
            INCLM: 800/002.000
INCL
            INCLS: 435/172.300; 435/069.100; 435/070.100; 435/325.000; 536/023.400;
                        536/024.100; 424/009.210
NCL
            NCLM:
                        800/018.000
                        435/069.100; 435/070.100; 435/325.000; 435/462.000; 435/463.000;
            NCLS:
                        514/152.000; 536/023.400; 536/024.100
IC
            [6]
            ICM: C12N005-00
            ICS: C12N015-00; C12N015-09
EXF 800/2; 435/69.1; 435/70.1; 435/172.3; 435/240.2; 435/240.4; 435/320.1; 435/325; 536/23.4; 536/24.1; 424/9.21 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
        ANSWER 111 OF 175
                                       USPATFULL on STN
                               USPATFULL
AN
            1999:56260
TI
            Methods of inducing T cell unresponsiveness to donor tissue or organ in
            a recipient with GP39 antagonists
           Noelle, Randolph J., Cornish, NH, United States
Durie, Fiona H., Seattle, WA, United States
Parker, David C., Grafton, MA, United States
Appel, Michael C., Grafton, MA, United States
IN
            Phillips, Nancy E., Shrewsbury, MA, United States Mordes, John P., Newton, MA, United States
           Grenier, Dale L., Hubbardston, MA, United States
Rossini, Aldo A., Sudbury, MA, United States
University of Massachusetts Medical Center, Worcester, MA, United States
PA
            (U.S. corporation)
            The Trustees of Dartmouth College, Hanover, NH, United States (U.S.
            corporation)
PI
            US 5902585
                                                     19990511
                                                                                                                    <--
            US 1997-906332
                                                     19970805 (8)
ΑI
            Division of Ser. No. US 1994-234987, filed on 25 Apr 1994, now patented,
RLI
            Pat. No. US 5683693
DT
            Utility
FS
            Granted
LN.CNT
            1125
            INCLM: 424/144.100
INCL
            INCLS: 424/130.100; 424/133.100; 424/134.100; 424/141.100; 424/143.100;
                       424/154.100; 424/173.100; 514/002.000; 514/008.000; 514/885.000; 530/387.100; 530/387.300; 530/388.100; 530/388.200; 530/388.700; 530/388.750; 530/350.000
NCL
           NCLM:
                        424/144.100
                       424/130.100; 424/133.100; 424/134.100; 424/141.100; 424/143.100; 424/154.100; 424/173.100; 514/002.000; 514/008.000; 514/885.000; 530/350.000; 530/387.100; 530/387.300; 530/388.100; 530/388.200; 530/388.200; 530/388.750
           NCLS:
IC
            [6]
            ICM: A61K039-395
            ICS: A61K035-26; C07K016-28; C07K014-435
            424/130.1; 424/133.1; 424/134.1; 424/143.1; 424/144.1; 424/173.1; 514/2; 514/8; 514/885; 530/350; 530/387.1; 530/387.3; 530/388.2; 530/388.22; 530/388.73; 530/388.75; 435/70.21; 435/452; 435/332; 435/334; 435/343.1;
EXF
            435/343.2
L9
        ANSWER 112 OF 175
                                       USPATFULL on STN
                               USPATFULL
AN
            1999:43226
TI
            Non-steroidal anti-inflammatory agents inhibition of fibrotic response
            to an implanted device
            Lanza, Robert P., Clinton, MA, United States Chick, William L., Wellesley, MA, United States
IN
            Biohybrid Technologies, Inc., Shrewsbury, MA, United States (U.S.
PA
            corporation)
US 5891477
ΡI
                                                    19990406
                                                                                                                    <--
```

(

```
DT
       Utility
FS
       Granted
LN.CNT
       1565
INCL
       INCLM: 424/501.000
       INCLS: 424/426.000; 424/502.000; 435/180.000; 435/182.000
              424/501.000
NCL
       NCLM:
       NCLS:
              424/426.000; 424/502.000; 435/180.000; 435/182.000
IC
       [6]
       ICM: A61F002-02
       ICS: A61K009-50; C12N011-04; C12N011-08
       424/426; 424/501; 424/502; 435/180; 435/182
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 113 OF 175
Ь9
                        USPATFULL on STN
       1999:40399
                   USPATFULL
AN
       Methods for regulating gene expression
TI
       Bujard, Hermann, Heidelberg, Germany, Federal Republic of
IN
       Gossen, Manfred, El Cerrito, CA, United States
       Salfeld, Jochen G., North Grafton, MA, United States
       Voss, Jeffrey W., West Boylston, MA, United States
PA
       BASF Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of
       (non-U.S. corporation)
       Knoll Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of
       (non-U.S. corporation)
PΙ
       US 5888981
                                19990330
                                                                      <--
AI
       US 1995-479306
                                19950607 (8)
       Continuation-in-part of Ser. No. US 1994-260452, filed on 14 Jun 1994,
RLI
       now patented, Pat. No. US 5650298 which is a continuation-in-part of
            No. US 1993-76327, filed on 14 Jun 1993, now abandoned
       Ser.
DT
       Utility
FS
       Granted
LN.CNT
       3270
       INCLM: 514/044.000
INCL
       INCLS: 424/093.210; 435/172.300; 935/034.000; 935/062.000
NCL
       NCLM:
              514/044.000
       NCLS:
              424/093.210; 435/455.000; 435/463.000; 435/465.000
IC
       [6]
       ICM: A61K048-00
       ICS: C12N015-00
       514/44; 435/69.1; 435/172.3; 435/240.2; 435/320.1; 536/24.1; 536/23.4;
EXF
       935/62; 935/34; 424/93.21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
     ANSWER 114 OF 175 USPATFULL on STN
AN
       1999:36949 USPATFULL
TI
       Engineering oral tissues
       Mooney, David J., Ann Arbor, MI, United States
IN
       Rutherford, Robert B., Ann Arbor, MI, United States
The Regents of the University of Michigan, Ann Arbor, MI, United States
PA
       (U.S. corporation)
PI
       US 5885829
                                19990323
                                                                      <--
                                19970528 (8)
AΙ
       US 1997-864494
       US 1996-18450P
                           19960528 (60)
PRAI
       Utility
DT
FS
       Granted
LN.CNT
       8001
INCL
       INCLM: 435/325.000
       INCLS: 424/049.000; 424/422.000; 424/435.000; 435/069.500; 435/374.000;
              435/378.000
              435/325.000
NCL
       NCLM:
       NCLS:
              424/049.000; 424/422.000; 424/435.000; 435/069.100; 435/374.000;
              435/378.000
IC
       [6]
       ICM: C12N005-00
L9
     ANSWER 115 OF 175
                        USPATFULL on STN
AN
       1999:34025
                   USPATFULL
TI
       Compositions and methods for treating and preventing pathologies
       including cancer
```

Samid, Dvorit, Rockville, MD, United States

IN

```
and Human Services, Washington, DC, United States (U.S. government)
ΡI
                                    19990316
        US 5883124
        US 1995-484615
ΑI
                                    19950607
        Division of Ser. No. US 1994-207521, filed on 7 Mar 1994 which is a continuation-in-part of Ser. No. US 1993-135661, filed on 12 Oct 1993
RLI
        which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21
        Oct 1991, now abandoned
DT
        Utility
FS
        Granted
        7729
LN.CNT
INCL
        INCLM: 514/538.000
        INCLS: 514/557.000; 514/563.000; 514/567.000; 514/568.000; 514/570.000; 514/725.000
                514/538.000
NCL
        NCLM:
                514/557.000; 514/563.000; 514/567.000; 514/568.000; 514/570.000;
        NCLS:
                514/725.000
IC
        [6]
        ICM: A01N037-12
        ICS: A01N037-44; A61K031-24
EXF
        514/538; 514/557; 514/563; 514/567; 514/568; 514/570; 514/725
    INDEXING IS AVAILABLE FOR THIS PATENT.
CAS
Ь9
     ANSWER 116 OF 175
                          USPATFULL on STN
                      USPATFULL
AN
        1999:22101
ΤI
        Apoptosis regulating composition
        Nakai, Satoru, Tokushima, Japan
IN
        Aihara, Koutoku, Tokushima, Japan
        Mori, Hitomi, Tokushima, Japan
        Tominaga, Michiaki, Tokushima, Japan
        Adachi, Masakazu, Gunma, Japan
Ichikawa, Hiroyuki, Tokushima, Japan
        Akamatsu, Seiji, Tokushima, Japan
        Saito, Fumio, Gunma, Japan
        Otsuka Pharmaceutical Co.
                                       Ltd.,
                                              Tokyo, Japan (non-U.S. corporation)
PA
                                    19990216
PΙ
        US 5872120
ΑI
        US 1997-854074
                                    19970509
                                              (8)
        Division of Ser. No. US 1995-466449, filed on 6 Jun 1995, now patented,
RLI
        Pat. No. US 5672603 which is a continuation of Ser. No. US 1993-989028,
        filed on 30 Apr 1993, now abandoned
                               19910703
PRAI
           1991-162587
        JP 1992-33469
                               19920220
        JP 1992-45178
                               19920303
                               19920325
        JP 1992-100585
        WO 1992-JP841
                               19920702
DT
        Utility
FS
        Granted
LN.CNT
       1240
INCL
        INCLM: 514/254.000
                514/253.070
NCL
        NCLM:
IC
        [6]
        ICM: A61K031-495
        ICS: A61K031-50
        514/254
EXF
CAS
    INDEXING IS AVAILABLE FOR THIS PATENT.
L9
     ANSWER 117 OF 175
                           USPATFULL on STN
AN
        1999:21928
                     USPATFULL
        Modulators of anchoring protein function
Lockerbie, Robert Owen, Kirkland, WA, United States
Howard, Monique L., Seattle, WA, United States
Gallatin, W. Michael, Mercer Island, WA, United States
TI
IN
PA
        ICOS Corporation, Bothell, WA, United States (U.S. corporation)
                                    19990216
PI
        US 5871945
AI
        US 1995-503226
                                    19950717 (8)
        Continuation-in-part of Ser. No. US 1995-404731, filed on 15 Mar 1995,
RLI
        now patented, Pat. No. US 5744354 which is a continuation-in-part of
             No. US 1994-344227, filed on 23 Nov 1994, now patented, Pat. No. US
        Ser.
        5807693
DT
        Utility
FS
        Granted
LN.CNT
        2221
INCL
        INCLM: 435/007.930
        INCLS: 435/004.000; 435/007.100; 435/007.200
NCL
        NCLM:
                435/007.930
        NCLS:
                435/004.000; 435/007.100; 435/007.200
```

```
ICM: C12Q001-00
ICS: G01Ñ033-53
EXF 435/4; 435/7.1; 435/7.2; 435/7.93
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 118 OF 175 USPATFULL on STN
AN
         1999:15930
                        USPATFULL
TI
         Epoxide-containing compounds
         Underiner, Gail, Brier, WA, United States
Klein, J. Peter, Vashon, WA, United States
Michnick, John, Seattle, WA, United States
Leigh, Alistair, Brier, WA, United States
IN
         Kumar, Anil, Seattle, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5866576 19990202 <--</pre>
PA
         US 5866576
PI
         US 1997-778563
                                        19970103 (8)
ΑI
         Continuation of Ser. No. US 1993-167600, filed on 13 Dec 1993, now
RLI
         abandoned which is a continuation-in-part of Ser. No. US 1992-991655,
         filed on 16 Dec 1992, now abandoned
DT
         Utility
         Granted
FS
         3141
LN.CNT
         INCLM: 514/256.000
INCLS: 514/396.000; 514/263.000; 544/242.000; 548/300.100; 548/311.100
INCL
         INCLS:
         NCLM:
                  514/256.000
NCL
                  514/262.100; 514/263.230; 514/396.000; 544/242.000; 548/300.100;
         NCLS:
                  548/311.100
         [6]
IC
         ICM: A61K031-505
         ICS: C07D239-02
544/269; 544/266; 544/267; 544/268; 544/270; 544/272; 544/273; 544/271;
544/242; 514/263; 514/256; 548/300.1; 548/311.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 119 OF 175 USPATFULL on STN
L9
AN
         1999:4960 USPATFULL
TI
         Mice transgenic for a tetracycline-controlled transcriptional activator
         Bujard, Hermann, Heidelberg, Germany, Federal Republic of
Gossen, Manfred, El Cerrito, CA, United States
Salfeld, Jochen G., Noth Graton, MA, United States
Voss, Jeffrey W., West Boylson, MA, United States
BASF Aktiengesellschaft, Heidelberg, Germany, Federal Republic of
TN
PA
         (non-U.S. corporation)
PI
         US 5859310
                                        19990112
                                                                                         <--
         US 1995-481970
                                        19950607 (8)
ΑI
         Continuation-in-part of Ser. No. US 1994-260452, filed on 14 Jun 1994,
RLI
         now patented, Pat. No. US 5650298 which is a continuation-in-part of
               No. US 1993-76327, filed on 14 Jun 1993, now abandoned
         Ser.
DT
         Utility
FS
         Granted
LN.CNT
         3328
INCL
         INCLM: 800/002.000
         INCLS: 435/172.300; 435/069.100; 435/070.100; 435/325.000; 435/320.100;
                  536/023.400; 536/024.100; 424/009.210
NCL
         NCLM:
                  800/009.000
                  435/069.100; 435/070.100; 435/320.100; 435/325.000; 514/152.000; 536/023.400; 536/024.100; 800/004.000; 800/018.000; 800/022.000;
         NCLS:
                  800/025.000
IC
         [6]
         ICM: C12N005-00
         ICS: C12N015-00; C12N015-09
EXF
         800/2; 435/69.1; 435/70.1; 435/172.3; 435/240.2; 435/240.4; 435/320.1;
         435/325; 536/23.4; 536/24.1; 424/9.21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 120 OF 175 USPATFULL on STN
L9
ΑN
         1998:159986
                        USPATFULL
TI
         Phenylacetate and derivatives alone or in combination with other
         compounds against neoplastic conditions and other disorders
         Samid, Dvorit, Rockville, MD, United States
TN
PA
         The United States of America as represented by the Department of Health
         and Human Services, Washington, DC, United States (U.S. government)
PΙ
         US 5852056
                                        19981222
                                                                                         <--
                         19950420
                                                                                         <---
         WO 9510271
AΙ
         US 1996-633833
                                        19960410 (8)
```

```
PCT 371 date
PCT 102(e) date
                                                      19960410
                                                      19960410
            Continuation of Ser. No. US 1994-207521, filed on 7 Mar 1994, now patented, Pat. No. US 5605930 And Ser. No. US 1993-135661, filed on 12 Oct 1993, now patented, Pat. No. US 5635532, each Ser. No. US - which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct
RLI
                                                                                                                             - which
            1991, now abandoned
DT
            Utility
FS
            Granted
LN.CNT 5051
INCL
            INCLM: 514/510.000
            INCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
                        514/567.000
                        514/510.000
NCL
            NCLM:
                        514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
            NCLS:
                        514/567.000
            [6]
IC
            ICM: A01N037-12
            ICS: A01N037-44; A61K031-195; A61K031-24
            514/510; 514/513; 514/515; 514/529; 514/538; 514/563; 514/567
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
        ANSWER 121 OF 175 USPATFULL on STN
            1998:159764
                                  USPATFULL
AN
ΤI
            In vitro growth and proliferation of multipotent ***neural***
                                                                                                                              stem
            cells and their progeny
Weiss, Samuel, Alberta, Canada
IN
           Reynolds, Brent, Alberta, Canada
Hammang, Joseph P., Barrington, RI, United States
Baetge, E. Edward, Barrington, RI, United States
            Neurospheres, Ltd., Canada (non-U.S. corporation)
PA
                                                      19981222
PI
            US 5851832
            US 1995-486648
ΑI
                                                     19950607 (8)
           Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned which is a continuation of Ser. No. US 1991-726812, filed
RLI
           on 8 Jul 1991, now abandoned And a continuation-in-part of Ser. No. US 1995-385404, filed on 7 Feb 1995, now abandoned which is a continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 726812 And Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned which is a continuation of Ser. No. US 1994-221655, filed on 1 Apr 1994, now abandoned which is a continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned which is a continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned which is a continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned which is a continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned which is a continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned which is a continuation of Ser. No. US 1991-726812
            abandoned which is a continuation-in-part of Ser. No. US 1991-726812
            filed on 8 Jul 1991, now abandoned And Ser. No. US 1995-376062, filed on
            20 Jan 1995, now abandoned which is a continuation of Ser. No. US
            1993-10829, filed on 29 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 726812 And Ser. No. US 1993-149508,
            filed on 9 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 726812 And Ser. No. US 1994-311099, filed on 23 Sep 1994,
           now abandoned which is a continuation-in-part of Ser. No. US 726812 And Ser. No. US 1994-338730, filed on 14 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 726812
DT
            Utility
FS
            Granted
LN.CNT
           4487
INCL
            INCLM: 435/368.000
            INCLS: 435/325.000; 435/366.000; 435/383.000; 435/384.000
NCLM: 435/368.000
NCL
            NCLS:
                        435/325.000; 435/366.000; 435/377.000; 435/383.000; 435/384.000
IC
            [6]
            ICM: C12N005-06
            ICS: C12N005-08; C12N005-02
            435/240.2; 435/325; 435/366; 435/368; 435/377; 435/383; 435/384
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
                                         USPATFULL on STN
L9
        ANSWER 122 OF 175
AN
            1998:150994 USPATFULL
TI
            Compositions and methods for treating and preventing pathologies
            including cancer
TN
            Samid, Dvorit, Rockville, MD, United States
            The United States of America as represented by the Department of Health
PA
            and Human Services, Washington, DC, United States (U.S. government)
PI
            US 5843994
                                                     19981201
```

19950607

Division of Ser. No. US 1994-207521, filed on 7 Mar 1994, now patented,

AI

RLI

US 1995-478264

```
1993-135661, filed on 12 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991,
           now abandoned
           Utility
DT
FS
           Granted
LN.CNT
          7935
INCL
           INCLM: 514/510.000
           INCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
                     514/567.000
                     514/510.000
NCL
          NCLM:
                     514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
          NCLS:
                     514/567.000
           [6]
IC
           ICM: A61K031-21
                 A01N047-40
           ICS:
           514/510; 514/513; 514/515; 514/529; 514/538; 514/563; 514/567
EXF
      INDEXING IS AVAILABLE FOR THIS PATENT.
CAS
       ANSWER 123 OF 175
                                   USPATFULL on STN
L9
           1998:128265
                             USPATFULL
AN
           Substituted amino alcohol compounds
TI
          Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
IN
           Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5824677 19981020 <--
PA
PI
ΑI
          US 1995-474816
                                               19950607 (8)
          Division of Ser. No. US 1994-303842, filed on 8 Sep 1994, now patented,
          Pat. No. US 5641783 which is a continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993, now patented, Pat. No. US 5801181 And Ser. No. US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No. US 5470878, said Ser. No. US -152650 And Ser. No. US -164081, each Ser. No. US - which is a continuation-in-part of Ser. No. US
RLI
           1993-40820, filed on 31 Mar 1993, now abandoned
DT
           Utility
           Granted
FS
LN.CNT
          3136
          INCLM: 514/222.500
INCLS: 514/223.500; 514/224.500; 514/226.800; 514/227.500; 514/228.800; 514/229.200; 514/230.500; 514/230.800; 514/237.800; 514/248.000; 514/249.000; 514/255.000; 514/258.000; 514/274.000; 514/301.000; 514/351.000; 514/361.000;
INCL
                     514/362.000; 514/363.000; 514/364.000; 514/365.000; 514/367.000;
                     514/372.000; 514/373.000; 514/374.000; 514/375.000; 514/376.000;
                     514/378.000; 514/379.000; 514/380.000;
                                                                                 514/387.000;
                                                                                                     514/395.000;
                                                                                 514/425.000;
346/113.000;
549/050.000;
544/003.000;
                                                                                                     514/433.000;
346/114.000;
549/075.000;
                                         514/418.000; 514/424.000;
                     514/415.000;
                                         514/432.000;
346/300.000;
549/368.000;
                                                             514/438.000;
549/014.000;
                     514/452.000;
                     346/164.000;
                     549/367.000;
                                                             544/002.000;
                                                                                                     544/005.000;
                     544/008.000;
                                                                                 544/065.000;
                                         544/053.000;
                                                             544/063.000;
                                                                                                     544/066.000;
                                                             544/091.000;
                                         544/090.000;
                                                                                 544/127.000;
                                                                                                     544/128.000;
                     544/067.000;
                                                                                                     544/235.000;
544/353.000;
                                         544/215.000;
544/255.000;
                                                             544/219.000;
544/278.000;
                                                                                 544/229.000;
                     544/162.000;
                                                                                 544/311.000;
                     544/237.000;
                                         548/123.000;
                                                             548/125.000;
                                                                                                     548/134.000;
                     544/385.000;
                                                                                 548/131.000;
                                        548/146.000; 548/153.000; 548/174.000; 548/207.000; 548/215.000; 548/217.000; 548/221.000; 548/228.000; 548/237.000; 548/240.000; 548/241.000; 548/243.000; 548/267.200; 548/303.700; 548/307.100; 548/453.000; 548/543.000; 548/546.000
                     548/143.000;
                     548/214.000;
                     548/229.000;
548/247.000;
548/486.000;
                     514/222.500
NCL
          NCLM:
          NCLS:
                     514/223.500; 514/224.500; 514/226.800; 514/227.500; 514/228.800;
                     514/229.200; 514/230.500; 514/230.800; 514/237.800; 514/248.000;
                     514/249.000; 514/255.020; 514/260.100; 514/274.000; 514/301.000;
                                        514/351.000; 514/351.000; 514/360.000; 514/361.000; 514/363.000; 514/364.000; 514/365.000; 514/367.000; 514/373.000; 514/374.000; 514/375.000; 514/376.000; 514/379.000; 514/380.000; 514/387.000; 514/395.000; 514/418.000; 514/425.000; 514/422.000;
                     514/303.000;
                     514/362.000;
                     514/372.000;
                     514/378.000;
                     514/415.000;
                                                                                 544/002.000;
                     514/433.000; 514/438.000;
                                                             514/452.000;
                                                                                                     544/003.000;
                     544/005.000; 544/008.000; 544/053.000;
                                                                                 544/063.000;
                                                                                                     544/065.000;
                     544/066.000; 544/067.000; 544/090.000;
                                                                                 544/091.000;
                                                                                                     544/127.000;
                     544/128.000; 544/162.000; 544/215.000;
                                                                                 544/219.000; 544/229.000;
                     544/235.000; 544/237.000; 544/255.000; 544/278.000; 544/311.000;
                     544/353.000; 544/385.000; 546/113.000; 546/114.000; 546/164.000; 546/300.000; 548/123.000; 548/125.000; 548/131.000; 548/134.000;
```

```
548/214.000; 548/215.000; 548/217.000; 548/221.000; 548/228.000;
                             548/229.000; 548/237.000; 548/240.000; 548/241.000; 548/243.000; 548/247.000; 548/267.200; 548/303.700; 548/307.100; 548/453.000;
                             548/486.000; 548/543.000; 548/546.000; 549/014.000; 549/050.000; 549/075.000; 549/367.000; 549/368.000
IC
               [6]
               ICM: A61K031-385
              ICM: A61KU31-385
ICS: A61KU31-445; A61KU31-47; A61KU31-505
549/75; 549/50; 549/14; 549/367; 549/368; 514/432; 514/438; 514/222.5;
514/223.5; 514/224.5; 514/226.8; 514/227.5; 514/228.8; 514/229.2;
514/230.5; 514/230.8; 514/237.8; 514/248; 514/249; 514/255; 514/258;
514/274; 514/301; 514/303; 514/311; 514/351; 514/360; 514/361; 514/362;
514/363; 514/364; 514/365; 514/367; 514/372; 514/373; 514/374; 514/375;
514/376; 514/378; 514/379; 514/380; 514/387; 514/395; 514/415; 514/418;
514/424; 514/425; 514/433; 514/452; 544/2; 544/3; 544/8; 544/8; 544/53;
EXF
              514/424; 514/425; 514/433; 514/452; 544/2; 544/3; 544/5; 544/6, 544/63; 544/65; 544/66; 544/67; 544/90; 544/91; 544/127; 544/128; 544/162; 544/215; 544/219; 544/229; 544/235; 544/237; 544/255; 544/278; 544/311; 544/353; 544/385; 546/113; 546/114; 546/164; 546/300; 548/123; 548/125; 548/131; 548/134; 548/145; 548/146; 548/153; 548/174; 548/207; 548/214; 548/215; 548/217; 548/221; 548/228; 548/229; 548/237; 548/240; 548/241; 548/243; 548/247; 548/267.2; 548/303.7; 548/307.1; 548/453; 548/496: 548/53; 548/548
               548/486;
                                 548/543; 548/546
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
          ANSWER 124 OF 175 USPATFULL on STN
AN
               1998:124453
                                         USPATFULL
              Monoclonal antibody specific for novel PKA binding proteins
Lockerbie, Robert Owen, Murray, UT, United States
Gallatin, W. Michael, Mercer Island, WA, United States
ΤI
IN
PA
               ICOS Corporation, Bothell, WA, United States (U.S. corporation)
              US 5821125
                                                                 19981013
_{
m PI}
AΙ
              US 1997-865422
                                                                 19970529 (8)
              Continuation of Ser. No. US 1996-682265, filed on 17 Jul 1996, now
RLI
              abandoned
              US 1995-1043P
Utility
                                                      \cdot19950717 (60)
PRAI
DT
FS
              Granted
LN.CNT
              976
INCL
              INCLM: 435/346.000
              INCLS: 435/326.000; 435/334.000; 530/358.100; 530/388.220; 530/387.200
NCL
                             435/346.000
              NCLM:
              NCLS:
                             435/326.000; 435/334.000; 530/387.200; 530/388.100; 530/388.220
IC
               [6]
               ICM: C12N005-12
              ICS: C07K016-28; C12P021-08
435/346; 435/326; 435/334; 530/388.1; 530/388.22; 530/387.2
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
Ь9
          ANSWER 125 OF 175 USPATFULL on STN
ΑN
              1998:119134
                                        USPATFULL
TI
              Methods for regulating gene expression
              Bujard, Hermann, Heidelberg, Germany, Federal Republic of
Gossen, Manfred, El Cerrito, CA, United States
BASF Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of
IN
PA
               (non-U.S. corporation)
              Knoll Aktiengesellchaft, Ludwigshafen, Germany, Federal Republic of
               (non-U.S. corporation)
PI
              US 5814618
                                                                 19980929
ΑI
              US 1995-485978
                                                                 19950607 (8)
              Continuation-in-part of Ser. No. US 1994-260452, filed on 14 Jun 1994, now patented, Pat. No. US 5650298 Ser. No. Ser. No. US 1993-76726, filed on 14 Jun 1993, now patented, Pat. No. US 5464758 Ser. No. Ser. No. US 1995-383754, filed on 6 Feb 1995 And Ser. No. US 1994-275876, filed on 15 Jul 1994, now patented, Pat. No. US 5654168 which is a continuation-in-part of Ser. No. US 1994-270637, filed on 1 Jul 1994, now abandoned, said Ser. No. US 260452 which is a continuation-in-part of Ser. No. US 1993-76327, filed on 14 Jun 1993, now abandoned
RLI
DT
              Utility
FS
              Granted
LN.CNT
             4512
INCL
              INCLM: 514/044.000
              INCLS: 424/093.210; 435/172.300; 935/034.620
NCL
                             514/044.000
              NCLM:
              NCLS:
                             424/093.210
IC
               [6]
```

```
ICS: C12N015-00
         424/93.1; 424/93.21; 435/320.1; 435/240.2; 435/172.3; 435/69.1;
EXF
         536/24.1; 536/23.5; 536/23.4; 514/44; 935/6; 935/10; 935/36; 935/47;
         935/34; 935/62
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 126 OF 175 USPATFULL on STN 1998:111941 USPATFULL
AN
         Amine substituted xanthinyl compounds
ΤI
        Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Ridgers, Lance H., Bothell, WA, United States
IN
        Rice, Glenn C., Seattle, WA, United States
        Leung, David W., Mercer Island, WA, United States
PA
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
        US 5807861
US 1995-476911
PΙ
                                     19980915
AI
                                     19950607 (8)
RLI
        Continuation-in-part of Ser. No. US 1994-217051, filed on 24 Mar 1994,
        now abandoned
        Utility
DT
FS
        Granted
LN.CNT
        1713
INCL
        INCLM: 514/263.000
NCL
        NCLM:
                 514/263.350
        NCLS:
                 514/081.000; 514/151.000; 514/210.210; 514/263.200; 514/263.220;
                 514/263.230
IC
         [6]
        ICM: A61K031-52
514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 127 OF 175
L9
                            USPATFULL on STN
AN
        1998:104752
                       USPATFULL
TI
        Amine substituted compounds
        Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Ridgers, Lance H., Bothell, WA, United States
IN
PA
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI
        US 5801182
                                     19980901
ΑI
        US 1995-485777
                                     19950607
                                                (8)
RLI
        Continuation-in-part of Ser. No. US 1994-217051, filed on 24 Mar 1994,
        now abandoned
DT
        Utility
FS
        Granted
LN.CNT
        1706
        INCLM: 514/269.000
INCL
        INCLS: 514/274.000; 544/310.000; 544/311.000; 544/312.000
NCL
                514/269.000
        NCLM:
        NCLS:
                514/274.000; 544/310.000; 544/311.000; 544/312.000
IC
        [6]
        ICM: A61K031-505
        ICS: C07D239-02
        544/312; 514/269; 514/274; 514/310; 514/311
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
     ANSWER 128 OF 175 USPATFULL on STN
AN
                      USPATFULL
        1998:101649
TI
        Apoptosis regulating composition
IN
        Nakai, Satoru, Itano-gun, Japan
        Aihara, Koutoku, Itano-gun, Japan
        Mori, Hitomi, Tokushima, Japan
        Tominaga, Michiaki, Itano-gun, Japan
        Adachi, Masakazu, Takasaki, Japan
Ichikawa, Hiroyuki, Tokushima, Japan
        Akamatsu, Seiji, Naruto, Japan
        Saito, Fumio, Takasaki, Japan
PA
        Otsuka Pharmaceutical Co., Ltd.,
                                               Tokyo, Japan (non-U.S. corporation)
PΙ
        US 5798358
                                    19980825
        US 1997-853746
ΑI
                                     19970509 (8)
RLI
        Division of Ser. No. US 1995-466449, filed on 6 Jun 1995, now patented,
        Pat. No. US 5672603 which is a continuation of Ser. No. US 1993-989028,
        filed on 30 Apr 1993, now abandoned
PRAI
        JP 1991-162587
                                19910703
```

```
JP 1992-45178
                                 19920303
         JP 1992-100585
                                 19920325
DT
         Utility
FS
         Granted
        1241
LN.CNT
INCL
         INCLM: 514/254.000
         NCLM:
                 514/253.070
NCL
IC
         [6]
         ICM: A61K031-495
         ICS: A61K031-50
         514/254
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 129 OF 175
                            USPATFULL on STN
AN
         1998:98921
                      USPATFULL
         Oxohexyl methylxanthine compounds
TI
IN
        Underiner, Gail, Brier, WA, United States
         Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
        US 5795897
PI
                                     19980818
        US 1994-227295
ΑI
                                     19940413
                                                (8)
RLI
        Continuation of Ser. No. US 1992-977993, filed on 18 Nov 1992
DT
        Utility
FS
        Granted
LN.CNT
        592
INCL
         INCLM: 514/261.000
                514/885.000; 514/886.000
514/211.070
514/029.000; 514/171.000; 514/253.080; 514/254.070; 514/263.320;
        INCLS:
NCL
        NCLM:
        NCLS:
                 514/885.000; 514/886.000
IC
         [6]
        ICM: A61K031-52
        514/261; 514/885
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 130 OF 175 USPA' 1998:98764 USPATFULL
L9
                            USPATFULL on STN
AN
TI
        Isolated polynucleotides encoding PKA-binding proteins and methods of
        producing the proteins recombinantly
        Lockerbie, Robert Owen, Kirkland, WA, United States
IN
        Kashishian, Adam, Mountlake Terrace, WA, United States
PA
        ICOS Corporation, Bothell, WA, United States (U.S. corporation)
        US 5795735
US 1995-503172
Utility
PI
                                     19980818
ΑI
                                     19950717 (8)
DT
        Granted
LN.CNT
        1284
        INCLM: 435/069.100
INCL
        INCLS: 536/023.100; 536/023.500; 536/024.300; 435/320.100; 435/326.000;
                 435/172.300; 435/252.300
NCL
        NCLM:
                 435/069.100
        NCLS:
                 435/252.300; 435/320.100; 435/326.000; 536/023.100; 536/023.500;
                 536/024.300
IC
        [6]
        ICM: C07K014-435
        ICS: C12N001-21;
                            C12N015-12
        536/23.1; 536/23.5; 536/24.3; 435/320.1; 435/326; 435/69.1; 435/172.3;
EXF
        435/252.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 131 OF 175 USPATFULL on STN
        1998:95545 USPATFULL
AN
ΤI
        Enatiomerically pure hydroxylated xanthine compounds
        Bianco, James A., Seattle, WA, United States Woodson, Paul, Bothell, WA, United States
TN
        Porubek, David, Edmonds, WA, United States
        Singer, Jack, Seattle, WA, United States
PA
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5792772 19980811 <--
ΡI
ΑI
        US 1995-458957
                                     19950601 (8)
RLI
        Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now patented,
        Pat. No. US 5652243 which is a division of Ser. No. US 1994-307554,
        filed on 16 Sep 1994, now patented, Pat. No. US 5648357 which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of
```

```
Utility
 DT
 FS
           Granted
 LN.CNT
           1734
 INCL
           INCLM: 514/263.000
NCL
           NCLM: 514/263.360
 IC
            [6]
           ICM: A61K031-52
514/263
EXF
      INDEXING IS AVAILABLE FOR THIS PATENT.
CAS
L9
        ANSWER 132 OF 175 USPATFULL on STN
AN
           1998:79344 USPATFULL
           Method for preparing substituted amino alcohol compounds
ΤI
           Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
IN
           Kumar, Anil M., Seattle, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5777117
19980707
PA
PI
           US 1995-472569
ΑI
                                                19950607 (8)
          Division of Ser. No. US 1994-303842, filed on 8 Sep 1994 which is a continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993 And Ser. No. US 1993-164081, filed on 8 Dec 1993 which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993, now abandoned, said Ser. No. US -152650 which is a continuation-in-part of Ser. No. US -40820
RLI
DT
           Utility
FS
           Granted
LN.CNT
           3153
           INCLM: 544/267.000
INCLS: 544/257.000; 544/285.000; 544/286.000; 544/287.000; 544/311.000; 546/141.000; 546/243.000; 546/246.000; 548/477.000; 548/546.000
INCL
NCL
           NCLM:
                      544/267.000
           NCLS:
                      544/257.000; 544/285.000; 544/286.000; 544/287.000; 544/311.000;
                      546/141.000; 546/243.000; 546/246.000; 548/477.000; 548/546.000
IC
           [6]
           ICM: C07D473-10
           ICS: C07D239-80; C07D211-94; C07D209-48
           544/267; 544/257; 544/285; 544/286; 544/287; 544/311; 546/141; 546/243; 546/246; 548/477; 548/546
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
        ANSWER 133 OF 175 USPATFULL on STN
AN
           1998:79342 USPATFULL
           Acetal-and ketal-substituted pyrimidine compounds
TI
IN
          Leigh, Alistair, Brier, WA, United States
Underiner, Gail, Brier, WA, United States
          Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5777115 19980707 <--
PA
ΡI
          US 1994-193331
AΙ
                                               19940207 (8)
          Continuation-in-part of Ser. No. US 1993-4353, filed on 14 Jan 1993, now
RLI
          abandoned
DT
          Utility
FS
           Granted
LN.CNT
          1632
          INCLM: 544/242.000
INCLS: 544/267.000; 514/269.000; 514/270.000; 514/256.000
NCLM: 544/242.000
NCLS: 544/267.000
INCL
NCL
IC
           [6]
          ICM: C07D239-26
          ICS: A61K031-505
EXF
          544/267; 544/242; 546/242; 546/243; 514/256; 514/269; 514/270
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 134 OF 175 USPATFULL on STN 1998:75151 USPATFULL
L9
AN
          Hematopoietic facilitatory cells and their uses Ildstad, Suzanne T., Pittsburgh, PA, United States Simmons, Richard L., Pittsburgh, PA, United States
TI
IN
          Ricordi, Camillo, Miami Beach, FL, United States Wren, Sherry M., Pittsburgh, PA, United States
          Kaufman, Christina, Munhall, PA, United States
The University of Pittsburgh, Pittsburgh, PA, United States (U.S.
PA
          corporation)
US 5772994
PΙ
                                               19980630
                                                                                                        <--
```

```
RLI
         Continuation of Ser. No. US 1993-69315, filed on 28 May 1993, now
         abandoned
DТ
         Utility
FS
         Granted
LN.CNT
         2333
         INCLM: 424/093.700
 INCL
         INCLS: 424/093.710; 435/002.000; 435/724.000; 435/355.000; 435/372.000
NCL
                  424/093.700
         NCLM:
                  424/093.710; 435/002.000; 435/007.240; 435/355.000; 435/372.000
         NCLS:
IC
          [6]
         ICM: A01N063-00
         ICS: C12N015-00
         424/93.7; 424/93.71; 424/529; 424/537; 435/2; 435/7.24; 435/240.1-240.2;
EXF
         435/352; 435/353; 435/354; 435/355; 435/363; 435/366; 435/372
      ANSWER 135 OF 175 USPA' 1998:72620 USPATFULL
L9
                              USPATFULL on STN
AN
         Oxime substituted therapeutic compounds
TI
         Klein, J. Peter, Vashon, WA, United States
Leigh, Alistair, Brier, WA, United States
IN
         Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
         US 5770595
ΡI
                                       19980623
ΑI
         US 1994-193344
                                       19940207
                                                  (8)
         Continuation of Ser. No. US 1993-6083, filed on 19 Jan 1993, now
RLI
         abandoned
DT
         Utility
FS
         Granted
LN.CNT
         2183
         INCLM: 514/263.000
INCLS: 544/271.000; 544/273.000
INCL
                  514/263.350
NCL
         NCLM:
         NCLS:
                  514/151.000; 544/271.000; 544/273.000
IC
         [6]
         ICM: M61K031-52
         514/263; 544/271; 544/273
EXF
L9
      ANSWER 136 OF 175
                             USPATFULL on STN
         1998:57873 USPATFULL
AN
TI
         Peptide T and related peptides in the treatment of inflammation,
         including inflammatory bowel disease
IN
         Andersen, Anders Jorgen, Kokkedal, Denmark
        Aston, Roger, Wiltshire, England
Carlen, Peter Louis, Ontario, Canada
Doob, Penelope Reed, Ontario, Canada
         MacFadden, Douglas Kevin, Ontario, Canada
        Phipps, David James, Ontario, Canada
Rathjen, Deborah, New South Wales, Australia
Widmer, Fred, New South Wales, Australia
        Peptide Technology Limited, Dee Why, Australia (non-U.S. corporation) Drug Royalty Corporation, New South Wales, Australia (non-U.S.
PA
        corporation)
US 5756449
PI
                                       19980526
                                                                                     <--
        WO 9320102
                       19931014
                                                                                     <--
ΑI
        US 1995-302829
                                       19950224
                                                  (8)
        WO 1993-GB649
                                       19930329
                                       19950224
                                                   PCT 371 date
PCT 102(e) date
                                       19950224
PRAI
        DK 1992-645
                                 19920514
DT
        Utility
FS
        Granted
LN.CNT
        2365
INCL
         INCLM: 514/008.000
NCL
        NCLM:
                 514/008.000
IC
         [6]
        ICM: A61K037-10
         514/8
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 137 OF 175
                             USPATFULL on STN
AN
        1998:51651 USPATFULL
TI
        Substituted amino alcohol compounds
        Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
IN
        Kumar, Anil M., Seattle, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
```

```
ΑI
           US 1995-475721
                                               19950607 (8)
           Division of Ser. No. US 1994-303842, filed on 8 Sep 1994, now patented,
RLI
           Pat. No. US 5641783 which is a continuation-in-part of Ser. No. US
           1993-152650, filed on 12 Nov 1993 And a continuation-in-part of Ser.
           US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No. US 5470878
           which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31
           Mar 1993, now abandoned
DT
           Utility
FS
           Granted
LN.CNT
          3115
           INCLM: 514/617.000
INCL
           INCLS: 514/653.000; 564/182.000; 564/355.000; 564/361.000
NCL
                     514/617.000
           NCLS:
                     514/653.000; 564/182.000; 564/355.000; 564/361.000
IC
           [6]
           ICM: A61K031-165
     ICS: A61K031-135; C07C233-35; C07C215-20 564/355; 564/182; 564/361; 514/617; 514/653 INDEXING IS AVAILABLE FOR THIS PATENT.
EXF
CAS
        ANSWER 138 OF 175 USPATFULL on STN
L9
ΑN
           1998:51605 USPATFULL
TI
           Apoptosis regulating compostion
IN
          Nakai, Satoru, Tokushima-ken, Japan
          Aihara, Koutoku, Tokushima-ken, Japan
          Mori, Hitomi, Tokushima, Japan
Tominaga, Michiaki, Tokushima-ken, Japan
Adachi, Masakazu, Takasaki, Japan
Ichikawa, Hiroyuki, Tokushima, Japan
          Akamatsu, Seiji, Naruto, Japan
Saito, Fumio, Takasaki, Japan
PA
          Otsuka Pharmaceutical Co., Ltd.,
                                                            Tokyo, Japan (non-U.S. corporation)
          US 5750529
US 1995-469505
ΡI
                                              19980512
ΑI
                                              19950606 (8)
          Division of Ser. No. US 1993-989028, filed on 30 Apr 1993, now abandoned JP 1991-162587 19910703
RLI
PRAI
          JP 1992-33469
                                        19920220
          JP 1992-45718
                                        19920303
          JP 1992-100585
                                        19920325
DT
          Utility
FS
          Granted
LN.CNT
          1233
          INCLM: 514/254.000
INCLS: 514/255.000
NCLM: 514/253.070
INCL
NCL .
          NCLM:
IC
           [6]
          ICM: A61K031-495
           ICS: A61K031-50
          514/254; 514/255
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 139 OF 175 USPAT
1998:51459 USPATFULL
L9
                                  USPATFULL on STN
AN
TI
          In vitro growth and proliferation of genetically modified multipotent
             ***neural***
                                   stem cells and their progeny
IN
          Weiss, Samuel, Alberta, Canada
          Reynolds, Brent, Alberta, Canada
          Hammang, Joseph P., Barrington, RI, United States Baetge, E. Edward, Barrington, RI, United States
          NeuroSpheres Holdings Ltd., Calgary, Canada (non-U.S. corporation)
PA
          US 5750376
                                              19980512
PΙ
          US 1995-483122
AI
                                              19950607 (8)
          Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned Ser. No. Ser. No. US 1995-385404, filed on 7 Feb 1995, now abandoned Ser. No. Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned Ser. No. Ser. No. US 1994-376062, filed on 20 Jan 1995, now abandoned Ser. No. Ser. No. US 1993-149508, filed on 20 Jan 1995, now abandoned Ser. No. Ser. No. US 1993-149508, filed on 23 Sep 1994, now abandoned Ser. No. Ser. No. US 1994-311099, filed on 23 Sep 1994, now
RLI
          abandoned And Ser. No. US 1994-338730, filed on 14 Nov 1994, now
          abandoned which is a continuation-in-part of Ser. No. US 1991-726812,
          filed on 8 Jul 1991, now abandoned , said Ser. No. US 1995-385404, filed
          on 7 Feb 1995, now abandoned which is a continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US 1994-359345, filed on 20 Dec 1994, now
```

```
Apr 1994, now abandoned which is a continuation of Ser. No. US
           1992-967622, filed on 28 Oct 1992, now abandoned which is a
           continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned which is a continuation of Ser. No. US 1993-10829, filed on 29
           Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US
           1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned Ser. No. Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned And Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned, each Ser. No. US which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8
           Jul 1991, now abandoned
DT
           Utility
FS
           Granted
LN.CNT
          4339
           INCLM: 435/069.520
INCL
           INCLS: 435/069.100; 435/172.300; 435/325.000; 435/368.000; 435/377.000; 435/384.000; 435/392.000; 435/395.000
                     435/069.520
NCL
           NCLM:
                     435/069.100; 435/325.000; 435/368.000; 435/377.000; 435/384.000; 435/392.000; 435/395.000; 435/455.000; 435/456.000; 435/458.000;
           NCLS:
                     435/461.000
IC
           [6]
           ICM: C12N005-00
           ICS: C12N005-08; C12N005-10; C12P001-00
EXF
           435/240.2; 435/172.3; 435/69.1; 435/69.52; 435/325; 435/368; 435/377;
435/384; 435/392; 435/395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
        ANSWER 140 OF 175 USPATFULL on STN
           1998:39529 USPATFULL
AN
TI
           Enantiomerically pure hydroxylated xanthine compounds to treat
           autoimmune diabetes
TN
          Bianco, James A., Seattle, WA, United States
          Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
          Singer, Jack, Seattle, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5739138 19980414
PA
PΙ
AΙ
          US 1995-457703
                                               19950601 (8)
RLI
          Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned
          which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994,
          now abandoned which is a continuation of Ser. No. US 1993-13977,
          on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992,
          now abandoned
          Utility
DT
FS
          Granted
LN.CNT
          1734
INCL
           INCLM: 514/263.000
          INCLS: 514/866.000
NCL
          NCLM:
                     514/263.360
          NCLS:
                     514/866.000
IC
           [6]
           ICM: A61K031-52
           514/263; 514/866
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
       ANSWER 141 OF 175 USPATFULL on STN
AN
           97:122850 USPATFULL
TI
          Sertoli cells as neurorecovery inducing cells for ***Parkinson***
                                                                                                                   ¹ s
          disease
          Sanberg, Paul R., Spring Hill, FL, United States
Cameron, Don F., Lutz, FL, United States
Borlongan, Cesario V., Lutz, FL, United States
University of South Florida, Tampa, FL, United States (U.S. corporation)
US 5702700 19971230 ---
IN
PA
ΡI
                                              19950313 (8)
ΑI
          US 1995-402389
DT
          Utility
FS
          Granted
LN.CNT
          348
INCL
          INCLM: 424/093.100
           INCLS: 424/093.700; 424/562.000; 424/558.000
NCL
                     424/093.100
```

```
IC
        ICM: A01N063-00
        ICS: A61K035-52; A61K038-22
        514/2; 514/44; 435/172.1; 435/172.2; 435/172.3; 435/240.1; 435/320.1;
EXF
        424/93.2; 424/93.21
      ANSWER 142 OF 175 USPATFULL on STN
L9
        97:109900 USPATFULL
AN
TI
        Apoptosis regulating composition
        Nakai, Satoru, Tokushima-ken, Japan
IN
        Aihara, Koutoku, Tokushima-ken, Japan
Tanaka, Hideo, Tokushima, Japan
        Iba, Hitomi, Wakayama, Japan
Kawai, Kazuyoshi, Tokushima-ken, Japan
Ichikawa, Hiroyuki, Tokushima, Japan
        Akamatsu, Seiji, Naruto, Japan
        Saito, Fumio, Takasaki, Japan
        Tominaga, Michiaki, Tokushima-ken, Japan
        Adachi, Masakazu, Takasaki, Japan
Otsuka Pharmaceutical Co., Ltd., US 5691341 19971125
PA
                                              Tokyo, Japan (non-U.S. corporation)
PΙ
        US 1995-520478
ΑI
                                    19950829 (8)
        Division of Ser. No. US 1994-211818, filed on 19 Apr 1994, now patented, Pat. No. US 5464833
RLI
PRAI
        JP 1992-220373
                               19920819
DT
        Utility
FS
        Granted
LN.CNT
        1599
        INCLM: 514/254.000
INCLS: 514/249.000; 514/250.000; 514/251.000; 514/255.000
NCLM: 514/253.070
INCL
NCL
        NCLS:
                514/249.000; 514/250.000; 514/251.000
IC
        [6]
        ICM: A61K031-495
        ICS: A61K031-50; A61K031-525
EXF
        514/249; 514/250; 514/251; 514/255; 514/254
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
     ANSWER 143 OF 175 USPATFULL on STN
ΑN
                   USPATFULL
        97:101884
TI
        Neurite growth regulatory factors, antibodies thereto, and
        pharmaceutical compositions
        Schwab, Martin E., Zurich, Switzerland
IN
        Caroni, Pierenrico W., Zurich, Switzerland
        Erziehungsdirektion of the Canton Zurich, Zurich, Switzerland (non-U.S.
PA
        corporation)
US 5684133
PI
                                    19971104
        US 1989-401212
AΙ
                                    19890830 (7)
        Continuation-in-part of Ser. No. US 1988-267941, filed on 4 Nov 1988,
RLI
        now abandoned
DT
        Utility
FS
        Granted
LN.CNT
        4086
INCL
        INCLM: 530/350.000
        INCLS: 530/399.000; 530/387.900; 530/388.240; 424/085.800; 514/002.000;
                514/008.000; 514/012.000; 435/020.210; 436/548.000; 436/519.000
530/350.000
NCL
        NCLM:
                435/070.210; 436/519.000; 436/548.000; 530/387.900; 530/388.240;
        NCLS:
                530/399.000
IC
        [6]
        ICM: C07K014-48
        ICS: C07K016-22
        530/350; 530/387; 530/399; 530/388.24; 530/387.9; 424/85.8; 435/70.2; 435/70.21; 514/8; 514/12; 436/548; 436/519
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
     ANSWER 144 OF 175 USPATFULL on STN
ΑN
                    USPATFULL
        97:101456
        Method for inducing T cell unresponsiveness to a tissue or organ graft
TI
        with anti-CD40 ligand antibody or soluble CD40
IN
        Noelle, Randolph J., Cornish, NH, United States
        Durie, Fiona H., Seattle, WA, United States
        Parker, David C., Grafton, MA, United States
        Appel, Michael C., Grafton, MA, United States
```

Phillips, Nancy E., Shrewsbury, MA, United States

```
Grenier, Dale L., Hubbardston, MA, United States
Rossini, Aldo A., Sudbury, MA, United States
Trustees of Dartmouth College, Hanover, NH, United States (U.S.
PA
         corporation)
         University of Massachusetts Medical Center, Worcester, MA, United States
         (U.S. corporation)
PI
         US 5683693
                                      19971104
ΑI
         US 1994-234987
                                      19940425 (8)
DT
         Utility
FS
         Granted
LN.CNT
        1153
INCL
         INCLM: 424/144.100
         INCLS: 424/130.100; 424/133.100; 424/134.100; 424/141.100; 424/143.100; 424/154.100; 424/193.100; 514/002.000; 514/008.000; 514/885.000
        NCLM:
                 424/144.100
NCL
        NCLS:
                 424/130.100; 424/133.100; 424/134.100; 424/141.100; 424/143.100;
                 424/154.100; 424/173.100; 514/002.000; 514/008.000; 514/885.000
IC
         [6]
         ICM: A61K039-395
         ICS: A61K038-17
         424/130.1; 424/133.1; 424/134.1; 424/141.1; 424/143.1; 424/144.1; 424/154.1; 424/173.1; 514/2; 514/8; 514/885
EXF
L9
      ANSWER 145 OF 175 USPATFULL on STN
         97:96549 USPATFULL
AN
         Cells with multiple altered epitopes on a surface antigen for use in
TI
           ***transplantation***
        Chappel, Scott C., Milton, MA, United States
Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)
IN
PA
        US 5679340
US 1994-240150
PΙ
                                      19971021
ΑI
                                       19940510
                                                  (8)
        Continuation-in-part of Ser. No. US 1994-220741, filed on 31 Mar 1994,
RLI
        now abandoned
DT
        Utility
FS
        Granted
LN.CNT
        994
INCL
         INCLM: 424/093.100
         INCLS: 435/240.200
                 424/093.100
435/325.000; 435/366.000; 435/368.000; 435/370.000; 435/371.000;
435/372.000
NCL
        NCLM:
        NCLS:
         [6]
IC
         ICM: C12N005-00
         ICS: A01N063-00
         424/93.1; 435/240.2
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 146 OF 175 USPATFULL on STN
AN
                    USPATFULL
         97:88984
TI
        Apoptosis regulating composition
IN
        Nakai, Satoru, Tokushima-ken, Japan
        Aihara, Koutoku, Tokushima-ken, Japan
        Mori, Hitomi, Tokushima, Japan
        Tominaga, Michiaki, Tokushima-ken, Japan
        Adachi, Masakazu, Takasaki, Japan
Ichikawa, Hiroyuki, Tokushima, Japan
        Akamatsu, Seiji, Naruto, Japan
Saito, Fumio, Takasaki, Japan
Otsuka Pharmaceutical Co., Ltd.
PA
                                                 Tokyo, Japan (non-U.S. corporation)
        US 5672603
                                      19970930
PΙ
                                                                                     <--
ΑI
        US 1995-466449
                                      19950606 (8)
        Continuation of Ser. No. US 1993-989028, filed on 30 Apr 1993, now
RLI
        abandoned
PRAI
        JP 1991-162587
                                 19910703
        JP 1992-33469
                                 19920220
        JP 1992-45178
                                 19920303
        JP 1992-100585
                                 19920325
        WO 1992-JP841
                                 19920702
        Utility
DT
FS
        Granted
LN.CNT
        1262
INCL
        INCLM: 514/254.000
NCL
        NCLM:
                 514/253.070
IC
         [6]
        ICM: A61K031-499
```

```
EXF
        514/254
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 147 OF 175
                            USPATFULL on STN
                   USPATFULL
AN
        97:86614
TI
        Halogen,
                   isothiocyanate or azide substituted xanthines
        Leigh, Alistair, Brier, WA, United States
Michnick, John, Seattle, WA, United States
IN
        Kumar, Anil, Seattle, WA, United States
        Underiner, Gail, Brier, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5670506 19970923 <--
PA
        US 5670506 US 1993-42946
PΙ
ΑI
                                     19930405 (8)
        Utility
DT
FS
        Granted
LN.CNT
        1994
INCL
        INCLM: 514/258.000
        INCLS: 514/263.000; 544/267.000; 544/272.000; 544/277.000
                 514/141.000
NCL
        NCLM:
        NCLS:
                544/267.000; 544/272.000; 544/277.000
IC
        [6]
        ICM: A61K031-52
        ICS: C07D473-00
        544/267; 544/276; 544/272; 544/277; 514/258
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 148 OF 175 USPATFULL on STN
AN
        97:86266
                    USPATFULL
TI
        Combined cellular and immunosuppressive therapies
        Sherwin, Stephen A., San Francisco, CA, United States
Dubridge, Robert B., Belmont, CA, United States
Cell Genesys, Inc., Foster City, CA, United States (U.S. corporation)
US 5670148
19970923
---
IN
PA
PI
AI
        US 1994-314452
                                     19940928 (8)
        Continuation of Ser. No. US 1991-781075, filed on 21 Oct 1991, now
RLI
        abandoned
DT
        Utility
FS
        Granted
LN.CNT
        700
INCL
        INCLM: 424/093.210
        INCLS: 435/192.300; 424/933.000; 424/937.000; 424/572.000
NCL
        NCLM:
                424/093.210
        NCLS:
                424/093.300; 424/093.700; 424/572.000
        [6]
IC
        ICM: C12N015-00
        ICS: A01N063-00; A61K035-12
        424/93.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 149 OF 175 USPATFULL on STN
AN
        97:73619
                   USPATFULL
TI
        Apoptosis regulating composition
IN
        Nakai, Satoru, Tokushima-ken, Japan
        Aihara, Koutoku, Tokushima-ken, Japan
        Mori, Hitomi, Tokushima, Japan
        Tominaga, Michiaki, Tokushima-ken, Japan
        Adachi, Masakazu, Takasaki, Japan
Ichikawa, Hiroyuki, Tokushima, Japan
Akamatsu, Seiji, Naruto, Japan
Saito, Fumio, Takasaki, Japan
        Otsuka Pharmaceutical Co., Ltd.,
PA
                                               Tokyo, Japan (non-U.S. corporation)
        US 5658912
PΙ
                                     19970819
AI
        US 1995-469922
                                     19950606
                                                (8)
        Division of Ser. No. US 1993-989028, filed on 30 Apr 1993, now abandoned
RLI
PRAI
                                19910703
        JP 1991-162587
        JP 1992-33469
                                19920220
        JP 1992-45718
                                19920303
        JP 1992-100585
                                19920325
DT
        Utility
FS
        Granted
LN.CNT
        1242
INCL
        INCLM: 514/254.000
        INCLS: 514/255.000
NCL
        NCLM:
                514/754.000
        NCLS:
                514/253.070
```

```
ICM: A61K031-495
          ICS: A61K031-50
EXF
          514/254; 514/255
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
       ANSWER 150 OF 175 USPATFULL on STN
AN
                       USPATFULL
          97:66130
          Methods of using enantiomerically pure hydroxylated xanthine compounds Bianco, James A., Seattle, WA, United States Singer, Jack, Seattle, WA, United States
ΤI
IN
          Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5652243 19970729 <--
PA
PΙ
ΑI
          US 1994-343810
                                           19941122 (8)
          Division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992,
RLI
          now abandoned which is a continuation-in-part of Ser. No. US
          1992-846354, filed on 4 Mar 1992, now abandoned
DT
          Utility
FS
          Granted
LN.CNT
          1731
INCL
          INCLM: 514/263.000
          INCLS: 514/262.000; 514/265.000; 514/814.000
NCL
                   514/263.360
          NCLM:
          NCLS:
                   514/814.000
IC
          [6]
ICM: A61K031-52
EXF 514/262; 514/263; 514/265
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
       ANSWER 151 OF 175
                                USPATFULL on STN
AN
                       USPATFULL
TI
          Enatiomerically pure hydroxylated xanthine compounds
IN
          Bianco, James A., Seattle, WA, United States
         Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
          Singer, Jack, Seattle, WA, United States
         Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5648357 19970715 <--
PΑ
PI
AΙ
          US 1994-307554
                                          19940916 (8)
          Continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993,
RLI
          abandoned_which is a continuation-in-part of Ser. No. US 1992-926665
          filed on 7 Aug 1992, now abandoned which is a continuation-in-part of
         Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned Utility
DT
FS
         Granted
LN.CNT
         1748
INCL
          INCLM: 514/263.000
          INCLS: 514/267.000; 514/270.000; 514/271.000
NCL
                   514/263.360
         NCLM:
         NCLS:
                   514/267.000; 514/270.000; 514/271.000
IC
          [6]
ICM: A61K031-52
EXF 514/263; 514/267; 544/267; 544/270; 544/271
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
                               USPATFULL on STN
L9
       ANSWER 152 OF 175
AN
         97:54233
                      USPATFULL
TI
         Substituted amino alcohol compounds
         Klein, J. Peter, Vashon, WA, United States
IN
         Underiner, Gail E., Brier, WA, United States
         Kumar, Anil M., Seattle, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
         US 5641783
PI
                                          19970624
         US 1994-303842
AΙ
                                          19940908
                                                      (8)
         Continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993
And Ser. No. US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No.
RLI
         US 5470878
DT
         Utility
FS
         Granted
LN.CNT
         3206
INCL
         INCLM: 514/263.000
         INCLS: 514/183.000; 514/222.500; 514/223.500; 514/224.200; 514/226.800; 514/227.500; 514/228.800; 514/229.200; 514/230.500; 514/230.800; 514/237.800; 514/241.000; 514/242.000; 514/243.000; 514/246.000; 514/247.000; 514/248.000; 514/249.000; 514/255.000; 514/256.000;
```

```
514/300.000;
514/307.000;
514/351.000;
                                                                                               514/301.000;
514/311.000;
514/357.000;
514/363.000;
 514/270.000; 514/274.000;
                                                514/297.000;
 514/302.000;
                        514/303.000;
                                                514/306.000;
 514/312.000;
                                                514/345.000;
                        514/315.000;
 514/359.000;
                        514/360.000;
                                                514/361.000;
                                                                        514/362.000;
 514/364.000;
                        514/365.000;
                                                514/367.000;
                                                                        514/369.000;
                                                                                               514/372.000;
                        514/374.000;
                                                514/375.000;
                                                                                               514/378.000;
 514/373.000;
                                                                        514/376.000;
                        514/380.000;
514/395.000;
514/406.000;
 514/379.000;
                                                514/381.000;
                                                                        514/383.000;
                                                                                               514/389.000;
 514/394.000;
                                                514/398.000;
                                                                                               514/401.000;
                                                                       514/399.000;
 514/404.000;
                                                514/413.000;
                                                                                               514/416.000;
                                                                       514/415.000;
                        514/423.000;
544/001.000;
514/418.000;
                                                514/424.000;
544/002.000;
                                                                       514/425.000;
                                                                                               514/427.000;
 514/428.000;
                                                                       544/003.000;
                                                                                               544/008.000;
 544/053.000;
                                                544/065.000;
                                                                       544/066.000;
544/215.000;
544/235.000;
544/262.000;
                        544/063.000;
                                                                                               544/067.000;
                                                                                               544/216.000;
544/239.000;
544/272.000;
                                                544/162.000;
544/224.000;
544/090.000;
                        544/091.000;
 544/219.000;
                        544/220.000;
                                                544/257.000;
544/254.000;
                        544/255.000;
                        544/278.000;
544/277.000;
                                                544/280.000;
                                                                       544/283.000;
                                                                                               544/286.000;
544/301.000;
544/353.000;
                        544/311.000;
                                                544/335.000;
                                                                       544/336.000;
                                                                                               544/350.000;
                       544/385.000;
546/115.000;
546/138.000;
546/164.000;
546/246.000;
                                               544/401.000;
                                                                       546/102.000;
                                                                                               546/113.000;
                                               546/117.000;
546/139.000;
546/176.000;
546/264.000;
546/114.000;
                                                                                               546/119.000;
                                                                       546/118.000;
                                                                      546/150.000;
546/150.000;
546/178.000;
546/300.000;
548/127.000;
548/153.000;
548/215.000;
                                                                                              546/153.000;
546/242.000;
546/334.000;
548/128.000;
548/179.000;
546/122.000;
546/157.000;
546/243.000;
                        548/123.000;
548/100.000;
                                                548/125.000;
                        548/134.000;
                                               548/146.000;
548/131.000;
                                               548/214.000;
548/186.000;
                        548/207.000;
                                                                                               548/217.000;
548/221.000;
                        548/225.000;
                                               548/228.000;
                                                                       548/229.000;
                                                                                               548/235.000;
548/237.000;
548/252.000;
548/307.100;
                        548/240.000;
                                               548/241.000;
                                                                       548/243.000;
                                                                                               548/247.000;
                        548/267.200;
548/309.700;
548/349.100;
                                               548/267.800;
548/319.100;
548/356.100;
548/453.000;
                                                                       548/303.700;
                                                                                               548/306.400;
                                                                       548/323.500;
548/370.100;
548/470.000;
                                                                                               548/340.100;
548/348.100;
                                                                                               548/375.100;
548/482.000;
548/532.000;
548/379.400;
                        548/452.000;
                        548/486.000;
                                               548/491.000; 548/503.000; 548/550.000; 548/565.000;
548/485.000;
548/543.000;
                        548/546.000;
                                                                                               548/566.000
514/263.350
                       514/222.500; 514/223.500; 514/224.200; 514/228.800; 514/229.200; 514/230.500; 514/241.000; 514/242.000; 514/243.000; 514/248.000; 514/249.000; 514/252.160; 514/264.100; 514/266.300; 514/270.000; 514/300.000; 514/301.000; 514/302.000; 514/307.000; 514/311.000; 514/312.000; 514/351.000; 514/359.000;
514/183.000;
514/227.500;
514/237.800;
514/247.000;
                                                                                               514/226.800;
                                                                                              514/230.800;
                                                                                              514/246.000;
                                                                                              514/256.000;
514/274.000;
514/303.000;
514/315.000;
514/360.000;
514/259.500;
514/297.000;
514/306.000;
514/345.000;
                                               514/357.000;
                                                                       514/359.000;
                        514/351.000;
514/361.000;
                        514/362.000;
                                               514/363.000;
                                                                      514/364.000;
                                                                                              514/365.000;
                       514/369.000;
514/376.000;
514/383.000;
514/399.000;
514/367.000;
514/375.000;
514/381.000;
                                               514/372.000;
                                                                      514/373.000;
                                                                                               514/374.000;
                                               514/372.000;
514/378.000;
514/389.000;
514/401.000;
514/416.000;
514/427.000;
                                                                      514/379.000;
                                                                                              514/380.000;
                                                                      514/394.000;
514/404.000;
514/418.000;
                                                                                              514/395.000;
514/398.000;
                                                                                              514/406.000;
                        514/415.000;
514/413.000;
                                                                                              514/423.000;
544/001.000;
                        514/425.000;
514/424.000;
                                                                       514/428.000;
                        544/003.000;
                                               544/008.000;
544/002.000;
                                                                      544/053.000;
                                                                                              544/063.000;
544/065.000;
                        544/066.000;
                                                                      544/090.000;
                                               544/067.000;
                                                                                              544/091.000;
544/162.000;
544/224.000;
544/257.000;
544/280.000;
                                               544/216.000;
                                                                      544/219.000;
544/254.000;
                        544/215.000;
                                                                                              544/220.000;
                                              544/216.000;

544/239.000;

544/272.000;

544/286.000;

544/350.000;

546/113.000;

546/119.000;

546/153.000;
                       544/235.000;
544/262.000;
544/283.000;
544/336.000;
546/102.000;
                                                                                              544/255.000;
                                                                      544/277.000;
544/301.000;
544/353.000;
546/114.000;
546/122.000;
                                                                                              544/278.000;
                                                                                              544/311.000;
544/385.000;
546/115.000;
546/138.000;
544/335.000;
544/401.000;
546/117.000;
                        546/118.000;
                                                                       546/157.000;
                                                                                              546/164.000;
546/246.000;
                       546/150.000;
546/139.000;
546/176.000;
                       546/178.000;
                                               546/242.000;
                                                                      546/243.000;
                                               546/334.000;
546/264.000;
                       546/300.000;
                                                                      548/100.000;
                                                                                              548/123.000;
548/125.000;
                       548/127.000;
                                               548/128.000;
                                                                      548/131.000;
                                                                                              548/134.000;
                                              548/128.000; 548/131.000; 548/179.000; 548/186.000; 548/217.000; 548/221.000; 548/237.000; 548/247.000; 548/252.000; 548/306.400; 548/307.100; 548/340.100; 548/379.400; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100; 548/379.100;
548/146.000;
548/214.000;
548/228.000;
548/241.000;
                       548/153.000;
548/215.000;
548/229.000;
548/243.000;
                                                                                              548/207.000;
                                                                                              548/225.000;
                                                                                              548/240.000;
                                                                                              548/267.200;
548/309.700;
548/349.100;
548/267.800;
                       548/303.700;
                       548/323.500;
548/319.100;
                       548/370.100;
548/356.100;
                                                                                              548/452.000;
                                               548/482.000;
548/453.000;
                       548/470.000;
                                                                      548/485.000;
                                                                                              548/486.000;
548/491.000; 548/503.000;
                                               548/532.000;
                                                                      548/543.000; 548/546.000;
548/550.000; 548/565.000; 548/566.000
```

IC [6] ICM: A61K031-415

NCL

NCLM:

NCLS:

ICS: A61K031-42; A61K031-425; A61K031-52

```
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
       ANSWER 153 OF 175
                                 USPATFULL on STN
AN
          97:40793
                       USPATFULL
          Treatment of diseases using enantiomerically pure hydroxylated xanthine
TI
          compounds
IN
          Bianco, James A., Seattle, WA, United States
          Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
          Singer, Jack, Seattle, WA, United States
          Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5629315 19970513 <--
PA
PΙ
AI
          US 1995-456900
                                             19950601 (8)
          Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned
RLI
          which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994,
          now abandoned which is a continuation of Ser. No. US 1993-13977, filed
          on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992,
          now abandoned
          Utility
DT
FS
          Granted
LN.CNT 1736
          INCLM: 514/263.000
INCL
          INCLS: 514/866.000
NCL
          NCLM:
                    514/263.360
          NCLS:
                    514/866.000
IC
          [6]
          ICM: A61K031-52
          514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
       ANSWER 154 OF 175 USPATFULL on STN
AN
          97:31820
                        USPATFULL
          Process for preparing enantiomerically pure xanthine derivatives
Bianco, James A., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
TI
IN
          Singer, Jack, Seattle, WA, United States
PA
          Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5621102 19970415
          US 5621102
PI
ΑI
          US 1995-456897
                                             19950601 (8)
RLI
          Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned
         which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994, now abandoned which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992,
          now abandoned
DT
          Utility
FS
          Granted
LN.CNT
          1763
          INCLM: 544/267.000
INCLS: 514/340.000
NCLM: 544/267.000
INCL
NCL
IC
          [6]
          ICM: C07D473-06
          ICS: C07D473-08; C07D473-12
EXF
          544/267
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
       ANSWER 155 OF 175 USPATFULL on STN
AN
                        USPATFULL
          97:31706
          Enatiomerically pure hydroxylated xanthine compounds to treat inflammatory diseases
TI
          Bianco, James A., Seattle, WA, United States
IN
          Woodson, Paul, Bothell, WA, United States
          Porubek, David, Edmonds, WA, United States
          Singer, Jack, Seattle, WA, United States
          Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5620984 19970415 <--
PA
          US 5620984
US 1995-456898
PI
                                             19950601 (8)
ΑI
         Division of Ser. No. US 1994-343810, filed on 22 Nov 1994 which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now
RLI
```

```
filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT
         Utility
FS
         Granted
LN.CNT
         1721
INCL
         INCLM: 514/263.000
NCL
         NCLM:
                  514/263.360
IC
         [6]
         ICM: A61K031-52
514/263
EXF
CAS
     INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 156 OF 175
                             USPATFULL on STN
         97:22792
                     USPATFULL
AN
TI
         Enantiomerically pure hydroxylated xanthine compounds to treat shock
IN
         Blanco, James A., Seattle, WA, United States
         Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
         Singer, Jack, Seattle, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5612349

19970318

---
PA
ΡI
         US 1995-457062
ΑI
                                       19950601 (8)
\mathtt{RLI}
         Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned
         which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994,
         now abandoned which is a continuation of Ser. No. US 1993-13977,
        on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992,
         now abandoned
         Utility
DT
FS
         Granted
LN.CNT
        1725
INCL
         INCLM: 514/263.000
         INCLS: 514/921.000
                 514/263.360
NCL
         NCLM:
         NCLS:
                  514/921.000
IC
         [6]
         ICM: A61K031-52
514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 157 OF 175
                              USPATFULL on STN
         97:16085 USPATFULL
\mathbf{AN}
TI
         Compositions and methods for treating and preventing pathologies
         including cancer
         Samid, Dvorit, Rockville, MD, United States
IN
         The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PA
PI
         US 5605930
                                       19970225
        US 1994-207521
                                       19940307 (8)
AΙ
RLI
         Continuation-in-part of Ser. No. US 1993-135661, filed on 12 Oct 1993
        which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21
         Oct 1991
DT
        Utility
FS
         Granted
        7722
LN.CNT
         INCLM: 514/510.000
INCL
         INCLS:
                 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
                 514/567.000
NCL
        NCLM:
                 514/510.000
        NCLS:
                 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
                 514/567.000
IC
         [6]
         ICM: A61K031-21
         ICS: A01N037-00; A01N047-40; A01N047-46
         514/538; 514/563; 514/567; 514/510; 514/513; 514/515; 514/529
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 158 OF 175
                              USPATFULL on STN
ΑN
         96:120774 USPATFULL
TI
        Tetracycline regulated transcriptional modulators with altered DNA
        binding specificities
        Bujard, Hermann, Heidelberg, Germany, Federal Republic of Gossen, Manfred, El Cerrito, Germany, Federal Republic of
IN
```

```
Helbl, Vera, Fuerth, Germany, Federal Republic of
Schnappinger, Dirk, Bad Driburg, Germany, Federal Republic of
            BASF Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of
 PA
             (non-U.S. corporation)
            Knoll Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of
            (non-U.S. corporation)
            US 5589362
US 1995-485971
PI
                                                   19961231
AΙ
           US 1995-485971

Continuation-in-part of Ser. No. US 1995-383754, filed on 3 Feb 1995 And a continuation-in-part of Ser. No. US 1994-275876, filed on 15 Jul 1994 And a continuation-in-part of Ser. No. US 1994-260452, filed on 14 Jun 1994 And a continuation-in-part of Ser. No. US 1993-76726, filed on 14 Jun 1993, now patented, Pat. No. US 5464758, said Ser. No. US -275876 which is a continuation-in-part of Ser. No. US 1994-270637, filed on 1 Jul 1994, now abandoned, said Ser. No. US -260452 which is a continuation-in-part of Ser. No. US -260452 which is a continuation-in-part of Ser. No. US -260452 which is a
                                                   19950607 (8)
RLI
            continuation-in-part of Ser. No. US 1993-76327, filed on 14 Jun 1993,
            now abandoned
DT
            Utility
FS
            Granted
LN.CNT
            4415
            INCLM: 435/069.100
INCL
            INCLS:
                       435/172.300; 536/023.400; 536/024.100; 935/006.000; 935/010.000;
                        935/034.000; 935/047.000; 935/036.000
NCL
            NCLM:
                       435/069.100
            NCLS:
                       435/320.100; 435/325.000; 435/358.000; 435/455.000; 536/023.400;
                       536/024.100
IC
            [6]
            ICM: C12P021-00
            ICS: C12N015-31; C07H021-04
            435/69.1; 435/172.3; 536/23.4; 536/24.1; 935/6; 935/10; 935/34; 935/36;
EXF
            935/47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
        ANSWER 159 OF 175
                                      USPATFULL on STN
AN
                            USPATFULL
            96:111463
ΤI
            Enatiomerically pure hydroxylated xanthine compounds
           Bianco, James A., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
IN
           Singer, Jack, Seattle, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5580874
19961203
---
PA
PI
AΙ
           US 1995-457685
                                                   19950601 (8)
RLI
           Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned
           which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993,
           now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992,
           now abandoned
DT
           Utility
FS
           Granted
LN.CNT
           1733
INCL
            INCLM: 514/263.000
                       514/263.360
NCL
           NCLM:
IC
            [6]
           ICM: A61K031-52
EXF
            514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
        ANSWER 160 OF 175 USPATFULL on STN
AN
           96:111462
                            USPATFULL
TI
           Enatiomerically pure hydroxylated xanthine compounds to treat
           proliferative vascular diseases
           Bianco, James A., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
IN
           Singer, Jack, Seattle, WA, United States
           Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5580873 19961203 <--
PA
ΡĮ
           US 5580873
AΙ
           US 1995-456899
                                                   19950601 (8)
           Division of Ser. No. US 1994-343810, filed on 22 Nov 1994 which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now
RLI
```

abandoned which is a continuation-in-part of Ser. No. US 1992-926665,

```
Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT
          Utility
FS
          Granted
LN.CNT 1728
INCL
          INCLM: 514/263.000
NCL
          NCLM:
                   514/263.360
IC
          [6]
          ICM: A61K031-52
EXF
          514/263
     INDEXING IS AVAILABLE FOR THIS PATENT.
CAS
L9
       ANSWER 161 OF 175 USPATFULL on STN
                      USPATFULL
          96:97041
AN
         R-enatiomerically pure hydroxylated xanthine compounds to treat baldness Bianco, James A., Seattle, WA, United States
TI
IN
          Woodson, Paul, Bothell, WA, United States
          Porubek, David, Edmonds, WA, United States
          Singer, Jack, Seattle, WA, United States
         Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5567704 19961022 <--
PA
         US 5567704
US 1995-457683
PΙ
                                          19950601 (8)
ΑI
         Division of Ser. No. US 1994-343810, filed on 22 Nov 1994 which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now
RLI
         abandoned which is a continuation-in-part of Ser. No. US 1992-926665
          filed on 7 Aug 1992, now abandoned which is a continuation-in-part of
          Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
         Utility
DT
         Granted
FS
LN.CNT
         1736
         INCLM: 514/263.000
INCLS: 514/262.000
NCLM: 514/263.360
INCL
NCL
         NCLS:
                   424/070.100
IC
          [6]
ICM: A61K031-52
EXF 514/263; 514/262
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
       ANSWER 162 OF 175 USPATFULL on STN
AN
         96:70451 USPATFULL
         Hepatitis treatment with carbostyril compounds
ΤI
IN
         Nakai, Satoru, Tokushima-ken, Japan
         Aihara, Koutoku, Tokushima-ken, Japan
         Mori, Hitomi, Tokushima, Japan
         Tominaga, Michiaki, Tokushima-ken, Japan
Adachi, Masakazu, Takasaki, Japan
Ichikawa, Hiroyuki, Tokushima, Japan
Akamatsu, Seiji, Naruto, Japan
         Saito, Fumio, Takasaki, Japan
         Otsuka Pharmaceutical Co., Ltd.,
US 5543412 19960806
PA
                                                     Tokyo, Japan (non-U.S. corporation)
PI
ΑI
         US 1995-469893
                                          19950606 (8)
         Division of Ser. No. US 1993-989028, filed on 30 Apr 1993, now abandoned
RLI
         JP 1991-162587
JP 1992-33469
PRAI
                                    19910703
                                    19920220
         JP 1992-45178
                                    19920303
         JP 1992-100585
                                    19920325
DT
         Utility
FS
         Granted
LN.CNT
         1245
INCL
         INCLM: 514/255.000
         NCLM: 514/253.070
NCL
IC
         [6]
         ICM: A61K031-495
514/255
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 163 OF 175
                                USPATFULL on STN
AN
                      USPATFULL
ΤI
         Olefin substituted long chain compounds
         Underiner, Gail, Brier, WA, United States
Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon, WA, United States
Eiseman, Elisa, Seattle, WA, United States
IN
```

```
Kumar, Anil, Seattle, WA, United States Michnick, John, Seattle, WA, United States
PA
         Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI
         US 5521315
                                      19960528
ΑI
         US 1993-59697
                                      19930510 (8)
         Continuation-in-part of Ser. No. US 1993-3372, filed on 12 Jan 1993, now
RLI
         patented, Pat. No. US 5354756
DT
         Utility
FS
         Granted
LN.CNT
         2761
INCL
         INCLM: 546/243.000
         INCLS: 546/242.000; 544/285.000
                 546/243.000
NCL
         NCLM:
         NCLS:
                 544/285.000; 546/242.000
IC
         [6]
         ICM: C07D211-88
         ICS: C07D239-80
         548/545; 548/546; 548/547; 546/243; 544/285
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 164 OF 175
                             USPATFULL on STN
         95:108287
                     USPATFULL
ΑN
TI
         Substituted long chain alcohol xanthine compounds
IN
         Underiner, Gail, Brier, WA, United States
        Porubek, David, Edmonds, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
         Woodson, Paul, Bothell, WA, United States
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5473070 19951205
PA
PΙ
        US 1992-976353
AT
                                      19921116 (7)
         Utility
DT
FS
         Granted
LN.CNT
        890
INCL
         INCLM: 544/267.000
         INCLS: 514/263.000
NCL
        NCLM:
                 544/267.000
IC
         [6]
         ICM: C07D473-04
         ICS: A61K031-52
         544/267; 514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 165 OF 175 USPATFULL on STN
AN
         95:99146 USPATFULL
        Apoptosis regulating composition
Nakai, Satoru, Itano, Japan
Aihara, Koutoku, Itano, Japan
ΤI
IN
        Tanaka, Hideo, Tokushima, Japan
         Iba, Hitomi, Wakayama, Japan
        Kawai, Kazuyoshi, Itano, Japan
Ichikawa, Hiroyuki, Tokushima, Japan
        Akamatsu, Seiji, Tokushima, Japan
Saito, Fumio, Takasaki, Japan
        Tominaga, Michiaki, Tokushima, Japan
Adachi, Masakazu, Takasaki, Japan
Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PA
ΡI
        US 5464833
                                      19951107
                                                                                   <--
        WO 9404504
                       19940303
                                                                                    <--
AI
        US 1994-211818
                                      19940419
                                                 (8)
        WO 1993-JP1144
                                      19930812
                                      19940419
                                                  PCT 371 date
                                                  PCT 102(e) date
                                      19940419
        JP 1992-220373
Utility
PRAI
                                 19920819
DT
FS
        Granted
LN.CNT
        1474
INCL
        INCLM: 514/251.000
        INCLS:
                 514/249.000; 514/250.000; 514/255.000
NCL
                 514/251.000
        NCLM:
        NCLS:
                 514/249.000; 514/250.000; 514/253.070
IC
        [6]
        ICM: A61K031-495
514/249; 514/250; 514/251; 514/255
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
95:71491 USPATFULL
AN
          Acetal or ketal substituted xanthine compounds
TI
          Leigh, Alistair, Edmonds, WA, United States
Underiner, Gail, Brier, WA, United States
IN
PA
          Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
          US 5440041
US 1994-194135
PΙ
                                          19950808
AΙ
                                          19940208 (8)
RLI
          Continuation of Ser. No. US 1993-4353, filed on 14 Jan 1993, now
          abandoned
DT
          Utility
FS
          Granted
LN.CNT 874
INCL
          INCLM: 544/267.000
          INCLS: 544/268.000
NCL
          NCLM:
                   544/267.000
                   544/268.000
          NCLS:
IC
          [6]
          ICM: C07D473-06
544/267; 544/268; 514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
       ANSWER 167 OF 175 USPATFULL on STN
                      USPATFULL
AN
          94:88699
          Olefin-substituted long chain xanthine compounds
TI
IN
          Underiner, Gail, Brier, WA, United States
         Porubek, David, Edmonds, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
          Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5354756 19941011
PA
         US 5354756
PΙ
         US 1993-3372
AΙ
                                          19930112 (8)
DT
         Utility
FS
         Granted
LN.CNT 846
INCL
          INCLM: 514/263.000
         INCLS: 544/267.000; 544/272.000; 544/273.000

NCLM: 514/263.340

NCLS: 514/263.350; 514/263.360; 544/267.000; 544/272.000; 544/273.000
NCL
IC
          [5]
          ICM: A61K031-52
          ICS: C07D473-02
EXF
          544/267; 544/272; 544/273; 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 168 OF 175 USPATFULL on STN
L9
AN
         94:73300 USPATFULL
TI
         Substituted aminoalkyl xanthine compounds
         Klein, J. Peter, Vashon, WA, United States
Underiner, Gail, Bothell, WA, United States
Leigh, Alistair, Edmonds, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5340813
19940823
---
IN
PA
         US 5340813
US 1992-973804
Utility
PΙ
AΙ
                                          19921109 (7)
DT
FS
         Granted
LN.CNT
         725
INCL
         INCLM: 514/263.000
         INCLS: 544/272.000
                  514/263.350
544/272.000
NCL
         NCLM:
         NCLS:
IC
         [5]
         ICM: C07D473-04
         ICS: A61K031-52
         544/267; 544/272; 514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 169 OF 175
                                USPATFULL on STN
AN
         94:15745 USPATFULL
ΤI
         Substituted epoxyalkyl xanthines
         Klein, J. Peter, Vashon, WA, United States
Porubek, David, Edmonds, WA, United States
Rice, Glenn C., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
IN
PA
         Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5288721 19940222 <--
PI
AΙ
         US 1992-949330
                                          19920922 (7)
```

```
FS
         Granted
LN.CNT
        945
INCL
         INCLM: 514/263.000
         INCLS: 544/267.000
NCL
         NCLM:
                  514/263.230
                  514/263.320; 544/267.000
         NCLS:
         [5]
IC
         ICM: A61K031-52
         ICS: C07D473-04
         544/267; 514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 170 OF 175 USPATFULL on STN
AN
         93:82731
                    USPATFULL
TI
         Diagnostic methods using neurite growth regulatory factors
IN
         Schwab, Martin E., Zurich, Switzerland
         Caroni, Pierenrico W., Zurich, Switzerland
         Paganetti, Paolo A., Zurich, Switzerland
         Erziehungsdirektion of the Canton Zurich, Zurich, Switzerland (non-U.S.
PA
         corporation)
         US 5250414
PI
                                       19931005
         US 1991-719692
AΙ
                                       19910624 (7)
RLI
         Continuation-in-part of Ser. No. US 1989-401212, filed on 30 Aug 1989
         which is a continuation-in-part of Ser. No. US 1988-267941, filed on 4
         Nov 1988, now abandoned
DT
         Utility
FS
         Granted
LN.CNT
         5260
         INCLM: 435/007.720
INCL
         INCLS: 435/007.230; 530/350.000; 514/002.000; 514/021.000; 436/064.000;
                 436/813.000
NCL
         NCLM:
                 435/007.720
         NCLS:
                 435/007.230; 436/064.000; 436/813.000; 514/002.000; 514/021.000;
                 530/350.000
IC
         [5]
ICM: C12N009-64
EXF 530/350; 514/2; 514/21; 435/7.72; 435/7.23; 436/64; 436/813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
      ANSWER 171 OF 175
                             WPIDS
                                      COPYRIGHT 2004 THOMSON DERWENT on STN
AN
      2001-536475 [59]
                              WPIDS
DNC.
      C2001-159715
      New azolo-pyridine carboxamide compounds, are poly adenosine diphosphate-ribose polymerase inhibitors useful e.g. for treating neurodegenerative disease, epilepsy, cardiac ischemia, tumors, sepsis,
TI
      inflammation and diabetes mellitus.
DC
      GRANDEL, R; HOEGER, T; KOCK, M; LUBISCH, W; MUELLER, R; SCHULT, S (BADI) BASF AG; (GRAN-I) GRANDEL R; (HOEG-I) HOEGER T; (KOCK-I) KOCK M; (LUBI-I) LUBISCH W; (MUEL-I) MUELLER R; (SCHU-I) SCHULT S
IN
PA
CYC
      95
PI
      WO
         2001057038 A1 20010809 (200159)* DE
                                                         29p
                                                                  C07D471-04
          RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
               NL OA PT
                         SD SE SL SZ
                                         TR TZ
                                                UG ZW
              AE AG AL AM AT AU AZ
                                         BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
              DZ EE ES FI GB GD GE GH GM HR HU
               LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
               SG SI SK SL TJ TM TR TT TZ UA UG US UZ
                                                                  YU ZA ZW
                                                               VN
      AU 2001040542 A
                           20010814 (200173)
                                                                  C07D471-04
      EP 1257551
                       A1 20021120
                                       (200301)
                                                   DE
                                                                  C07D471-04
           R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
               RO SE SI TR
         2003134843 A1 20030717 (200348)
                                                                  A61K031-551
      WO 2001057038 A1 WO 2001-EP790 20010125; AU 2001040542 A AU 2001-40542
ADT
      20010125; EP 1257551 A1 EP 2001-911528 20010125, WO 2001-EP790 20010125; US 2003134843 A1 WO 2001-EP790 20010125, US 2002-182532 20021118 AU 2001040542 A Based on WO 2001057038; EP 1257551 A1 Based on WO
FDT
      2001057038
PRAI DE 2000-10004238 20000201
IC
      ICM
            A61K031-551; C07D471-04
      ICS
            A61K031-437; A61K031-4745; A61K031-496; A61K031-5377; A61K031-55;
            A61P025-00; C07D471-02
L9
      ANSWER 172 OF 175
                             WPIDS
                                      COPYRIGHT 2004 THOMSON DERWENT on STN
AN
```

2001-441671 [47]

WPIDS

```
2004-042230 [04]
DNC
       C2001-133424
      Producing embryonic or stem-like cells by transplanting differentiated donor cell nuclei into enucleated oocytes of a different species, to form nuclear transfer unit which is activated, cultured to obtain the cells.
TI
DC
       B04 C06 D16
       CIBELLI, J; LANZA, R; ROBL, J
IN
       (UYMA-N) UNIV MASSACHUSETTS
PA
CYC
       92
                                                            70p
PI
       WO 2001046401 A1 20010628 (200147)* EN
                                                                     C12N015-09
          RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
                   PT
                       SD SE SL SZ TZ UG
            W: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ
                EE ES FI GB GD GE GH GM HR HU ID
               EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI
                                                                                                 LK
                SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
      AU 2000048309 A
                            20010703 (200164)
                                                                     C12N015-09
                                                                                          <--
      BR 2000016561 A
                            20020910 (200269)
                                                                     C12N015-09
      EP 1240318
                        A1 20020918 (200269)
                                                     EN
                                                                     C12N015-09
            R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
               RO SE SI
       CN 1425064
                             20030618 (200358)
                                                                     C12N015-09
       JP 2004500066 W
                                        (200410)
                             20040108
                                                           108p
                                                                     C12N015-09
                        Α
                            20040227 (200418)
          519346
                                                                     C12N015-09
      WO 2001046401 A1 WO 2000-US12631 20000510; AU 2000048309 A AU 2000-48309
ADT
      20000510; BR 2000016561 A BR 2000-16561 20000510, WO 2000-US12631 20000510; EP 1240318 A1 EP 2000-930498 20000510, WO 2000-US12631 20000510; CN 1425064 A CN 2000-818280 20000510; JP 2004500066 W WO 2000-US12631 20000510, JP 2001-546899 20000510; NZ 519346 A NZ 2000-519346 20000510, WO 2000-US12631 20000510
      AU 2000048309 A Based on WO 2001046401; BR 2000016561 A Based on WO
FDT
      2001046401; EP 1240318 A1 Based on WO 2001046401; JP 2004500066 W Based on
      WO 2001046401; NZ 519346 A Based on WO 2001046401
PRAI US 1999-467076
                            19991220
IC
      ICM
             C12N015-09
      ICS
             C12N005-00; C12N005-10; C12N015-00; C12N015-63
      ANSWER 173 OF 175 2001-335518 [35]
L9
                               WPIDS
                                       COPYRIGHT 2004 THOMSON DERWENT on STN
AN
                               WPIDS
      2001-301276 [32]
CR
DNC
      C2001-103613
      Azepinoindole derivatives are PARP inhibitors and are useful for the
TT
      treatment of neurodegenerative diseases, ischemia, tumor, septic shock,
      inflammation, rheumatic diseases, ARDS and diabetes mellitus.
DC
IN
      GRANDEL, R; HOEGER, T; KOCK, M; LUBISCH, W; MUELLER, R; SCHULT, S; HOGER,
      T; MULLER, R
PA
       (BADI) BASF AG
CYC
      95
PΙ
      WO 2001023390 A2 20010405 (200135) * DE
                                                           21p
                                                                     C07D487-06
          RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
               NL OA PT SD SE SL SZ TZ UG ZW
           W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
               DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
               LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW .012712 A 20010430 (200142) C07D487-06 <--
      AU 2001012712 A
      NO 2001002567 A
                            20010625
                                        (200147)
                                                                     C07D487-06
                                                                                         <--
      BR 2000007174 A
                            20010904
                                        (200160)
                                                                     C07D487-06
                                                                                         <--
      SK 2001000884 A3 20020107
                                        (200213)
                                                                     C07D487-06
      KR 2001087401 A
                            20010915
                                        (200219)
                                                                     C07D487-06
                                                                                         <--
                                        (200223)
      DE 10039610
                        A1 20020228
                                                                     C07D487-06
      EP 1183259
                        A2 20020306 (200224)
                                                    DE
                                                                     C07D487-06
           R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
               RO SE SI
      HU 2001004917 A2 20020429 (200238)
                                                                     C07D487-06
          2001002373 A3
                            20020515
                                        (200241)
                                                                     C07D487-06
                                        (200311)
      CN 1374961
                            20021016
                                                                     C07D487-06
      JP 2003510328 W
                            20030318
                                        (200321)
                                                                     C07D487-06
                                                           28p
      MX 2001005199 A1 20020301 (200362)
                                                                    A61K031-55
                            20031231 (200408)#
      ZA 2002001494 A
                                                          105p
                                                                    C07D000-00
      WO 2001023390 A2 WO 2000-EP9024 20000915; AU 2001012712 A AU 2001-12712 20000915; NO 2001002567 A WO 2000-EP9024 20000915, NO 2001-2567 20010525; BR 2000007174 A BR 2000-FP9024 20000915, WO 2000-EP9024 20000915; SK 2001000884 A3 WO 2000-EP9024 20000915, WO 2000-EP9024 20000915; SK
ADT
      2001000884 A3 WO 2000-EP9024 20000915, SK 2001-884 20000915; KR 2001087401
```

```
1183259 A2 EP 2000-974379 20000915, WO 2000-EP9024 20000915; HU 2001004917 A2 WO 2000-EP9024 20000915, HU 2001-4917 20000915; CZ 2001002373 A3 WO
       2000-EP9024 20000915, CZ 2001-2373 20000915; CN 1374961 A CN 2000-802408 20000915; JP 2003510328 W WO 2000-EP9024 20000915, JP 2001-526542 20000915; MX 2001005199 A1 WO 2000-EP9024 20000915, MX 2001-5199 20010524;
       ZA 2002001494 A ZA 2002-1494 20020222
       AU 2001012712 A Based on WO 2001023390; BR 2000007174 A Based on WO
FDT
       2001023390; SK 2001000884 A3 Based on WO 2001023390; EP 1183259 A2 Based
       on WO 2001023390; HU 2001004917 A2 Based on WO 2001023390; CZ 2001002373
A3 Based on WO 2001023390; JP 2003510328 W Based on WO 2001023390; MX 2001005199 A1 Based on WO 2001023390
PRAI DE 2000-10039610 20000809; DE 1999-19946289 19990928; ZA 2002-1494
       20020222
             A61K031-55; C07D000-00; C07D487-06
IC
       ICM
             A61K031-437; A61P003-10; A61P009-10; A61P011-00; A61P013-12; A61P019-02; A61P025-00; A61P025-08; A61P025-10; A61P025-14;
       ICS
             A61P025-16; A61P025-28; A61P029-00; A61P035-00; C07D209-00;
             C07D223-00; C07D471-06
ICI
       C07D209:00; C07D209:00; C07D223:00; C07D487-06; C07D223:00, C07D487-06;
             C07D209:00; C07D223:00; C07D487-06; C07D209:00; C07D223:00;
             C07D487-06
L9
       ANSWER 174 OF 175 WPIDS
                                       COPYRIGHT 2004 THOMSON DERWENT on STN
AN
       2000-572034 [53]
                               WPIDS
DNC
       C2000-170511
ΤI
       Composition comprising
                                     ***cyclosporin***
                                                                 dissolved in dimethyl
       sulfoxide, useful as e.g. neuroprotective or immunosuppressing agent.
DC
       ELMER, E; KEEP, M
(ELME-I) ELMER E; (KEEP-I) KEEP M
IN
PA
CYC
       85
ΡI
       WO 2000050058 A1 20000831 (200053)* EN
                                                            13p
                                                                     A61K038-00
          RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
                OA PT SD SE SL SZ UG ZW
            W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD
               GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW
      AU 9928825
                        A 20000914 (200063)
A1 20010418 (200123) EN
                                                                     A61K038-00
                                                                                          <--
      EP 1091750
                                                                     A61K038-00
                                                                                          < - -
           R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
                RO SE SI
      NZ 508376
                            20030131 (200319)
                                                                     A61K038-08
      WO 2000050058 A1 WO 1999-US4359 19990226; AU 9928825 A AU 1999-28825
ADT
      19990226, WO 1999-US4359 19990226; EP 1091750 A1 EP 1999-909670 19990226, WO 1999-US4359 19990226; NZ 508376 A NZ 1999-508376 19990226, WO
      1999-US4359 19990226
FDT
      AU 9928825 A Based on WO 2000050058; EP 1091750 A1 Based on WO 2000050058;
      NZ 508376 A Based on WO 2000050058
PRAI WO 1999-US4359
                           19990226
IC
      ICM A61K038-00; A61K038-08
L9
      ANSWER 175 OF 175 WPIDS COPYRIGHT 2004 THOMSON DERWENT ON STN
      2000-293478 [26]
AN
                               WPIDS
DNC
      C2000-088806
      Isolated precursor cells containing sensory receptors are useful for treating ***Parkinson*** 's disease, ***Alzheimer*** 's disease,
TI
         ***Huntington*** 's disease, Multiple Sclerosis, stroke and spinal cord
      injury.
DC
      B04 D16
IN
      GLOSTER, A; MILLER, F
PA
       (GLOS-I) GLOSTER A; (MILL-I) MILLER F; (UYMC-N) UNIV MCGILL
CYC
PI CA 2213780 A 19980226 (200026)*
ADT CA 2213780 A CA 1997-2213780 19970822
PRAI US 1996-24456P 19960827; US 1996-24
                                                            43p
                                                                     C12N005-08
                            19960827; US 1996-24590P
                                                               19960826
IC
            C12N005-08
      ICM
            A61K035-30; C12N005-06; C12N005-10; C12Q001-02; C12Q001-18
```

STN INTERNATIONAL LOGOFF AT 16:01:27 ON 17 MAR 2004